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List of abreviations 
a.u.  asymmetric unit 
CR  Complement receptor 
CD  Cluster of Differenciation 
EC  Endothelial Cells 
iC3b  inactivated Complement 3b 
ICAM  Intercellular Adhesion Molecule 
LFA-1  Leukocyte Function-associated Antigen 1 
LRR  Leucine-rich repeat 
Mac-1  Macrophage antigen alpha polypeptide-1 
MIDAS Metal Ion Dependent Adhesion Site 
TTP  Thrombotic Thrombocytopenic Purpura 
VCAM-1 Vascular Cell Adhesion Molecule-1 
VLA  Very Late Antigen 
VWF  von Willebrand Factor 
vWFcp von Willebrand Factor cleaving protease, also known as ADAMTS13 
ADAMTS A Desintegrin And Metalloprotease with Thrombospondin Motives 
General introduction on vWF 
 3
Chapter 1 Introduction 
 
Discovery of Von Willebrand Factor 
 
In 1926 the Finnish Internist Eric A. von Willebrand reported a case of patients from the 
Åland Islands with “hereditary pseudohaemophilia” 1. Elongated bleeding and clotting times were 
manifested. It was not real haemophilia, because both male and female were affected. In 1953 it was 
found that patients with von Willebrand Disease also lacked factor VIII. In 1972 von Willebrand 
Factor was purified and the protein was sequenced by Edman degradation in 1986 2. The cDNA was 
cloned and sequenced in 1985 3; 4. The last decades, von Willebrand factor (vWF) is intensively 
studied and slowly the secret of its action becomes clear. 
 
Normal haemostasis is dependent on vWF 
 Haemostasis can be divided in two different processes, i) staunching, which is the process that 
stops the bleeding due to the formation of a platelet plug and ii) coagulation, which is the process of 
fibrin formation that stabilises the platelet plug. Coagulation is dependent on the presence of 
coagulation proteins, calcium and the negatively charged phospholipid phosphatidyl serine. The latter 
two compounds are provided by platelets that become adhered at the site of vascular damage. Platelet 
plug formation is dependent on von Willebrand Factor and adhesive compounds from the vascular 
matrix 5. 
Upon damage of the vessel wall, contents of the vessel wall are exposed to the blood. In vitro 
it has been shown that vWF can bind to fibrillar collagen types I, III and IV 6. In vivo, however, vWF 
is co-localised with collagen types I, III and VI in the subendothelium 7; 8 and not with collagen type 
IV 9. When vWF is immobilised to the subendothelium, it can bind to platelet glycoprotein (Gp) Ibα 
via its A1 domain 10. The interaction of the A1 domain with GpIbα has relative high association- and 
dissociation rate constants, thereby preventing permanent arrest of the platelet 11-13. In other words, 
the platelets tether and or roll over the surface. However, tethering platelets do slow down via 
interactions of platelet receptor GPVI with collagen 14. Due to the interaction of GpVI with collagen, 
the platelet becomes activated (the activation process involves many signal transduction pathways 
and will not be discussed here) that results in binding of integrin α2β1 to collagen and binding of 
integrin α2bβ3 to the RGD sequences of fibrinogen and vWF 15. The latter event results in platelet-
platelet interactions leading to platelet plug formation. The adhered platelets spread, release their 
granular contents (calcium, ADP and coagulation factors) and the negatively charged phospholipid 
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phosphatidyl serine becomes exposed. Now coagulation starts and the thrombus obtains it final 
strength.  
 
Biosynthesis of vWF 
 The vWF gene is located on chromosome 12p13.3 and spans approximately 178 kilo 
basepairs. It contains 52 exons which code for 2813 amino acid residues 2; 4. A pseudogene is located 
on chromosome 22q11.1, is 21-29 kbp in length and spans exons 23-34 16. The overall homology 
between the vWF gene and pseudogene is 96.9 %. There is slight divergence between the sequences 
corresponding to the exons (97.5 %) and slightly more divergence for the introns (96.8 %). 
VWF is synthesised as pre-pro-vWF in megakaryocytes 17 and endothelial cells (EC) 18; 19. 
After synthesis, the 22 amino-acid residues of the vWF pre-peptide are cleaved off in the 
endoplasmatic reticulum, vWF is dimerised at the C-terminus and partially glycosylated 20; 21. VWF-
dimers are transported to the Golgi apparatus and multimerisation takes place in the trans Golgi 
network 22. Sorting to the Golgi-apparatus does not require the propeptide, also known as vWF-Ag II 
23, whereas multimerisation does 24. For multimerisation the propeptide does not have to be 
covalently linked to the protein 25. The protease furin cleaves the pro-peptide but  the peptide remains 
non-covalently associated with mature vWF 22; 26. Any uncleaved propeptide is removed from the 
multimer in the plasma, but the enzyme responsible for this process remains unknown 27. Additional 
N-linked and O-linked glycosylation 28; 29 and sulfation 22 occurs. VWF is N-glycosylated at 
asparagine residues 94, 384, 468, 752, 811, 1460, 1527, 1594, 1637, 1783, 1822 and 2027. O-linked 
glycosylation sites are threonine residues 485, 492, 493, 705, 714, 724, 916 and 1535 and serine 500 
and 723 2. 
After synthesis, vWF is partitioned between two pathways. Approximately 95 % is 
constitutively secreted. The remainder is stored in the tubular structures in α-granula of 
megakaryocytes 29 and in Weibel-Palade bodies of endothelial cells 29; 30. Weibel-Palade bodies are 
not formed in vWF deficient cells, whereas α-granula are still present, but these granula lack the 
tubular systems 31. Sorting of vWF to storage granules requires the propeptide, and Arg416 has been 
shown to be essential 23; 32. This implies that the propeptide functions as a catalyst in multimerisation 
and as a molecular chaperone in translocation to storage granules. The stoichiometry of the 
propeptide and mature vWF is 1:1 in the Weibel-Palade bodies.  
In vivo, vWF and propeptide plasma levels are 10 and 1 µg/ml, respectively. Half-lifes are 12 
h and 2 h, respectively 33. VWF plasma levels depent on the blood group 34. Blood group AB persons 
have an average plasma level of 12.2 µg/ml, blood groups A and B 10.6 µg/ml and blood group O 8.8 
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µg/ml. Propeptide levels are not blood group type sensitive, because the propeptide does not contain 
the A and B oligosaccharides whereas mature vWF does 35; 36. Increased plasma levels can result 
from stimulation of endothelial cells by for example 1-desamino-8-D-arginine vasopressin (DDAVP) 
37. 
 
Functional domains of mature vWF 
Mature, monomeric vWF consists of 2050 amino acid residues in twelve domains (figure 1) 
38. VWF multimerises upto 80 monomers in a multimer 39. The D3 domain contains cysteins that 
form the N-terminal intermolecular disulfide bridges. Intermolecular disulfide bridges are formed 
involving Cys379 40, and at least one cysteine of triplet Cys459-Cys462-Cys464 40; 41. The CK domain, 
residues 1961 – 2050, contains cysteins that are involved in C-terminal intermolecular disulfide 
bridges probably requiring Cys2008, Cys2010 and Cys2048 42. Intra-molecular disulfide bridges are 
formed between Cys1961-Cys2011, Cys1987-Cys2041, Cys1991-Cys2043 and Cys1976-Cys2025 within the CK 
domain 42. The D´ and the D3 domains are involved in binding clotting factor VIII 43-45 thereby 
preventing factor VIII from binding to membrane surfaces and activation and degradation by a 
variety of serine proteases 46. Factor VIII binding affinity decreases when vWF is bound to collagen 
47. The A1 domain binds GpIbα 10, heparin 10, collagen type III and VI 8; 48-50 and sulfatides 50-52. The 
linker between the A1 and A2 domains is involved in binding to leukocytes 53. The A2 domain 
contains the proteolytic cleavage site for the vWF protease 54. The A3 domain contains the collagen 
binding site 48; 55. No specific function has been assigned for the D4 and B domains. The C domains 
contain the recognition sequence RGD at residues 2507-2509, which bind to platelet integrin α2bβ3 56. 
The vWF multimeric structure is essential for its function 57; 58. In collagen binding, multimeric vWF 
displays an apparent Kd of 1 – 7 nM 59, while monomeric, recombinant A3 binds collagen with a Kd 
of 2 µM 60.  In contrast, factor VIII binding only requires N-terminal dimers.  
 
 
Figure 1: Schematic representation of the pre-pro-vWF domain organisation. Scissors indicate sites where vWF is 
cleaved during synthesis (before Ala23 and Ser764) or in plasma in the A2 domain (after Tyr1605) by the vWFcp. Of note, 
the diagram is not on scale. 
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A-type domains 
A-type domains (and homologous integrin I- or inserted domains) are recognized in vWF A1, 
A2 and A3 domains, integrins of the β1 family, α1β1, α2β1, α10β1, α11β1, integrins of the β2 family, 
αLβ2, αXβ2, αMβ2, integrins αD, αEβ7, different collagen subtypes, complement components 61 and 
other proteins. A brief summary of A type domains is given in Table I and figure 2. 
A-type domains adopt a so-called Rossman or di-nucleotide binding fold that consists of a 
central hydrophobic β-sheet, flanked on both sides by amphipathic α-helices (figure 3). The top face 
consists of loops connecting the α-helices and the β-strands and contains the metal-ion-dependent-
adhesion-site (MIDAS) motive. The MIDAS motive will be discussed below. The bottom face 
consists of loops connecting the α-helices and the β-strands and contains a disulfide bridge. 
 
Table I 
vWF domains and integrin receptors containing A- or I-type domains 
Receptor Alternative name(s) Ligand(s) References 
vWF-A1  
GpIbα, collagen type III 
and VI, botrocetin, 
ristocetin, heparin, 
sulfatides, bitiscetin 
10; 41; 62-66 
vWF-A2  vWFcp 67; 68 
vWF-A3  collagen type I and III, bitiscetin 
55; 69 
α1β1 VLA-1, CD49a/CD29 collagen, laminin-1 56; 70 
α2β1 VLA-2, GpIa/IIa, 
 CD49b/CD29 
collagen I and III 
echovirus,  laminin-1 
56; 71-75 
α10β1  collagen II 76 
α11β1  collagen 56; 77 
αDβ2 CD11d/CD18, ADB2, leucointegrin alpha D 
VCAM1 78 
αEβ7 
CD103, 
mucosal lymphocyte-1 
antigen 
E-Cadherin 56 
αLβ2 CD11a/CD18, LFA-1 
lymphocyte function-
associated antigen 1 
ICAM-1, -2, -3, -4, -5 56; 79 
80 
αMβ2 Mac-I, CR3 
CD11b/CD18, Mo1 
iC3b, Factor X, ICAM-1, 
neutrophil inhibitory factor 
56; 81 
80; 82 
αXβ2 
Leukocyte adhesion-
receptor p150,95, 
CD11c/CD18 
iC3b 56 
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      β1          α1      β2        β3  α2 
vWF-A1   498 DISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSEL 
vWF-A2   722 VSTLGPKRN---SMVLDVAFVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGDI 
vWF-A3   922 ----------DCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITTIDVPWNVVPEKAHL 
Alpha 1  131 -----------CSTQLDIVIVLDGSNSIYP--WDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEV 
alpha 2  137 --------RSSCPSLIDVVVVCDESNSIYP--WDAVKNFLEKFVQGLDIGPTKTQVGLIQYANNPRVVFNLNTYKTKEEM 
Alpha 10 159 --------AQRCPTYMDVVIVLDGSNSIYP--WSEVQTFLRRLVGKLFIDPEQIQVGLVQYGESPVHEWSLGDFRTKEEV 
Alpha 11 157 ---------QRCQTYMDIVIVLDGSNSIYP--WVEVQHFLINILKKFYIGPGQIQVGVVQYGEDVVHEFHLNDYRSVKDV 
Alpha D 142 --------PECPHQEMDIVFLIDGSGSIDQNDFNQMKGFVQAVMGQFEGT--DTLFALMQYSNLLKIHFTFTQFRTSPSQ 
Alpha E 194 --------EEEEEAGTEIAIILDGSGSIDPPDFQRAKDFISNMMRNFYEKCFECNFALVQYGGVIQTEFDLRDSQDVMAS 
alpha L  125 ----------CIKGNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLSN--TSYQFAAVQFSTSYKTEFDFSDYVKRKDP 
Alpha M  134 ---------GCPQEDSDIAFLIDGSGSIIPHDFRRMKEFVSTVMEQLK--KSKTLFSLMQYSEEFRIHFTFKEFQNNPNP 
Alpha X 143 --------QECPRQEQDIVFLIDGSGSISSRNFATMMNFVRAVISQFQRP-S-TQFSLMQFSNKFQTHFTFEEFRRTSNP 
 
           α3     β4       α4     β5 
vWF-A1       RRIASQVKYAGSQVASTSEVLKYTLFQIFSKI--DRPEASRIALLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIG- 
vWF-A2       LQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPN-LVYMVTGNPASD---EIKR-LPG----DIQVVPIGVG- 
vWF-A3       LSLVDVMQREGG-PSQIGDALGFAVRYLTSEMHGARPGASKAVVILVTDVSVDS----VDAAADAARSNRVTVFPIGIG- 
Alpha 1      LVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNH--RLKKVIQDCEDENIQRFSIAILG 
alpha 2      IVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVVVTDGESHDGS--MLKAVIDQCNHDNILRFGIAVLG 
Alpha 10     VRAAKNLSRREGRETKTAQAIMVACTEGFSQSHGGRPEAARLLVVVTDGESHDGE--ELPAALKACEAGRVTRYGIAVLG 
Alpha 11     VEAASHIEQRGGTETRTAFGIEFARSEAF-Q-KGGRKGAKKVMIVITDGESHDSP--DLEKVIQQSERDNVTRYAVAVLG 
Alpha D      QSLVDPIVQLKG-LTFTATGILTVVTQLFHHKNGARKSAKKILIVITDGQKYKDPL-EYSDVIPQAEKAGIIRYAIGVG- 
Alpha E      LARVQNITQVGS-VTKTASAMQHVLDSIFTSSHGSRRKASKVMVVLTDGGIFEDPL-NLTTVINSPKMQGVERFAIGVG- 
alpha L      DALLKHVKHMLL-LTNTFGAINYVATEVFREELGARPDATKVLIIITDGEATDS------GNIDAAK--DIIRYIIGIG- 
Alpha M      RSLVKPITQLLG-RTHTATGIRKVVRELFNITNGARKNAFKILVVITDGEKFGDPLGY-EDVIPEADREGVIRYVIGVG- 
Alpha X      LSLLASVHQLQG-FTYTATAIQNVVHRLFHASYGARRDATKILIVITDGKKEGDSL-DYKDVIPMADAAGIIRYAIGVG- 
 
        α5’     α5      β6     α6  (α7) 
vWF-A1       -----PHAN---LKQIRLIEKQAPENKAFVLSSVDELEQQRD---EIVSYLCDLAPEAPPPT     
vWF-A2       -----PNAN---VQELERIGWP---NAPILIQDFETLPREAP---DLVLQRCCSGEGLQIPT      
vWF-A3       -----DRYD---AAQLRILAGPAGDSNVVKLQRIEDLPTMVTLGNSFLHKLCSG--------  
Alpha 1      SYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVK---TLGERIFALEATADQSA  
alpha 2      YLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAALLEKAG---TLGEQIFSIEGGT----    
Alpha 10     HYLRRQRDPSSFLREIRTIASDPDERFFFNVTDEAALTDIVD---ALGDRIFGLEGSHAENE   
Alpha 11     YYNRRGINPETFLNEIKYIASDPDDKHFFNVTDEAALKDIVD---ALGDRIFSLEGTN-KNE    
Alpha D      ----HAFQGPTARQELNTISSAPPQDHVFKVDNFAALGSIQK---QLQEKIYAVEGTQSRAS     
Alpha E      ----EEFKSARTARELNLIASDPDETHAFKVTNYMALDGLLS---KLRYNIISMEGTVG---   
alpha L      -KHFQTKES---QETLHKFASKPASEFVKILDTFEKLKDLFT---ELQKKIYVIEG------   
Alpha M      -DAFRSEKS---RQELNTIASKPPRDHVFQVNNFEALKTIQN---QLREKIFAIEG------    
Alpha X      ----LAFQNRNSWKELNDIASKPSQEHIFKVEDFDALKDIQN---QLKEKIFAIEGTETTSS  
 
 
Figure 2: Alignment of vWF-A and integrin-I domains. The domains were pre-aligned using ClustalW 1.81 at the EBI 
website (http://www.ebi.ac.uk/clustalw/). Alignments of domains with known crystal structures were optimised based on 
a superposition of the models. The alignment of domains with unknown crystal structure were adjusted to the crystal-
structure optimised alignment. Residues in Bold form the MIDAS motive, α-helices and β-strands are indicated by the 
dark and blue boxes, respectively. 
 
 
click on this link for rotating image 
 
 
Figure 3: Structure of the A- or I-type domains. The vWF-A1 domain is shown. A-
type domains contain a so-called dinucleotide binding or Rossmann fold that 
consists of a central β-sheet which is flanked on both sides by α-helices (colour 
coded in red and blue, respectively). The top- and bottom faces contain loops 
connecting the α-helices and β-sheet. The bottom-face contains the disulfide bridge 
and in integrin I-domains the top face contains the MIDAS motif. In the vWF-A1 
domain vWD type 2B mutations cluster at the bottom of the domain and vWD type 
2M mutations scatter all over A1.  
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A1 domain 
The vWF-A1 domain spans residues 509 – 695 and contains the GpIbα binding site 10; 41; 63. 
The crystal structure has been solved 83; 84. It binds to GpIbα 10, collagen 48 48; 64, ristocetin 66, 
botrocetin 65, bitiscetin 85, sulfatides 50-52 and heparin 10; 50; 86. The sulfatide- and heparin-binding sites 
probably do not overlap 52. The N- and C-termini are linked by a disulfide bridge. The formation of 
this disulfide bridge is an absolute requirement for a proper function of the vWF-A1 domain. In the 
absence of the disulfide bridge, the GpIbα binding affinity is strongly reduced 87-90. Moreover, the 
function of the A1 domain is modulated by the number of residues in the N- and C-terminal peptides 
91 and the presence of O-linked glycans. The number of residues in the flanking peptides required for 
a proper modulation of the A1-domain is still a matter of debate (table II). Removal of the O-linked 
glycans 89; 92 or desialisation 93 pro-activates the A1 domain. The antibiotic ristocetin A and the snake 
toxins botrocetin and bitiscetin bind to specific sequences in A1 resulting in activation of A1. 
The A1 domain does not bind spontaneously to GpIbα, therefore it needs to be activated. 
Activation can be achieved via vWF-immobilisation to a surface (for example the vessel wall), 
although it is not clear whether activation occurs due to a conformational change in vWF or because 
the local vWF-concentration is increased. Additionally, vWF can be activated due to vWD type 2B 
mutations and activators like ristocetin or botrocetin and will be discussed below. The strucure of the 
A1•GpIbα complex and conformational changes in the A1 domain that result in GpIbα binding are 
the subject of chapters five and six of this thesis. 
 
Table II 
Effect of the length of the N- and C-terminal flanking peptides on the activation-state of A1 
Construct Origin Effect in GpIb binding References
plasma vWF human No spontaneous binding to GpIb, ristocetin and botrocetin activate binding  
441-730 CHO/COS-7 No spontaneous binding to GpIb, ristocetin activates 94; 95 
481-718 human No spontaneous binding to platelets, ristocetin and botrocetin activate 
87 
481-718 ∆sialic acid human Bit spontaneous binding to platelets, ristocetin does not activate, botrocetin activates 
87 
475-709 COS-7 No spontaneous binding to GpIb, ristocetin activates 89 
441-704 E. coli Little bit spontaneous binding to platelets, botrocetin activates 
96 
475-709 E. coli No spontaneous binding to GpIb, less ristocetin required for activation 
89 
508-704 E. coli 
Binds spontaneous to platelets, less platelets bind to 
A1-coated surface at high shear stress and the platelets 
that become attached to the surface do not tether 
90 
508-733 E. coli Spontaneous binding to platelet, botrocetin activates 96 
General introduction on vWF 
 9
A2 domain 
Defining the borders of the A2 domain is not straightforward, because the A2 domain does 
not contain a disulfide bridge connecting the N- and C-termini. Based on sequence homology with 
other A-type domains, we define the borders between residues Ser731 and Cys907 (figure 2). The A2 
domain contains the cleavage site for the von Willebrand Factor cleaving protease (vWFcp) that is 
also known as ADAMTS13 54; 97; 98. The gene for the vWFcp is located on chromosome 9q34. This 
enzyme cleaves the A2 domain between residues Tyr842 and Met843 resulting in lower vWF multimers 
99; 100. The A2 domain contains a disulfide bridge at the bottom of the domain, but this disulfide 
bridge does not connect the N- and C-terminal flanking peptides. The disulfide bridge is formed 
between two consecutive residues. The aberrant disulfide bridge is essential, because otherwise a 
proteolytic cleavage within the A2 domain does not decrease the multimeric size of vWF. 
A number of mutations in the A2 domain (and also some in the A1 domain), so-called vWD 
type 2A mutations, have been identified in patients that make vWF more sensitive towards the 
vWFcp 101. Most likely, these mutations partially unfold the A2 domain thereby making the A2 
domain more susceptible to the protease. As a result, these patients lack the high-molecular-weight 
multimers in their plasma. The partial unfolding (or sensitisation) of vWF is probably required for 
efficient proteolysis for several reasons. i) Based on homology with other A-type domains it is most 
likely that the Tyr842-Met843 peptide bond is located in the interior of the domain (figure 4), ii) in vivo 
application of shear increases the proteolysis 102, iii) In vitro low ionic strength buffers and 
denaturating agents are required for proteolysis 100. A deficiency in vWFcp-activity results in the 
presence of ultra-large vWF multimers that may cause thrombotic thrombocytopenic purpura (TTP), 
which is manifested by thrombocytopenia, microangiophatic hemolytic anemia, bleedings and other 
symptoms 103. 
 
 
 
 
 
 
 
Figure 4: Model of the A2 domain. This hypothetical model of the A2-domain 
has been constructed based on the homologous vWF-A1 domain (PDB accession 
code 1auq), which, based on amino-acid sequence, is the most closely related A-
type domain and has been prepared by the internet 3dpssm server 
(http://www.sbg.bio.ic.ac.uk/servers/3dpssm). Of note, the connectivity of the 
model is not complete, which is most significant for helix α4 that is absent in A2. 
Strand β2 is drawn transparent for clarity. The von Willebrand Factor cleaving 
protease cuts between residues Tyr842 and Met843, which are shown in ball-and-
stick representation and are located at the centre of the β-sheet in the interior of 
the domain. 
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A3 domain 
The A3 domain spans residues 923 to 1109 and contains the binding site for fibrillar collagen 
types I and III 55; 60. The multimeric structure of vWF is important for vWF binding to collagen. The 
Kd of monomeric A3 and multimeric vWF for the binding to collagen is 2 µM and 4 nM, 
respectiviely 59; 60; 104. Crystal structures have been solved by two groups independently 105; 106. The 
putative vWF-A3 MIDAS motif at the top-face of A3 is formed by residues Asp934, Ser936, Ser938, 
Ser1005 and Thr1038 (figure 2). The latter two residues are threonine and aspartic acid in I-domains. In 
A3 however, the aspartic acid (Asp1039) has been shifted by one residue and the hydroxyl group of 
Thr1038 is not able to coordinate to the metal ion. In addition, the side chain of Asp1039 (which is 
glycine in the case of integrin I-domains) prevents a metal-ion from entering the MIDAS motive. The 
MIDAS motif of integrin I-domains usually contains a magnesium or manganese ion 75; 79; 82; 107 
which is absolutely required for ligand binding 108-110. The MIDAS motif of A3 does not contain a 
metal-ion and the binding of A3 to collagen type I and III is metal-ion independent 105; 106; 111. 
The collagen-binding site of integrin α2 I-domain, and most likely also of the I-domain of 
integrins α1β1 70, α10β1 76, α11β1 77, is located at the top-face of the domain  74; 112. A divalent cation, 
either Mg2+ or Mn2+ 108; 109, bound to the MIDAS motif is involved in collagen binding 71; 74 and the 
protruding additional helix determines the specificity towards certain collagen subtypes 75; 113. The 
top face of the vWF-A3 domain is not involved in collagen binding 59;106; 114 and therefore the 
collagen-binding site on A3 must be located somewhere else. Two other studies on the collagen-
binding site were conducted. Cruz et al. constructed an A1/A3 chimer, spanning residues 475-
598/1018-1114 104. Collagen binding of this chimer was similar compared to wt-A3. Based on a 
cyanogen bromide digestion of vWF, Roth et al. localized a collagen-binding site within residues 
948-998. An additional collagen binding site, however, was identified within residues 542-662 in A1 
48 sugesting that the collagen binding affinity of the A1/A3 chimer may also originate from residues 
479-598 of the A1 domain. The exact location of the collagen-binding site in the A3 domain is the 
subject of chapters two, three and four of this thesis. 
 The nature of the collagen triple helix interacting with vWF has been studied by Verkleij et 
al. 115. A collagen type III related-peptide from the α1 chain containing residues 541 – 558 (in 
sequence GAA GRP* GPP* GSA GTP* GLQ (P* = hydroxyproline)) was able to bind vWF directly. 
However, in a perfusion system platelets also adhered to a collagen-related-peptide spanning residues 
511 – 540 in a vWF dependent manner. This discrepancy was also observed for collagen type IV that 
does not bind vWF directly, but platelet adhesion to a collagen type IV coated surface is vWF 
dependent 55; 62; 116. In analogy to the α2 I-domain, it seems likely that vWF binds to multiple collagen 
sequences with different affinities 70. 
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Glycoprotein Ib-IX-V complex 
 The glycoprotein Ib-IX-V complex contains the proteins GpIbα, GpIbβ, GpIX and GpV in 
stoichiometry 2:2:2:1 (figure 5) and it is the platelet receptor for vWF, α-thrombin, P-selectin and 
αMβ2 (reviewed in 117 and 118). Approximately 20,000 copies of the complex are present per platelet. 
GpIbα associates covalently with GpIbβ outside the cell via a disulfide bridge close to the trans-
membrane helices of both proteins. GpIbβ non-covalently associates with GpIX 119. Via GpIbα, two 
GpIbα-GpIbβ-GpIX trimers associate non-covalently with one GpV molecule. Within the cell, GpIb-
IX-V associates with actin-binding protein, phosphatidylinositol 3-kinase 120 and the signalling 
protein 14-3-3ζ 120; 121. It has been hypothesised that upon vWF- or thrombin-binding to the GpIb-IX-
V complex, 14-3-3ζ delivers phosphatidylinositol 3-kinase to the cytoskeleton 120 and thereby keeps 
integrin α2bβ3 in its phosphorylated, active conformation 122. All extra-cellular members of the GpIb-
IX-V complex contain so-called leucine-rich repeats (LRRs). GpIbα and GpV contain a heavily 
glycosylated stalk. The glycosylated stalk of GpIbα is extremely long and positions the vWF 
binding-site at 45 nm from the platelet surface. Expression of the GpIbα-GpIbβ-GpIX trimeric 
complex at the platelet membrane requires all three components, whereas GpV is not required 123. 
Impaired expression of the GpIb-IX-V complex results in a not well developed demarcation 
membrane of megakaryocytes resulting in giant platelets and low platelet numbers 124. It has been 
suggested that GpV enhances the avidity of the GpIb-IX complex and thereby strengthens the 
interaction of vWF with the platelet 125. GpV also binds to collagen type I 126. 
 
 
 
 
 
Figure 5: Model of the GpIbα-Ibβ-V-IX complex. At the platelet 
surface, GPIbα is disulphide-linked to GPIbβ that is associated in 
a non-covalent manner with GPIX. GpIbα is also non-covalently 
associated with GPV. The stoichiometry of the complex is 
2:2:2:1. All members of the complex are linked to the platelet 
membrane via a transmembrane helix. O- and N-linked 
glycosylation sites are indicated by circles and squares, 
respectively. (adapted from Berndt et al. 118) 
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GpIbα contains the vWF-binding site. The binding site is located in the N-terminal 293 
residues of the GpIbα that contains several distinguishable domains: 
 
• Residues 1-35: N-terminal flanking sequence. 
• Residues 36-200: seven leucine-rich repeats (LRRs). 
• Residues 201-268: double-loop- or C-terminal flanking sequence. 
• Residues 269-282: anionic region. 
 
It is not clear whether the N-terminal flanking sequence interacts directly with A1, because 
botrocetin induced vWF binding is not dependent on this loop whereas the loop appears to be 
involved in ristocetin-induced vWF binding 127. 
 
Leucine-rich repeats, which are found in numerous proteins involved in hormone-receptor 
interactions, enzyme inhibition and cell adhesion processes (reviewed in 128), contain 20-29 amino-
acid residues repeating sequences. The LRRs of the GpIb-IX-V complex belong to the “typical” LRR 
subfamily with the repeating sequence LxxLxxLxLxxN/CxLxxLpxxoFx-x, in which “x” is any 
residue, “o” is any non-polar residue and “–” is a possible insertion site. Within a protein the different 
LRRs typically contain the same number of residues. An alignment of LRRs from human GpIbα is 
given in figure 6A. A LRR forms a “U”-shaped structure in which one leg is a β-strand and the other 
leg a helical structure (figure 6B). The type of helical structure depends on the type of protein; in 
ribonuclease inhibitor it is an α-helix, in internalin B it is a 310-helices and in U2B”-U2A’ it contains 
α-helices, 310-helices and short loops 128. A number of consecutive LRRs form a horseshoe-like 
structure, with on the inner-face a parallel β-strand and on the outer-face the helical structures that 
determine the curvature of the horse-shoe. Conserved asparagine (or cysteine) residues at the base of 
the LRR form hydrogen bonds with the preceding LRR.  The parallel β-strands and the β-α loops 
form the interaction surface with other proteins, although sequences outside the LRRs may contribute 
in ligand binding 128. The LRR is flanked on both sides by structures that protect the hydrophobic 
core of the ``U``-shaped structure. These flanking sequences are typically amphipathic α-helices or 
cysteine-rich structures. 
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A            B 
 
 
LRR1        46  PKDTTILHLSENLLYTFSLATLMP  69 
LRR2        70  YTRLTQLNLDRCELTKLQVDG-T-  91 
LRR3        92  LPVLGTLDLSHNQLQSLPLLGQT- 114 
LRR4       115  LPALTVLDVSFNRLTSLPLGALRG 138 
LRR5       139  LGELQELYLKGNELKTLPPGLLTP 162 
LRR6       163  TPKLEKLSLANNNLTELPAGLLNG 186 
LRR7       187  LENLDTLLLQENSLYTIPKGFFGS 210 
“typical” LRR     LxxLxxLxLxxNxLxxLpxxoFx-x 
 
 
 
Figure 6: The GpIbα leucine rich repeats. A: The GpIbα leucine rich repeats were aligned using the program ClustalW 
1.81 and adopts the consensus sequence of the so-called “typical” sub-family of LRR-proteins, except for the 
phenylalanine residue after the non-polar residue that is absent in LRRs 1-6. Residues that form the β-strand and helical-
like structure are underlined and in bold, respectively. The indicated numbering starts at the ATG of the 16-residue signal 
peptide. B: The seven GpIb-LRRs form a horseshoe like structure 129. GpIbα-LRR 5 (see chapter 5 of this thesis) is 
shown as a typical example. Residues that form the β-strand and α-helix are colour-coded red and blue, respectively. 
 
 
The LRRs of human, canine and mouse GpIbα have been modelled using the known crystal 
structure of internalin B 129. The inner face of the hypothetical GpIbα-LRRs model contain β-sheets, 
whereas the outer face most likely contains 310 helices. It has been suggested that the LRRs interact 
with the vWF-A1 domain for several reasons. Firstly, LRRs in other proteins are known to form a 
structural framework required for protein-protein interactions 128. Secondly, human vWF does not 
bind to GpIbα containing canine GpIbα LRRs 2-4 127. Thirdly, a number of Bernard-Soulier 
syndrome mutations are located in the LRRs (Table III). However, since these mutations involve 
buried residues in the hydrophobic core, these mutations most likely alter the conformation of the 
LRR that is most likely the underlaying cause of the observed reduced A1 binding. 
 
The double-loop domain is essential for the interaction with A1. Its function has been 
investigated in only one, recent study 130. It contains two disulfide bonds between Cys209-Cys248 and 
Cys211-Cys264. It has been proposed that the first disulfide loop and its N-terminal flanking peptide up 
to residue Phe201 interacts with LRR-6 and this interaction is required for proper binding to A1. 
Disruption of this interaction results in a loss-of-function phenotype. All platelet-type vWD 
mutations are located in the first disulfide loop. The second disulfide loop is required for the 
interaction of botrocetin but not ristocetin with GpIbα. These findings confirm the hypothesis that 
ristocetin and botrocetin do not share the same binding-site on GpIbα. Replacement of the second 
double-loop by canine sequences results in a gain-of-function phenotype. The second disulfide loop 
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of human and canine differ only at five residues; charge alternations at positions Asp249Val, 
Asp252Lys, Lys253Asn, Lys258Thr and Gly263Asp. The mechanism by which these mutations 
activate GpIbα is not understood. 
 
The anionic region contains ten aspartic and glutamic acid residues and three sulphated 
tyrosines at positions 276, 278 and 279. Although no consensus sequence exists for sulfation, 
negative charged residues at both sides of the tyrosines are required for a proper sulfation 131. When 
the tyrosines are not sulfated, shear induced rolling of platelets over vWF or ristocetin- or botrocetin 
induced binding of vWF to GpIbα are strongly reduced 125; 132; 133. Interestingly, mutation of the 
tyrosines to glutamic acid abolishes botrocetin induced vWF binding, but does not have an effect in 
ristocetin-induced vWF binding and shear-induced rolling of cells. This suggests that just negative 
charges are satisfactory for ristocetin- or shear induced binding 133. Neutralising or charge reversal 
mutations of the negatively charged aspartic and glutamic acid residues in the anionic region 
decreases botrocetin- and ristocetin induced binding 134 131. The negative charges between residues 
251-279 are essential for both ristocetin- and botrocetin induced binding, whereas the negative 
charges between residues 280-302 are also required for botrocetin induced vWF binding 134. 
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Table III 
Bernard-Soulier and platelet-type vWD mutations 
Syndrome Protein Mutation Consequences Reference 
Bernard-Soulier 
Syndrome 
GpIbα K19R frameshift and premature stop 135 
  S39STOP frameshift and premature stop 
compound hetrozygote with Y492C 
136 
  L57F  137 
  C65R compound hetrozygote with W98STOP 138 
  L76R frameshift and premature stop 139 
  A80STOP frameshift and premature stop 140 
  L129P  141 
  A156V  142 
  L179∆  143 
  C209S  144 
  N226V identified by scanning 145 
  K231V identified by scanning 145 
  Q232V identified by scanning 145 
  A238V identified by scanning 145 
  T240V identified by scanning 145 
  A244V identified by scanning 145 
  V295S frameshift and premature stop 146 
  W343STOP  147 
  S444I  146 
  S444STOP  148 
  K451STOP frameshift and premature stop 146; 149 
  Y492C frameshift and premature stop. Might be 
compound hetrozygote with S39STOP 
136; 150; 151 
  W498STOP might be compound hytrozygote with 
C65R 
138; 152 
     
 GpIbβ absent protein  153-155 
  R17C  156 
  P74R  157 
  Y88C  158; 159 
  A108P  158 
     
 GpIX C8R  160 
  D21G compound hetrozytote with N45S 161-163 
  L40P  164 
  N45S compound hetrozytote with D21G 161-163; 165 
  F55S  166 
  C73Y  167 
  W127STOP  149 
  A139T  168 
     
Platelet-type vWD GpIbα G233V  169; 170 
  V234G  171 
  D235V  145 
  K237V  145 
  M239V  172; 173 
Numbering starts at the first residue of the mature peptide.  
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Modulators of the collagen–vWF–GpIbα axis 
 
In vitro vWF functions can be influenced by several modulators. A number of molecules have 
been described that interfere with the binding of vWF to collagen or to GpIbα. These modulators act 
either by a loss-of-function or a gain-of-function mechanism (Table IV). 
 
 
Table IV 
Modulators of the collagen-vWF-GpIbα axis 
Modulation Modulator Isolated from Family Function Reference
Ristocetin Nocardia lurida antibiotics activates A1 174-176 Gain-of-
function Botrocetin Bothrops jararaca C-type lectin activates A1 177-179 
 Jararhagin Bothrops jararaca metalloproteinase-
desintegrin 
activates A1 180 
 Bitiscetin Bitis arientans C-type lectin activates A1 but 
binds to A1 and A3 
domain 
69; 85; 181; 182 
 Jaracetin Bothrops jararaca metalloproteinase 
desintegrin 
activates A1 180 
Heparin  poly glycan blocks A1 50; 86; 183; 184 Loss-of-
function Flavocetin-A/B Trimeresurus flavoviridis C-type lectin Blocks GpIb 185-187 
 Alboaggregin-B  C-type lectin Blocks GpIb 188 
 Mamushigin Agkistrodon halys blomhoffii C-type lectin Blocks GpIb 189 
 Agkistin Agkistrodon acutus C-type lectin Blocks GpIb 190 
 Echicetin Echis carinatus C-type lectin Blocks GpIb 191-193 
 Jararaca GpIb-BP Bothrops jararaca C-type lectin Blocks GpIb 194; 195 
 Tocaracetin Trimeresurus tokarensis C-type lectin Blocks GpIb 196 
 Heparin  glycosamineglycan Blocks A1 86; 184 
 Aurintricarboxylic acid   Blocks A1 197 
 
These modulators belong to the C-type lectin super-family (although they do not possess 
lectin activity), metalloproteinase desintegrin family, glycopeptide antibiotics or aromatic chemical 
compounds. Botrocetin and ristocetin-A are relevant to the work described in this thesis and will be 
described in more detail. 
 
Botrocetin 
 
Botrocetin belongs to the C-type lectin super-family 179. It is a hetero-dimeric molecule 
containing a 133 amino-acid (15 kDa) α-subunit and a 125 amino-acid (14.5 kDa) β-subunit, each 
containing three intra-chain disulfide bonds and one inter-chain disulfide bond. Also a one-chain 
botrocetin variant (32 kDa) has been isolated, but this variant is less active in vWF activation and 
belongs to the metalloproteinase desintegrin family 178. The crystal-structure of botrocetin has been 
solved (figure 7) 198. A large loop protrudes from each of the subunits and interacts with its 
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counterpart. One magnesium ion is bound to the α-chain of the botrocetin hetrodimer. A distinctive 
negatively charged region at the centre of the molecule is hypothesized to interact with positive 
charges on A1. Binding of botrocetin to A1 does not introduce conformational changes within A1. 
Mutagenesis and crystallographic studies identified residues in helices α4A, α4B and α5 of A1 that 
are essential for botrocetin binding 199;200. These residues are close to Lys599, which is involved in 
GpIbα binding, indicating that botrocetin binds close to the GpIbα binding site. Botrocetin also 
interacts directly with GpIbα, see above. It has been hypothesized that botrocetin binds to A1 and 
thereby provides additional surface that interacts with GpIbα 200. 
 
 
 
 
 
Figure 7: Structure of A1 activator botrocetin. 
Botrocetin activates the vWF-A1 domain that 
leads to GpIbα binding. A: The botrocetin 
crystal structure is shown. The botrocetin α 
(pink) and β (green) chains tightly interact via a 
large protruding loop. B: Surface potential of 
botrocetin. Positive- and negative potentials are 
coloured blue and red, respectively. It is 
hypothesised that the major negatively charged 
surface at the centre of botrocetin interacts with 
positive charges on A1. 
 
 
Ristocetin 
 
Ristocetin-A belongs to the glycopeptide antibiotics. It contains a poly-tyrosine backbone in 
which the aromatic rings are linked to each other via ether bonds. It also contains several glycan 
residues (figure 8) 174. The glycan residues are probably essential for the activation of A1, because 
removal of rhamnose residues results in an inactive form of ristocetin 175. 
The ristocetin-binding site on A1 is different from the botrocetin binding site 176. Based on 
peptide inhibition studies it has been suggested that residues Cys474-Pro488 in the N-terminal flanking 
peptide and residues Ser692-Pro708 in the C-terminal flanking peptide are involved in ristocetin 
binding 176; 201. A1 in which Pro702-703-704 were mutated could not be activated by ristocetin, 
suggesting that these residues are essential for ristocetin binding 94. In contrast to botrocetin, 
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ristocetin-induced vWF binding to GpIbα correlates with shear-induced binding 202. Ristocetin does 
not only bind to A1, but also interacts with GpIbα, see above. 
 
 
 
 
 
 
 
 
 
Figure 8: Strucutre of A1 activator ristocetin. Ristocetin is a glycopeptidic 
antibioticum and is homologous to vancomycin. Most likely a ristocetin 
dimer binds to specific sequences within the N- and C-terminal flanking 
peptides at the bottom of A1 via its modified tyrosine backbone. There is 
some evidence that ristocetin also may bind to the N-terminal part of GpIbα. 
(adapted from J.P. Scott et al. 174) 
 
 
Malfunction of the Von Willebrand Factor–GpIb axis 
 
Von Willebrand Disease (vWD) is the most common inherited bleeding disorder and can be 
divided in three different subtypes 101. 
 
• Type I vWD refers to a partial quantitative deficiency of vWF. 
• Type II vWD refers to a qualitative deficiency of vWF. 
• Type III  vWD refers to a total quantitative deficiency of vWF. 
 
Type II vWD is divided in four subtypes. 
• Type II A refers to a decreased platelet-dependent function, associated with absence of high 
molecular weight (HMW) multimers. 
• Type IIB refers to an increased GpIbα affinity and are so-called gain-of-function mutations. 
• Type IIM refers to a decreased GpIbα affinity, without absence of HMW and are so-called 
loss-of-function mutations. 
• Type IIN refers to a decreased affinity for factor VIII. 
 
An extensive database with all known mutations in the vWF gene available on the World-
Wide-Web, http://www.shef.ac.uk/vwf/. A summary of vWD type IIB and 2M mutations, both found 
in patients and identified by site directed mutagenesis, is given in appendix I. 
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Type 2B mutations are scattered throughout the A1 domain and its N- and C-terminal 
flanking peptides. In the three dimensional structure of A1 these residues are spatially close together 
and are located in a region at the bottom of the domain (figure 3). It is hypothesized that amino acid 
residues susceptible for vWD type 2B mutations involve interactions with the N-terminal flanking 
peptide 84. In contrast, type 2B mutation I546V induces a conformational change in hair-pin β2-β3 as 
has been shown in a crystallographic study 203.  
 
Type 2M mutations scatter over the domain (figure 3). Several residues are buried and are 
essential for the conformation of the A1 domain. Mutation of these residues most likely results in a 
missfolded domain that is not capable to bind to GpIbα. Other residues causing type 2M vWD are 
solvent exposed.  
 
Other bleeding disorders affecting the vWF-GpIbα axis occur in the GpIb-IX-V complex and 
are platelet-type vWD (gain-of-function) 204, that consernce mutations in the first loop of the GpIbα 
C-terminal flanking sequence, and Bernard-Soulier syndrome mutations 205 (loss-of-function) (Table 
III). 
 
 
Scope of the Thesis 
 
 Von Willebrand Factor is essential for platelet adhesion and thrombus formation. Mechanisms 
at a molecular level involved in this process are only partially understood. Therefore we conducted 
several studies in which we investigated i) the binding of the vWF-A3 domain to collagen, ii) the 
complex formation of the A1 domain with its platelet receptor GpIbα and iii) conformational changes 
that activate the vWF-A1 domain. 
 Chapters two and three describe the identification of the collagen-binding site in the vWF-
A3 domain using a combination of protein crystallography and site-directed mutagenesis. We have 
identified the collagen-binding site at the front face of A3. 
 Chapter four concerns mutation Ser968Thr in the A3 domain that has been found in a patient. 
The effect of the mutation on collagen binding and platelet adhesion has been studied and the crystal 
structure of Ser968Thr-A3 has been solved. We suggest that the collagen-binding site of the vWF-A3 
domain undergoes a conformational change upon collagen binding. 
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 Chapter five describes the complex of the vWF-A1 domain with platelet receptor GpIbα. The 
structure explains at a molecular level the effect of vWD type 2B and 2M mutations that have been 
identified in patients. The results of this study may be of great interest in the development of anti-
arterial thrombotic drugs. 
 Chapter six was conducted to identify conformational changes in the vWF-A1 domain that 
result in vWF to GpIbα binding. Six crystal structures of wt-A1 and gain-of-function mutant 
Arg543Gln-A1 were solved and compared to A1 in the A1•GpIbα complex. The structures suggest 
that the N and C-terminal flanking peptides shield the GpIbα binding site on A1. Shear stress or gain-
of-function mutations change the conformation of the peptides that results in GpIbα binding.  
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APPENDIX I 
Effect of mutations in the vWF-A1 domain and flanking peptides in GpIbα binding 
Mutation(s)1,2 and Type RIPA3,4 vWF:RCo3,5 Botrocetin aggregatie3,6 
Botrocetin 
binding3,7 SIPA
3,8 Shear 
adhesion3,9 
Heparin 
binding3,10 Reference 
463-465 (2A) (S)  normal  normal norrmal    206 
472-476 (2A) (S)  normal  normal normal    206 
D486A (S)  normal  normal normal    206 
497-498-501-3A (S) 2B increased  normal normal    206 
P503L 2B Requires less risto reduced      207; 208 
H505D 2B requires less risto, increased  
• requires less botro 
• partial increased 
• normal 
normal    208; 209 
505-506-2A (S) 2B increased  normal normal    206 
C509G (S) 2B 2A 
• normal 
• spontaneous   not active    
210; 211 
C509R (S) 2B 2A 
• strong reduced 
• normal 
• spontaneous 
  not active   partial reduced 
210 211-213 
C509,695A (S) 2M Strong red.       88 
C509,695S (S) 2M not active       89 
R511A (S) 2B increased  normal normal    206 
L513P 2M        208 
D514A (Ab) (S) 2M not active  not active not active    206 
V516I 2M reduced in plasma reduced in plasma      
214 
L519R 2M reduced in plasma reduced in plasma      
214 
D520A (S) (Ab) 2M        199 
520-524(2A) (S) (Ab) 2M not active  normal normal    206 
S522F 2M reduced in plasma reduced in plasma      
214 
R524S (S) 2M reduced     not active  215 
R524A (S)  • normal 
• partial reduced  normal reduced   normal 
199; 216 
S526R (S) 2M reduced     not active  215 
E527A (S)  normal  normal normal    206 
527-531(2A) (S) 2M not active  normal normal    206 
E529A (S)  normal  normal normal    199 
E531A (S) 2M reduced  normal normal    199 
L533P 2M reduced in plasma reduced in plasma      
214 
K534A (S) 2M • reduced 
• not active  normal 
partial 
reduced   normal 
206; 216 
D539G 2M reduced in plasma reduced in plasma      
214 
539-542-543 (3A) (S) 2B increased  normal normal    206 
M540MM 2B 
• requires less 
risto., 
• normal 
• spontaneous 
 Normal partial reduced increased   
217 208; 212; 
218 
R543L 2B spontaneous       219 
General introduction on vWF 
 22
Mutation(s) and Type RIPA vWF:RCo Botrocetin aggregatie 
Botrocetin 
binding SIPA 
Shear 
adhesion 
Heparin 
binding Reference 
R543Q 2B 
• spontaneous 
• reduced 
• requires less risto 
reduced in 
plasma spontaan, normal   normal normal 
208; 213; 220-
222 
R543W 2B 
• Requires less 
ristocetin 
• spontaneous 
 • spontaneous 
• increased   reduced normal 
201; 208; 213; 
220; 222-227 
R543C 2B 2A        
208 
R545P 2B 
• spontaneous 
• increased 
• requires less risto 
 normal    normal 208; 213; 220 
R545C 2B Requires less risto reduced (pl), normal (rec.) normal    
• normal 
• reduced 
228 220; 224-
226; 229 
R545A (S) 2B • extra strong 
• spontaneous  
• extra strong 
• requires less botro normal    
206 
I546V 2B • Requires less risto 
• norm normal      
208; 224; 230 
I546V/G561S 2M      not active  203 
S547F 2B increased reduced      231 
K549A (S) 2B • Normal 
• requires less risto  
• normal 
• requires less botro 
partial 
reduced   normal 
199; 216 
 
K549-552(2A) (Ab) (S) 2M not active  not active     
206 
W550C 2B • spontaneous 
• requires less rist        
232 
V551F 2B • spontaneous 
• requires less risto.  reduced Norm.  increased  reduced 
213; 217; 225 
V551D 2B        unpublished 
V551L 2B spontaan, req.less rist       
225; 227 
R552C 2M 2A       
strong 
reduced 
213; 233 
R552A (S) (Ab) 2A        199 
R552A 2A strong reduced  reduced    reduced 216 
V553M 2B 
• spontaneous 
• requires less risto 
• partial reduced 
plasma 
reduced in 
plasma 
• normal 
• increased    normal 
201; 208; 213; 
217; 221; 224-
226; 234-236 
E557Q (S) 2M reduced     • reduced 
• not active  
203; 215 
557-559-560-563 (4A) 
(S)  normal  normal normal    
206 
D560S (S) 2M reduced     reduced  215 
H559F 2M      not active  203 
D560R (S) 2M partial reduced     not active  203; 215 
G561S 2M strong reduced  normal    normal 237 213; 238 
G561A 2M strong reduced  Norm  Strong reduced   
208; 217; 239 
G561S (S) 2M Normal     not active  215; 240 
I662F 2M        208 
H563T (S) 2M Norman     not active  215 
Y565A (S) 2M      not active  203; 240 
569KDRKR573(3A) (s) 2M • strong reduced 
• reduced  normal reduced   normal 
206; 216 
569-570-571-572-573 
(5A)        normal 
241 
K569A (S)  normal  reduced normal    199 
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Mutation(s)1,2 and Type RIPA3,4 vWF:RCo3,5 Botrocetin aggregatie3,6 
Botrocetin 
binding3,7 SIPA
3,8 Shear 
adhesion3,9 
Heparin 
binding3,10 Reference 
D570A (S)  normal  normal normal    199 
R571A (S) 2M not active  normal normal    199 
571-578 (6A)        strong reduced 
241 
K572A (S) 2M reduced  normal normal  not active  199; 203 
A572T 2M        A 
R573A (S)  normal  normal normal    199 
P574L 2B • not spontaneous 
• requires less risto       
208; 234; 242 
576-578-579 (3A) (S) 2B increased  normal normal    206 
R578L 2B 
• spontaneous 
• increased 
• requires less risto 
 • spontaneous 
• normal    normal 
208; 220 
R578Q 2B 
• spontaneous 
• requires less risto, 
• reduced in plasma 
• normal 
• increased 
reduced in 
plasma Normal    normal 
208; 213; 217; 
220; 224-226; 
235; 243 
R578W 2B        233 
R578P 2B        …… 
Q583R (S) 2M reduced     strong reduced  
215 
K585E (S) 2M reduced     strong reduced  
215 
K585A (S)  normal  normal normal  normal  203; 206 
Q590R 2M partial reduced     normal  215 
T594S/E596A (S) 2M normal     not active  215 
596-599 (2A) (S) 2M not active  reduced normal    206 
E596K 2M   Norm.  Strong red.  normal 208; 213; 217 
E596A (S) 2M not active  partial reduced normal  strong reduced  
199; 203; 240 
K599A (S) 2M not active  not active normal  not active  199; 203; 240 
K599T 2M not active       unpublished 
Q604R (S) 2M normal     not active  215 
F606I 2M reduced  normal     244 
S607R (S) 2M normal     not active  215 
K608A (S)  normal  normal reduced    199 
608-610-611(3A) (Ab) 
(S) 2M not active  not active not active    
206 
D610A (S) 2M normal  normal normal    199 
R611A (S) (Ab) 2M        199 
R611L 2M       partial reduced 
208; 213 
          
R611H 2M /2a reduced  reduced  reduced   
208; 217 
R611H 2B /2a reduced 
strong 
reduced     reduced 
213; 245-247 
R611C 2B /2a 
• reduced 
• no effect of risto 
strong 
reduced     reduced 
213; 246; 247 
  •         
General introduction on vWF 
 24
Mutation(s)1,2 and Type RIPA3,4 vWF:RCo3,5 Botrocetin aggregatie3,6 
Botrocetin 
binding3,7 SIPA
3,8 Shear 
adhesion3,9 
Heparin 
binding3,10 Reference 
R611C 2M /2a        
208 
E613A (S) 2M not active  normal normal    199 
613-616(2A) (S) (Ab) 2M not active  not active not active    206 
R616A (S) 2M not active  normal reduced    199 
E626A (S) 2M not active  normal bit reduced    199; 206 
Q628R 2M Norm. actief     strong reduced  
215 
629-639∆  2M not active  not active    not active 248 
R629,632,636A (S) 2M      reduced  240 
R629,632A (S) (Ab) 2M not active  not active not active    206 
R629A (S) 2M not active  reduced reduced  partial reduced  
199; 240 
R629E (S)  reduced     normal  215 
R632A (S)       normal  203; 240 
R632A (S) (Ab) 2M not active  not active not active    206 
R636A (S)  normal  strong reduced reduced  normal  199; 206; 240 
Y637F (S) 2M      reduced  240 
K642A (S) 2M not active  normal normal    199 
642-645∆K (S) 2M Strong reduced  normal    reduced 216 
642-643-644-645 (4A) 
(S) 2M not active  reduced normal   
partial 
reduced 
206; 241 
K643A (S)  normal  normal normal    199 
K643,645A (S) 2M      Reduced  240 
K644A (S)  bit reduced  normal normal  normal  199; 203; 240 
K645A (S)  normal  normal normal    199 
H656A (S)  normal  normal normal  normal  199; 203; 240 
656-660 (2A) (S)  normal  normal normal    206 
H656E (S) 2M reduced     strong reduced  
215 
L659R (S) 2M reduced     reduced  215 
K660A (S)  normal  reduced reduced  normal  199; 240 
K660E (S) 2M reduced     strong reduced  
215 
K661A        normal 241 
I662F (S) 2M reduced  normal  strong reduced  normal 
208; 213; 217; 
244 
R663A (S)  normal  normal normal  normal  199; 240 
663-666-667 (3A) (S)  normal  reduced reduced    206 
R663A        normal 241 
E666A (S) 2M reduced  normal normal    199 
K667A (S)  normal  reduced reduced    199 
671-673 (2A) (S)  normal  normal normal    206 
A674T 2M        unpublished 
681-682-684 (3A) (S)  partial reduced  normal normal    206 
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Mutation(s)1,2 and Type RIPA3,4 vWF:RCo3,5 Botrocetin aggregatie3,6 
Botrocetin 
binding3,7 SIPA
3,8 Shear 
adhesion3,9 
Heparin 
binding3,10 Reference 
687-688-689 (3A) (S) 2B • extra strong 
• not apontaneous  increased normal    
206 
L694V 2B reduced  normal     201 
C695G (S) 2B 2A not active  not active not active    
210; 211 
696-700 (2A) (S)  normal  normal normal    206 
L697V 2B 
• requires less risto 
• increased 
• reduced  
reduced • normal 
• increased    normal 
201; 208; 213; 
217; 221; 249 
A698V 2B 
• spontaneous 
• requires less risto. 
• increased 
• normal 
normal partial ncreased     201; 208; 221 
A698D 2B requires less risto       unpublished 
A701V 2B • requires less risto. 
• increased  normal     
201 
P702-703-704R/D (S)  not active       94 
P704S 2M • asymptomatic in patients       
unpublishe
d 
L706V 2M reduced  normal     201 
D709A (S)  normal  normal normal    206 
reduced/alkylated  
• binds spontaneous 
to GpIb, 
• no effect of risto. 
 partial increased not active    87; 88; 96; 250 
 
1. (S) represents identified by scanning mutagenesis. 
2. (Ab) indicates that a monoclonal Ab reacts less well with the mutant, suggesting that the mutation (partially) 
unfolds the domain. 
3. Normal indicates an activity > 90 %, partial reduced between 75 % - 90 %, reduced between 25 % - 75 %, strong 
reduced indicates activity between 10 – 25 % and not active < 10 %. 
4. Ristocetin induced platelet aggregation. 
5. vWF ristocetin cofactor activity. 
6. Botrocetin induced platelet aggregation. 
7. Binding of botrocetin to vWF. 
8. Shear induced platelet aggregation. 
9. Adhesion of platelets to a surface in a perfusion system. 
10. Binding of vWF to heparin. 
 
General introduction on vWF 
 26
Reference List 
 
1.  Owen CA. A History of Blood Coagulation. In: Anonymous. Mayo Foundation for Medical education and 
Research; 2001. 
2.  Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand Factor. Biochemistry. 
1986;25:3171-3184. 
3.  Verweij CL, de Vries CJ, Distel B, et al. Construction of cDNA coding for human von Willebrand factor using 
antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res. 1985;13:4699-
4717. 
4.  Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 
1989;264:19514-19527. 
5.  Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by 
factor VIII-von Willebrand factor bound to the subendothelium. Nature. 1979;279:636-638. 
6.  Kehrel B. Platelet-collagen interactions. Thromb Haemost. 1995;21:123-129. 
7.  Rand JH, Glanville RW, Wu XX, et al. The significance of subendothelial von Willebrand factor. Thromb 
Haemost. 1997;78:445-450. 
8.  Mazzucato M, Spessotto P, Masotti A, et al. Identification of domains responsible for von Willebrand factor type 
VI collagen interaction mediating platelet adhesion under high flow. J Biol Chem. 1999;274:3033-3041. 
9.  Sixma JJ, van Zanten GH, Huizinga EG, et al. Platelet adhesion to collagen: An update. Thromb Haemost. 
1997;78:434-438. 
10.  Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor 
on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem. 1991;196:369-375. 
11.  Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet 
thrombus formation under flow. Cell. 1998;94:657-666. 
12.  Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von 
Willebrand factor. Cell. 1996;84:289-297. 
13.  Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand Factor domain A1 with 
platelet glycoprotein Ibα-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem. 
2000;275:7539-7546. 
14.  Brakebusch C, Bergmeier W, Schulte V, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet 
interaction with collagen. EMBO J. 2001;20:2120-2130. 
15.  Goto S, Ikeda Y, Saldívar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of 
different shearing flow conditions. J Clin Invest. 1998;101:479-486. 
16.  Mancuso DJ, Tuley EA, Westfield L.A., et al. Human von Willebrand Factor gene and pseudogene: structural 
analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253-269. 
17.  Nachman R, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin 
Invest. 1977;60:914-921. 
18.  Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. 
Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756. 
19.  Yamamoto K, De Waard V, Fearns C, Loskutoff DJ. Tissue distribution and regulation of murine von Willebrand 
factor gene expression in vivo. Blood. 1998;92:2791-2801. 
General introduction on vWF 
 27
20.  Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. 
21.  Marti T, Rosselet SJ, Titani K, Walsh KA. Identification of disulfide-bridged substructures within human von 
Willebrand factor. Biochemistry. 1987;26:8099-8109. 
22.  Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation 
of Weibel-Palade bodies. Blood. 1994;83:3536-3544. 
23.  Haberichter SL, Montgomery RR. von Willebrand factor storage and multimerization: 2 independent intracellular 
processes. Blood. 2000;96:1808-1815. 
24.  Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWF) cDNA in heterologous 
cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J. 1987;6:2885-2890. 
25.  Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH.  The propeptide of von Willebrand factor independently 
mediates the assembly of von Willebrand multimers. Cell 1988; 52, 229-236.  
26.  Preininger A, Schlokat U, Mohr G, et al. Strategies for recombinant Furin employment in a biotechnological 
process: complete target protein precursor cleavage. Cytotechnology. 1999;30:1-15. 
27.  Turecek PL, Pichler L, Auer W, et al. Evidence for extracellular processing of pro-von Willebrand factor after 
infusion in animals with and without severe von Willebrand disease. Blood. 1999;94:1637-1647. 
28.  Sadler JE. von Willebrand factor. J Biol Chem. 1991;266:22777-22780. 
29.  Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-46.:217-246. 
30.  Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of 
human endothelial cells. J Cell Biol. 1982;95:355-360. 
31.  Chen CI, Federici AB, Cramer EM, et al. Studies of multimerin in patients with von Willebrand disease and 
platelet von Willebrand factor deficiency. Br J Haematol. 1998;103:20-28. 
32.  Haberichter SL, Montgomery RR. Identification of amino acids in the von Willebrand Factor propeptide critical 
for storage of vWF [abstract]. Thrombosis and Haemostasis, Supplement. 2001. 
33.  Van Mourik JA, Boertjes RC, Huisveld IA, et al. von Willebrand factor propeptide in vascular disorders: a tool to 
distinguish between acute and chronic endothelian cell pertuberation. Blood. 1999;94:179-185. 
34.  Romeuf C, Mazurier C. Comparison between von Willebrand Factor (vWF) and vWF antigen II in normal 
individuals and patients with von Willebrand disease. Thromb Haemost. 1998;80:37-41. 
35.  Sodetz JM, Paulson JC, Mc Kee PA. Carbohydrate composition and identification of blood group A, B and H 
oligosaccharide structures on human factor VIII/von Willebrand factor. J Biol Chem. 1979;254:10154-10160. 
36.  De Romeuf C, Samor B, Mazurier C. Characterisation of von Willebrand factor antigen II in a therapeutic von 
Willebrand Factor concentrate [abstract]. Br J Haematol. 1996;93. 
37.  Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological 
approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977;1:869-872. 
38.  Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a 
highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5:1839-1847. 
39.  Voorberg J, Fontijn R, Van Mourik JA, Pannekoek H. Domains involved in multimer assembly of von willebrand 
factor (vWF): multimerization is independent of dimerization. EMBO J. 1990;9:797-803. 
40.  Dong Z, Thoma RS, Crimmins DL, McCourt DW, Tuley EA, Sadler JE. Disulfide bonds required to assemble 
functional von Willebrand factor multimers. J Biol Chem. 1994;269:6753-6758. 
General introduction on vWF 
 28
41.  Fujimura Y, Titani K, Holland LZ, et al. von Willebrand Factor: A reduced and alkylated 52/48-kDa fragment 
beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem. 
1986;261:381-385. 
42.  Katsumi A, Tuley EA, Sadler JE, Sadler JE. localisation of disulfide bonds in the cysteine knot domain of human 
von Willebrand factor. J Biol Chem. 2000;275:25585-25594. 
43.  Kaufman RJ, Dorner AJ, Fass DN. von Willebrand factor elevates plasma factor VIII without induction of factor 
VIII messenger RNA in the liver. Blood. 1999;93:193-197. 
44.  Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the 
amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262:8443-8446. 
45.  Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Anderson LO, Meyer D. Localisation of a factor VIII binding 
domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand Factor. Blood. 1987;70:1679-
1682. 
46.  Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on 
activation of factor VIII by factor Xa. Eur J Biochem. 1990;189:229-234. 
47.  Bendetowicz AV, Wise RJ, Gilbert GE. Collagen-bound von Willebrand factor has reduced affinity for factor VIII. 
J Biol Chem. 1999;274:12300-12307. 
48.  Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for 
monomeric type III collagen. Biochemistry. 1986;25:8357-8361. 
49.  Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J. von Willebrand factor binds to native 
collagen VI primarily via its A1 domain. Biochem J. 1997;324:185-191. 
50.  Fujimura Y, Titani K, Holland LZ, et al. A heparin-binding domain of human von Willebrand factor. J Biol Chem. 
1987;262:1734-1739. 
51.  Christophe O, Obert B, Meyer D, Girma J-P. The binding domain of von Willebrand factor to sulfatides is distinct 
from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 
512 and Lys 673. Blood. 1991;78:2310-2317. 
52.  Data RE, Williams SB, Roberts DD, Gralnick HR. Platelets adhere to sulfatides by von willebrand factor 
dependent and independent mechanisms. Thromb Haemost. 1991;65:581-587. 
53.  Koivunen E, Ranta TM, Annila A, et al. Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-
leucine-glycine motif-containing peptides. J Cell Biol. 2001;153:905-916. 
54.  Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-
cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol 
Chem. 2001;276:41059-41063. 
55.  Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of von Willebrand factor 
with collagen type III. Thromb Haemost. 1996;75:950-958. 
56.  Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000;275:21785-
21788. 
57.  Fischer BE, Kramer G, Mitterer A, et al. Effect of multimerization of human and recombinant von Willebrand 
factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res. 
1996;84:55-66. 
58.  De Romeuf C, Mazurier C. Heparin binding assay of von willebrand factor (vWF) in plasma milieu - evidence of 
the importance of the mulktimerisation degree of vWF. Thromb Haemost. 1993;69:436-440. 
General introduction on vWF 
 29
59.  Van der Plas RM, Gomes L, Marquart JA, et al. Binding of von Willebrand Factor to Collagen type III: Role of 
specific amino acids in the collagen binding domain of vWF and effects of neighbouring domains. Thromb 
Haemost. 2000;84:1005-1011. 
60.  Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand Factor (vWF) with collagen. J 
Biol Chem. 1995;270:10822-10827. 
61.  Colombatti A, Bonaldo P, Doliana R. Type A Modules: Interacting domains found in several non-fibrillar 
collagens and in other extracellular matrix proteins. Matrix. 1993;13:297-306. 
62.  van Zanten GH, Saelman EUM, Schut-Hese KM, et al. Platelet adhesion to collagen type IV under flow 
conditions. Blood. 1996;88:3862-3871. 
63.  Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting 
with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol 
Chem. 1989;264:17361-17367. 
64.  Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J. von Willebrand factor binds to native 
collagen VI primarily via its A1 domain. Biochem J. 1997;324:185-191. 
65.  Fujimura Y, Holland LZ, Ruggeri ZM, Zimmerman TS. The von willebrand factor domain-mediating botrocetin-
induced binding to glycoprotein IB lies between Val449 and Lys728. Blood. 1987;70:985-988. 
66.  Hoylaerts MF, Nuyts K, Peerlinck K, Deckmyn H, Vermylen J. Promotion of binding of von Willebrand factor to 
platelet glycoprotein Ib by dimers of ristocetin. Biochem J. 1995;306:453-463. 
67.  Verkleij MW, Morton LF, Knight CG, de-Groot PG, Barnes MJ, Sixma JJ. Simple collagen-like peptides support 
platelet adhesion under static but not under flow conditions: Interaction via αβ1 and von Willebrand factor with 
specific sequences in native collagen is a requirement to resist shear forces. Blood. 1998;91:3808-3816. 
68.  Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic 
thrombocytopenic purpura. Nature. 2001;413:488-494. 
69.  Obert B, Houllier A, Meyer D, Girma JP. Conformational changes in the A3 domain of von Willebrand factor 
modulate the interaction of the A1 domain with platelet glycoprotein Ib. Blood. 1999;93:1959-1968. 
70.  Rich RL, Deivanayagam CCS, Owens RT, et al. Trench-shaped binding sites promote multiple classes of 
interactions between collagen and the adherence receptors, α1β1 integrin and Staphylococcus aureus Cna 
MSCRAMM. J Biol Chem. 1999;274:24906-24913. 
71.  Kamata T, Liddington RC, Takada Y. Interaction between collagen and the α2 I-domain of integrin α2β1 - Critical 
role of conserved residues in the metal ion-dependent adhesion site (MIDAS) region. J Biol Chem. 
1999;274:32108-32111. 
72.  Estavillo D, Ritchie A, Diacovo TG, Cruz MA. Functional analysis of a recombinant glycoprotein Ia/IIa (integrin 
a2b1) I domain that inhibits platelet adhesion to collagen and endothelial matrix under flow conditions. J Biol 
Chem. 1999;274:35921-35926. 
73.  Ivaska J, Kapyla J, Pentikäinen O, et al. A peptide inhibiting the collagen binding function of integrin α2 I domain. 
J Biol Chem. 1999;274:3513-3521. 
74.  Smith C, Estavillo D, Emsley J, Bankston LA, Liddington RC, Cruz MA. Mapping the collagen-binding site in the 
I domain of the glycoprotein Ia/IIa (integrin α2β1). J Biol Chem. 2000;275:4205-4209. 
75.  Emsley J, King SL, Bergelson JM, Liddington RC. Crystal structure of the I domain from integrin α2β1. J Biol 
Chem. 1997;272:28512-28517. 
76.  Camper L, Hellman U, Lundgren-Åkerlund E. Isolation, cloning and sequence analysis of the integrin subunit 
alpha10, a beta1-associated collagen binding integrin expressed on chondrocytes. J Biol Chem. 1998;273:20383-
20389. 
General introduction on vWF 
 30
77.  Velling T, Kusche-Gullberg M, Sejersen T, Gullberg D. cDNA cloning and chromosomal localization of human 
α11 integrin - A collagen-binding, I domain-containing, β1-associated integrin α-chain present in muscle tissues. J 
Biol Chem. 1999;274:25735-25742. 
78.  Vieren van der M, Crowe DT, Hoekstra D, et al. The leukocyte integrin alpha D beta 2 binds VCAM-1: evidence 
for a binding interface between I domain and VCAM-1. J Immunol. 1999;163:1984-1990. 
79.  Qu A, Leahy DJ. Crystal structure of the I-domain from the CD11a/CD18 (LFA-1,αLβ2 integrin. Proc Natl Acad 
Sci U S A. 1995;92:10277-10281. 
80.  AnonymousCharacteristics of cation binding to the I domains of LFA-1 and MAC-1. J Biol Chem. 
1998;273:22113-22119. 
81.  Anonymousa novel divalent cation-binding site in the A domain of the β2 integrin CR3 (CD11b/CD18) is essential 
for ligand binding. Cell. 1993;72:857-867. 
82.  Lee JO, Rieu P, Arnaout MA, Liddington RC. Crystal structure of the A domain from the α subunit of integrin 
CR3 (CD11/CD18). Cell. 1995;80:631-638. 
83.  Celikel R, Varughese KI, Madhusudan, Yoshioka A, Ware J, Ruggeri ZM. Crystal structure of the von Willebrand 
factor A1 domain in complex with the function blocking NMC-4 Fab. Nature Struct Biol. 1998;5:189-194. 
84.  Emsley J, Cruz M, Handin R, Liddington RC. Crystal structure of the von Willebrand factor A1 domain and 
implications for the binding of platelet glycoprotein Ib. J Biol Chem. 1998;273:10396-10401. 
85.  Matsui T, Hamako J, Matsushita T, Nakayama T, Fujimura Y, Titani K. Binding site on human von Willebrand 
factor of bitiscetin, a snake venom-derived platelet aggregation inducer. Biochemistry. 2002;41:7939-7946. 
86.  Baruch D, Ajzenberg N, Denis C, Legendre P, Lormeau JC, Meyer D. Binding of heparins fractions to von 
Willebrand Factor: Effect of molecular weight and affinity for antithrombin III. Thromb Haemost. 1994;71:141-
146. 
87.  Miura S, Fujimura Y, Sugimoto M, et al. Structural elements influencing von Willebrand factor (vWF) binding 
affinity for platelet glycoprotein Ib within a dispase- digested vWF fragment. Blood. 1994;84:1553-1558. 
88.  Azuma H, Hayashi T, Dent JA, Ruggeri ZM, Ware J. Disulfide bond requirements for assembly of the platelet 
glycoprotein Ib-binding domain of von Willebrand factor. J Biol Chem. 1993;268:2821-2827. 
89.  Cruz MA, Handin RI, Wise RJ. The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein 
Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. J Biol 
Chem. 1993;268:21238-21245. 
90.  Miyata S, Ruggeri ZM. Distinct structural attributes regulating von Willebrand factor A1 domain interaction with 
platelet glycoprotein Ibα under flow. J Biol Chem. 1999;274:6586-6593. 
91.  Nakayama T, Matsushita T, Dong Z, et al. Identification of the regulatory elements of human von Willebrand 
factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by CYS509-CYS695 
disulfide bond. J Biol Chem. 2002. 
92.  Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-Linked carbohydrate of recombinant von Willebrand factor 
influences ristocetin-induced binding to platelet Glycoprotein Ib. J Clin Invest. 1992;90:2258-2267. 
93.  De Marco L, Girolami A, Russell S, Ruggeri ZM. Interaction of asialo-von Willebrand factor with glycoprotein Ib 
induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest. 
1985;75:1198-1203. 
94.  Azuma H, Sugimoto M, Ruggeri ZM, Ware J. A role for von Willebrand factor proline residues 702-704 in 
ristocetin-mediated binding to platelet glycoprotein Ib. Thromb Haemost. 1993;69:192-196. 
General introduction on vWF 
 31
95.  Azuma H, Dent JA, Sugimoto M, Ruggeri ZM, Ware J. Independent assembly and secretion of a dimeric adhesive 
domain of von Willebrand factor containing the glycoprotein Ib-binding site. J Biol Chem. 1991;266:12342-12347. 
96.  Sugimoto M, Dent J, McClintock R, Ware J, Ruggeri ZM. Analysis of structure-function relationships in the 
platelet membrane glycoprotein Ib-binding domain of von Willebrand's factor by expression of deletion mutants. J 
Biol Chem. 1993;268:12185-12192. 
97.  Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-
cleaving protease. Blood. 2001;98:1654-1661. 
98.  Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. Cloning, expression analysis, and 
structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and 
thrombospondin-1 domains. Gene. 2002;283:49-62. 
99.  Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma 
cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234. 
100.  Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation 
and requires calcium ion. Blood. 1996;87:4235-4244. 
101.  Sadler JE. a revised classification of von willebrand desease. Thromb Haemost. 1994;71:520-525. 
102.  Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. 
Blood. 1994;83:2171-2179. 
103.  Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single 
episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998;57:293-302. 
104.  Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen. 
Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides 
[published erratum appears in J Biol Chem 1995 Aug 18;270(33):19668]. J Biol Chem. 1995;270:10822-10827. 
105.  Huizinga EG, Van der Plas RM, Kroon J, Sixma JJ, Gros P. Crystal structure of the A3 domain of human von 
Willebrand factor: implications for collagen binding. Structure. 1997;5:1147-1156. 
106.  Bienkowska J, Cruz MA, Atiemo A, Handin RI, Liddington R. The von Willebrand Factor A3 domain does not 
contain a metal ion-dependent adhesion site motif. J Biol Chem. 1997;272:25162-25167. 
107.  Lee JO, Bankston LA, Arnout MA, Liddington RC. Two conformations of the integrin A domain (I domain): A 
pathway for activation? Structure. 1995;3:1333-1340. 
108.  Dickeson SK, Walsh JJ, Santoro SA. contributions of the I and EF hand domains to the divalent cation-dependent 
collagen binding activity of the α2β1 integrin. J Biol Chem. 1997;227:7661-7668. 
109.  Tuckwell DS, Calderwood DA, Green LJ, Humphries MJ. Integrin α2 I-domain is a binding site for collagens. J 
Cell Sci. 1995;108:1629-1637. 
110.  Tulla M, Pentikainen OT, Viitasalo T, et al. Selective binding of collagen subtypes by integrin alpha 1I, alpha 2I, 
and alpha 10I domains. J Biol Chem. 2001;276:48206-48212. 
111.  Pietu G, Fressinaud E, Girma JP, Nieuwenhuis HK, Rothschild C, Meyer D. Binding of human von Willebrand 
factor to collagen and to collagen- stimulated platelets. J Lab Clin Med. 1987;109:637-646. 
112.  Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by 
integrin α2β1. Cell. 2000;100:47-56. 
113.  Dickeson SK, Mathis NL, Rahman M, Bergelson JM, Santoro SA. Determinants of ligand binding specificity of 
the α1β1 and α2β1 integrins. J Biol Chem. 1999;274:32182-32191. 
General introduction on vWF 
 32
114.  Cruz MA, Bienkowska J, Mato A., Liddington R, Handin RI. Identification of the collagen binding site in the 
vWF-A3 domain by molecular structure and site specific mutagenesis [abstract]. Blood. 1997;Supplement I:23a. 
115.  Verkleij MW, IJsseldijk MJW, Heijnen-Snyder GJ, et al. Adhesive domains in the collagen III fragment 
α1(III)CB4 that support α2β1-and von Willebrand factor-mediated platelet adhesion under flow conditions. 
Thromb Haemost. 1999;82:1137-1144. 
116.  Beumer S, Heijnen HFG, IJsseldijk MJW, Orlando E, de Groot PG, Sixma JJ. Platelet adhesion to fibronectin in 
flow: The importance of von Willebrand factor and glycoprotein Ib. Blood. 1995;86:3452-3460. 
117.  Ware J. Molecular analyses of the platelet glycoprotein Ib-IX-V receptor. Thromb Haemost. 1998;79:466-478. 
118.  Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V 
complex. Thromb Haemost. 2001;86:178-188. 
119.  Kenny D, Morateck PA, Montgomery RR. The cysteine knot of platelet glycoprotein Ibbeta (GPIbbeta) is critical 
for the interaction of GPIbbeta with GPIX. Blood. 2002;99:4428-4433. 
120.  Munday AD, Berndt MC, Mitchell CA. Phosphoinositide 3-kinase forms a complex with platelet membrane 
glycoprotein Ib-IX-V complex and 14-3-3zeta. Blood. 2000;96:577-584. 
121.  Andrews RK, Berndt MC. Adhesion-dependent signalling and the initiation of haemostasis and thrombosis. Histol 
Histopathol. 1998;13:837-844. 
122.  Kovacsovics TJ, Bachelot C, Toker A, et al. Phosphoinositide 3-kinase inhibition spares actin assembly in 
activating platelets but reverses platelet aggregation. J Biol Chem. 1995;270:11358-11366. 
123.  Lopez JA, Leung B, Reynolds CC, Li CQ, Fox JE. Efficient plasma membrane expression of a functional platelet 
glycoprotein Ib-IX complex requires the presence of its three subunits. J Biol Chem. 1992;267:12851-12859. 
124.  Poujol C, Ware J, Nurden AT, Nurden P. Absence of GPIbalpha is responsible for aberrant membrane 
development during megakaryocyte maturation. Ultrastructural study using a transgenic model. Exp Hematol. 
2002;30:352-360. 
125.  Fredrickson BJ, Dong JF, McIntire LV, López JA. Shear-dependent rolling on von Willebrand factor of 
mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood. 1998;92:3684-3693. 
126.  Moog S, Mangin P, Lenain N, et al. Platelet glycoprotein V binds to collagen and participates in platelet adhesion 
and aggregation. Blood. 2001;98:1038-1046. 
127.  Shen Y, Romo GM, Dong JF, et al. Requirement of leucine-rich repeats of glycoprotein (GP) Ibα for shear-
dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. Blood. 
2000;95:903-910. 
128.  Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol. 2001;11:725-
732. 
129.  Whisstock JC, Shen Y, Lopez JA, Andrews RK, Berndt MC. Molecular modeling of the seven tandem leucine-rich 
repeats within the ligand-binding region of platelet glycoprotein Ibα. Thromb Haemost. 2002;87:329-333. 
130.  Shen Y, Dong JF, Romo G, et al. Functional analysis of the C-terminal flanking sequence of platelet glycoprotein 
Ibα  using canine-human chimers. Blood. 2002;99:145-150. 
131.  Tait AS, Dong JF, Lopez JA, Dawes IW, Chong BH. Site-directed mutagenesis of platelet glycoprotein Ibalpha 
demonstrating residues involved in the sulfation of tyrosines 276, 278, and 279. Blood. 2002;99:4422-4427. 
132.  Marchese P, Murata M, Mazzucato M, et al. Identification of three tyrosine residues of glycoprotein Ibα with 
distinct roles in von Willebrand factor and α-thrombin binding. J Biol Chem. 1995;270:9571-9578. 
General introduction on vWF 
 33
133.  Dong J, Ye P, Schade AJ, et al. Tyrosine sulfation of glycoprotein I(b)alpha. Role of electrostatic interactions in 
von Willebrand factor binding. J Biol Chem. 2001;276:16690-16694. 
134.  Murata M, Ware J, Ruggeri ZM. Site-directed mutagenesis of a soluble recombinant fragment of platelet 
glycoprotein Ibα demonstrating negatively charged residues involved in von Willebrand factor binding. J Biol 
Chem. 1991;266:15474-15480. 
135.  Li C, Pasquale DN, Roth GJ. Bernard-Soulier syndrome with severe bleeding: absent platelet glycoprotein Ib alpha 
due to a homozygous one-base deletion. Thromb Haemost. 1996;76:670-674. 
136.  Afshar-Kharghan V, Craig FE, Lopez JA. Bernard-Soulier syndrome in a patient doubly heterozygous for two 
frameshift mutations in the glycoprotein ib alpha gene. Br J Haematol. 2000;110:919-924. 
137.  Miller JL, Lyle VA, Cunningham D. Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha 
leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. Blood. 
1992;79:439-446. 
138.  Kenny D, Jonsson OG, Morateck PA, Montgomery RR. Naturally occurring mutations in glycoprotein Ibalpha that 
result in defective ligand binding and synthesis of a truncated protein. Blood. 1998;92:175-183. 
139.  Simsek S, Admiraal LG, Modderman PW, van der Schoot CE, dem Borne AE. Identification of a homozygous 
single base pair deletion in the gene coding for the human platelet glycoprotein Ib alpha causing Bernard- Soulier 
syndrome. Thromb Haemost. 1994;72:444-449. 
140.  Kenny D, Morateck PA, Gill JC, Montgomery RR. The critical interaction of glycoprotein (GP) 1bβ with GPIX - 
A genetic cause of Bernard-Soulier syndrome. Blood. 1999;93:2968-2975. 
141.  Li C, Martin SE, Roth GJ. The genetic defect in two well-studied cases of Bernard-Soulier syndrome: a point 
mutation in the fifth leucine-rich repeat of platelet glycoprotein Ib alpha. Blood. 1995;86:3805-3814. 
142.  Ware J, Russell SR, Marchese P, et al. Point mutation in a leucine-rich repeat of platelet glycoprotein Ibα resulting 
in the Bernard-Soulier syndrome. J Clin Invest. 1993;92:1213-1220. 
143.  de la Salle C, Baas MJ, Lanza F, et al. A three-base deletion removing a leucine residue in a leucine- rich repeat of 
platelet glycoprotein Ib alpha associated with a variant of Bernard-Soulier syndrome (Nancy I). Br J Haematol. 
1995;89:386-396. 
144.  Simsek S, Noris P, Lozano M, et al. Cys209 Ser mutation in the platelet membrane glycoprotein Ib alpha gene is 
associated with Bernard-Soulier syndrome. Br J Haematol. 1994;88:839-844. 
145.  Dong J, Schade AJ, Romo GM, et al. Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine 
mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol 
Chem. 2000;275:27663-27670. 
146.  Kanaji T, Okamura T, Kuroiwa M, et al. Molecular and genetic analysis of two patients with Bernard- Soulier 
syndrome - Identification of new mutations in glycoprotein Ibα gene. Thromb Haemost. 1997;77:1055-1061. 
147.  Ware J, Russell SR, Vicente V, et al. Nonsense mutation in the glycoprotein Ibα coding sequence associated with 
Bernard-Soulier syndrome. Proc Natl Acad Sci USA. 1990;87:2026-2030. 
148.  Kunishima S, Miura H, Fukutani H, et al. Bernard-Soulier syndrome Kagoshima: Ser 444-->stop mutation of 
glycoprotein (GP) Ib alpha resulting in circulating truncated GPIb alpha and surface expression of GPIb beta and 
GPIX. Blood. 1994;84:3356-3362. 
149.  Noda M, Fujimura K, Takafuta T, et al. Heterogeneous expression of glycoprotein Ib, IX and V in platelets from 
two patients with Bernard-Soulier syndrome caused by different genetic abnormalities. Thromb Haemost. 
1995;74:1411-1415. 
General introduction on vWF 
 34
150.  Kenny D, Newman PJ, Morateck PA, Montgomery RR. A dinucleotide deletion results in defective membrane 
anchoring and circulating soluble glycoprotein Ibα in a novel form of Bernard-Soulier syndrome. Blood. 
1997;90:2626-2633. 
151.  Afshar-Kharghan V, López JA. Bernard-Soulier syndrome caused by a dinucleotide deletion and reading 
frameshift in the region encoding the glycoprotein Ibα transmembrane domain. Blood. 1997;90:2634-2643. 
152.  Holmberg L, Karpman D, Nilsson I, Olofsson T. Bernard-Soulier syndrome Karlstad: Trp 498-->Stop mutation 
resulting in a truncated glycoprotein Ibα that contains part of the transmembramous domain. Br J Haematol. 
1997;98:57-63. 
153.  Ludlow LB, Schick BP, Budarf ML, et al. Identification of a mutation in a GATA binding site of the platelet 
glycoprotein Ibβ promoter resulting in the Bernard- Soulier Syndrome. J Biol Chem. 1996;271:22076-22080. 
154.  Budarf ML, Konkle BA, Ludlow LB, et al. Identification of a patient with Bernard-Soulier syndrome and a 
deletion in the DiGeorge/velo-cardio-facial chromosomal region in 22q11.2. Hum Mol Genet. 1995;4:763-766. 
155.  Ludlow LB, Schick BP, Budarf ML, et al. Identification of a mutation in a GATA binding site of the platelet 
glycoprotein Ibbeta promoter resulting in the Bernard-Soulier syndrome. J Biol Chem. 1996;271:22076-22080. 
156.  Kunishima S, Naoe T, Kamiya T, Saito H. Novel heterozygous missense mutation in the platelet glycoprotein Ib 
beta gene associated with isolated giant platelet disorder. Am J Hematol. 2001;68:249-255. 
157.  Kunishima S, Tomiyama Y, Honda S, et al. Homozygous Pro74-->Arg mutation in the platelet glycoprotein Ibbeta 
gene associated with Bernard-Soulier syndrome. Thromb Haemost. 2000;84:112-117. 
158.  Kunishima S, Lopez JA, Kobayashi S, et al. Missense mutations of the glycoprotein (GP) Ibβ gene impairing the 
GPIb α/β disulfide linkage in a family with giant platelet disorder. Blood. 1997;89:2404-2412. 
159.  Kurokawa Y, Ishida F, Kamijo T, et al. A missense mutation (tyr88 to cys) in the platelet membrane glycoprotein 
Ibbeta gene affects GPIb/IX complex expression--Bernard- Soulier syndrome in the homozygous form and giant 
platelets in the heterozygous form. Thromb Haemost. 2001;86:1249-1256. 
160.  Rivera CE, Villagra J, Riordan M, Williams S, Lindstrom KJ, Rick ME. Identification of a new mutation in 
platelet glycoprotein IX (GPIX) in a patient with Bernard-Soulier syndrome. Br J Haematol. 2001;112:105-108. 
161.  Wright SD, Michaelides K, Johnson DJ, West NC, Tuddenham EG. Double heterozygosity for mutations in the 
platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood. 1993;81:2339-2347. 
162.  Sae-Tung G, Dong JF, Lopez JA. Biosynthetic defect in platelet glycoprotein IX mutants associated with Bernard-
Soulier syndrome. Blood. 1996;87:1361-1367. 
163.  Dinesen B, Feddersen C. An enzyme immunoassay (ELISA) for the quantitation of human factor VIII coagulant 
antigen (VIII:CAg). Thromb Res. 1983;31:707-718. 
164.  Noris P, Arbustini E, Spedini P, Belletti S, Balduini CL. A new variant of Bernard-Soulier syndrome characterized 
by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV. Br J Haematol. 
1998;103:1004-1013. 
165.  Vanhoorelbeke K, Schlammadinger A, Delville JP, et al. Occurrence of the Asn45Ser mutation in the GPIX gene 
in a Belgian patient with Bernard Soulier syndrome. Platelets. 2001;12:114-120. 
166.  Noris P, Simsek S, Stibbe J, dem Borne AE. A phenylalanine-55 to serine amino-acid substitution in the human 
glycoprotein IX leucine-rich repeat is associated with Bernard-Soulier syndrome. Br J Haematol. 1997;97:312-320. 
167.  Noda M, Fujimura K, Takafuta T, et al. A point mutation in glycoprotein IX coding sequence (Cys73(TGT) to 
Tyr(TAT)) causes impaired surface expression of GPIb/IX/V complex in two families with Bernard-Soulier 
syndrome. Thromb Haemost. 1996;76:874-878. 
General introduction on vWF 
 35
168.  Wang Z, Shi J, Han Y. [A novel point mutation in the transmembrane domain of platelet glycoprotein IX gene 
identified in a Bernard-Soulier syndrome patient]. Zhonghua Xue Ye Xue Za Zhi. 2001;22:464-466. 
169.  Murata M, Russell SR, Ruggeri ZM, Ware J. Expression of the phenotypic abnormality of platelet-type von 
Willebrand disease in a recombinant glycoprotein Ib alpha fragment. J Clin Invest. 1993;91:2133-2137. 
170.  Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the alpha chain of platelet 
glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A. 1991;88:4761-4765. 
171.  Tait AS, Cranmer SL, Jackson SP, Dawes IW, Chong BH. Phenotype changes resulting in high-affinity binding of 
von Willebrand factor to recombinant glycoprotein Ib-IX: analysis of the platelet-type von Willebrand disease 
mutations. Blood. 2001;98:1812-1818. 
172.  Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene 
associated with a hyperactive surface receptor. Blood. 1993;81:1787-1791. 
173.  Moriki T, Murata M, Kitaguchi T, et al. Expression and functional characterization of an abnormal platelet 
membrane glycoprotein Ibα (Met239-->Val) reported in patients with platelet-type von Willebrand disease. Blood. 
1997;90:698-705. 
174.  Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates 
von Willebrand factor-dependent agglutination of platelets. J Biol Chem. 1991;266:8149-8155. 
175.  Bardsley B, Williams D.H., Baglin TP. Cleavage of rhamnose from ristocetin A removes its ability to induce 
platelet aggregation. Blood Coagul Fibrinolysis. 1998;9:241-244. 
176.  Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of 
von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost. 1990;64:326-332. 
177.  Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC. Purification of botrocetin from Bothrops jararaca 
venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet 
membrane glycoprotein Ib- IX complex. Biochemistry. 1989;28:8317-8326. 
178.  Fujimura Y, Titani K, Usami Y, et al. Isolation and chemical characterization of two structurally and functionally 
distinct forms of botrocetin, the platelet coagglutinin isolated from the venom of Bothrops jararaca. Biochemistry. 
1991;30:1957-1964. 
179.  Usami Y, Fujimura Y, Suzuki M, et al. Primary structure of two-chain botrocetin, a von Willebrand factor 
modulator purified from the venom of Bothrops jararaca. PNAS. 1993;90:928-932. 
180.  De Luca M, Ward CM, Ohmori K, Andrews RK, Berndt MC. Jararhagin and jaracetin: novel snake venom 
inhibitors of the integrin collagen receptor, alpha 2 beta 1. Biochem Biophys Res Commun. 1995;206:570-576. 
181.  Hamako J, Matsui T, Suzuki M, et al. Purification and characterization of bitiscetin, a novel von Willebrand factor 
modulator protein from Bitis arietans snake venom. Biochem Biophys Res Commun. 1996;226:273-279. 
182.  Hirotsu S, Mizuno H, Fukuda K, et al. Crystal structure of bitiscetin, a von Willebrand factor-dependent platelet 
aggregation inducer. Biochemistry. 2001;40:13592-13597. 
183.  Nurden P, Chretien F, Poujol C, Winckler J, Borel-Derlon A, Nurden A. Platelet ultrastructural abnormalities in 
three patients with type 2B von Willebrand disease. Br J Haematol. 2000;110:704-714. 
184.  Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function 
in vitro and in vivo. J Clin Invest. 1991;87:1787-1793. 
185.  Shin Y, Okuyama I, Hasegawa J, Morita T. Molecular cloning of glycoprotein Ib-binding protein, flavocetin-A, 
which inhibits platelet aggregation. Thromb Res. 2000;99:239-247. 
186.  Fukuda K, Mizuno H, Atoda H, Morita T. Crystal structure of flavocetin-A, a platelet glycoprotein Ib-binding 
protein, reveals a novel cyclic tetramer of C-type lectin-like heterodimers. Biochemistry. 2000;39:1915-1923. 
General introduction on vWF 
 36
187.  Taniuchi Y, Kawasaki T, Fujimura Y, et al. Flavocetin-A and -B, two high molecular mass glycoprotein Ib binding 
proteins with high affinity purified from Trimeresurus flavoviridis venom, inhibit platelet aggregation at high shear 
stress. Biochim Biophys Acta. 1995;1244:331-338. 
188.  Peng M, Lu W, Kirby EP. Characterization of three alboaggregins purified from Trimeresurus albolabris venom. 
Thromb Haemost. 1992;67:702-707. 
189.  Sakurai Y, Fujimura Y, Kokubo T, et al. The cDNA cloning and molecular characterization of a snake venom 
platelet gpycoprotein Ib-binding protein, mamushgin, from Agkistrodon halys blomhoffii venom. Thromb 
Haemost. 1998;79:1199-1207. 
190.  Yeh CH, Wang WC, Hsieh TTHTF. Agkistin, a snake venom-derived glycoprotein Ib antagonist, disrupts von 
Willebrand factor-endothelial cell interaction and inhibits angiogenesis. J Biol Chem. 2000;275:18615-18618. 
191.  Polgar J, Magnenat EM, Peitsch MC, Wells TN, Saqi MS, Clemetson KJ. Amino acid sequence of the alpha 
subunit and computer modelling of the alpha and beta subunits of echicetin from the venom of Echis carinatus 
(saw-scaled viper). Biochem J. 1997;323 ( Pt 2):533-537. 
192.  Peng M, Holt JC, Niewiarowski S. Isolation, characterization and amino acid sequence of echicetin beta subunit, a 
specific inhibitor of von Willebrand factor and thrombin interaction with glycoprotein Ib. Biochem Biophys Res 
Commun. 1994;205:68-72. 
193.  Peng M, Lu W, Beviglia L, Niewiarowski S, Kirby EP. Echicetin: a snake venom protein that inhibits binding of 
von Willebrand factor and alboaggregins to platelet glycoprotein Ib. Blood. 1993;81:2321-2328. 
194.  Kawasaki T, Fujimura Y, Usami Y, et al. Complete amino acid sequence and identification of the platelet 
glycoprotein Ib-binding site of jararaca GPIb-BP, a snake venom protein isolated from Bothrops jararaca. J Biol 
Chem. 1996;271:10635-10639. 
195.  Fujimura Y, Ikeda Y, Miura S, et al. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist 
specific to platelet glycoprotein Ib. Thromb Haemost. 1995;74:743-750. 
196.  Kawasaki T, Taniuchi Y, Hisamichi N, et al. Tokaracetin, a new platelet antagonist that binds to platelet 
glycoprotein ib and inhibits von Willebrand factor-dependent shear- induced platelet aggregation. Biochem J. 
1995;308 ( Pt 3):947-953. 
197.  Girma JP, Fressinaud E, Christophe O, et al. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by 
binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib. Thromb 
Haemost. 1992;68:707-713. 
198.  Sen U, Vasudevan S, Subbarao G, et al. Crystal Structure of the von Willebrand Factor Modulator Botrocetin. 
Biochemistry. 2001;40:345-352. 
199.  Matsushita T, Meyer D, Sadler JE. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib 
and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem. 2000;275:11044-11049. 
200.  Huizinga EG, Schouten A, Romijn RAP, et al. Crystal strucures of snake venom botrocetin and its complex with 
the von willebrand Factor A1 domain [abstract]. Thromb Haemost. 2001. 
201.  Hilbert L, Gaucher C, Mazurier C. Effects of different amino-acid substitutions in the leucine694-proline708 
segment of recombinant von Willebrand factor. Br J Haematol. 1995;91:983-990. 
202.  Dong JF, Berndt MC, Schade A, McIntire LV, Andrews RK, Lopez JA. Ristocetin-dependent, but not botrocetin-
dependent, binding of von willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-
dependent interactions. Blood. 2001;97:162-168. 
203.  Celikel R, Ruggeri ZM, Varughese KI. Von Willebrand Factor conformation and adhesive function is modulated 
by an internalized water molecule. Nature Struct Biol. 2000;7:881-884. 
204.  Miller JL. Platelet-type von Willebrand disease. Thromb Haemost. 1996;75:865-869. 
General introduction on vWF 
 37
205.  Nurden AT, Didry D, Rosa JP. Molecular defects of platelets in Bernard-Soulier syndrome. Blood Cells. 
1983;9:333-358. 
206.  Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to 
platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand 
factor. J Biol Chem. 1995;270:13406-13414. 
207.  Holmberg L, Dent JA, Schneppenheim R, Budde U, Ware J, Ruggeri ZM. von Willebrand factor mutation 
enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest. 1993;91:2169-
2177. 
208.  Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand 
disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. 
Thromb Haemost. 1997;78:451-456. 
209.  Rabinowitz I, Rand JH, Shindler KS, Tuley EA, Rustagi PK, Sadler JE. Type IIB mutation His-505-Asp implicates 
a nwew segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem. 
1993;268:20497-20501. 
210.  Siguret V, Ribba AS, Christophe O, et al. Characterization of recombinant von Willebrand factors mutated on 
cysteine 509 or 695. Thromb Haemost. 1996;76:453-459. 
211.  Girma JP, Ribba AS, Meyer D. Structure-function relationship of the A1 domain of von Willebrand factor. 
Thromb Haemost. 1995;74:156-160. 
212.  Christophe O, Ribba AS, Baruch D, et al. Influence of mutations and size of multimers in type II von Willebrand 
disease upon the function of von Willebrand factor. Blood. 1994;83:3553-3561. 
213.  Rastegar-Lari G, Ajzenberg N, Ribba AS, et al. Defect of heparin binding in plasma and recombinant von 
Willebrand factor with type 2 von Willebrand disease mutations. Thromb Haemost. 2001;86:1459-1465. 
214.  AnonymousIdentification of type 2M von Willebrand Disease of 5 new candidate mutations in the N-terminal part 
of the A1 loop of von Willebrand Factor [abstract]. Thrombosis and Haemostasis, Supplement. 1999;x:283-284. 
215.  Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ib-binding site in the von 
willebrand factor A1 domain. J Biol Chem 2000 Jun 23 ;275 (25 ):19098 -105.275:19098-19105. 
216.  Kroner PA, Frey AB. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted 
deletions and alanine-scanning mutagenesis. Biochemistry. 1996;35:13460-13468. 
217.  Ajzenberg N, Ribba AS, Rastegar-Lari G, Meyer D, Baruch D. effect of recombinant von Willebrand factor 
reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood. 2000;95:3796-3803. 
218.  Ribba AS, Lavergne JM, Bahnak BR, Derlon A, Pietu G, Meyer D. Duplication of a methionine within the 
glycoprotein Ib binding domain of von Willebrand factor detected by denaturing gradient gel electrophoresis in a 
patient with type IIB von Willebrand disease. Blood. 1991;78:1738-1743. 
219.  Facey DA, Favaloro EJ, Koutts J, Berndt MC, Hertzberg MS. Identification and characterization of a novel 
mutation in von Willebrand factor causing type 2B von Willebrand's disease. Br J Haematol. 1999;105:538-541. 
220.  Hilbert L. Identification of "new" type 2B von Willebrand disease mutations:R543Q, R545P and R578L [abstract]. 
Br J Haematol. 1996;93:310. 
221.  De Romeuf C, Hilbert L, Mazurier C. Platelet activation and aggregation induced by recombinant von Willebrand 
factors reproducing four type 2B von Willebrand disease missense mutations. Thromb Haemost. 1998;79:211-216. 
222.  Lankhof H, Damas C, Schiphorst ME, et al. Functional studies on platelet adhesion with recombinant von 
Willebrand factor type 2B mutants R543Q and R543W under conditions of flow. Blood. 1997;89:2766-2772. 
General introduction on vWF 
 38
223.  Facey DA, Favaloro EJ, Maxwell E, Baker R, Hertzberg MS. Type 2B von Willebrand's disease in thirteen 
individuals from five unrelated Australian families: phenotype and genotype correlations. Am J Hematol 2000; 63 
(4 ):197 -9.63:197-199. 
224.  Federici AB, Mannucci PM, Stabile F, et al. A type 2b von Willebrand disease mutation (Ile546-->Val) associated 
with an unusual phenotype. Thromb Haemost. 1997;78:1132-1137. 
225.  Cooney KA, Ginsburg D. Comparative analysis of type 2B von Willebrand Disease mutations: implications for the 
mechanism of von Willebrand Factor binding to platelets. Blood. 1996;87:2322-2328. 
226.  Rand JH, Jorieux S, Tuley EA, Mazurier C, Sadler JE. Recombinant von Willebrand factor Arg578-Gln. J Biol 
Chem. 1992;267:21187-21192. 
227.  Donner M, Kristoffersson AC, Lenk H, et al. Type IIB von Willebrand's disease: gene mutations and clinical 
presentation in nine fanilies fram Denmark, Germany and Sweden. Br J Haematol. 1992;82:58-65. 
228.  Donner M, Kristoffersson AC, Andersson AM, Nilsson AC, Dahlback B, Holmberg L. An Arg545Cys substitution 
mutation of the von Willebrand factor in type IIb von Willebrand's disease. Eur J Haematol. 1991;47:342-345. 
229.  Gurevitz O, Goldfarb A, Hod H, et al. Recombinant von Willebrand factor fragment AR545C inhibits platelet 
aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arterioscler Thromb Vasc Biol. 
1998;18:200-207. 
230.  Miyata S, Goto S, Federici AB, Ware J, Ruggeri ZM. Conformational changes in the A1 domain of von 
Willebrand factor modulating the interaction with platelet glycoprotein Ibα. J Biol Chem. 1996;271:9046-9053. 
231.  Wood N, Standen GR, Bowen DJ, et al. UHG-based mutation screening in type 2B von Willebrand's disease: 
detection of a candidate mutation Ser547Phe. Thromb Haemost. 1996;75:363-367. 
232.  Ware J, Dent JA, Azuma H, et al. Identification of a point mutation in type IIB von Willebrand disease illustrating 
the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc Natl 
Acad Sci USA. 1991;88:2946-2950. 
233.  Casana P, Martinez F, Espinos C, Haya S, Lorenzo JI, Aznar JA. Search for mutations in a segment of the exon 28 
of the human von Willebrand factor gene: new mutations, R1315C and R1341W, associated with type 2M and 2B 
variants. Am J Hematol. 1998;59:57-63. 
234.  Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from 
proteolysis of the constituent subunit. J Clin Invest. 1991;88:774-782. 
235.  Randi AM, Jorieux S, Tuley EA, Mazurier C, Sadler JE. Recombinant von Willebrand factor Arg578-->Gln. A 
type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin. J Biol 
Chem. 1992;267:21187-21192. 
236.  Murray E, Giles AR, Lillicrap D. Germ-line mosaicism for a Valine-to-Methionine substitutionn at residue 553 in 
the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease. Am J Hum 
Genet. 1992;50:199-207. 
237.  Rabinowitz I, Tuley EA, Mancuso DJ, et al. von Willebrand disease type B: a missense mutation selectively 
abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci U S A. 
1992;89:9846-9849. 
238.  Hilbert L, Gaucher C, Fressinaud E, Meyer D, Mazurier C. a new type 2M ("type B") vWD mutation (G1324A) 
also at position 561 of the mature vWF subunit [abstract]. Thrombosis and Haemostasis, Supplement. 
1997;77:654. 
239.  Hilbert L, Fressinaud E, Ribba AS, Meyer D, Mazurier C. Identification of a new type 2M von Willebrand disease 
mutation also at position 1324 of von Willebrand factor. Thromb Haemost. 2002;87:635-640. 
General introduction on vWF 
 39
240.  Vasudevan S, Roberts JR, McClintock RA, et al. Modeling and functional analysis of the interaction between von 
Willebrand factor A1 domain and glycoprotein Ibalpha. J Biol Chem 2000 Apr 28 ;275 (17 ):12763 -8.275:12763-
12768. 
241.  Rastegar-Lari G, Legendre P, Ribba AS, Meyer D, Baruch D. A cluster of six charged residues within the main 
heparin-binding site of von Willebrand Factor is essential for heparin binding [abstract]. Thrombosis and 
Haemostasis, Supplement. 2001. 
242.  Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. A Pro574>leu substitution in von Willebrand Factor 
enhances the binding of expressed protein to platelets and is linked to type IIB von Willebrand disease [abstract]. 
Thrombosis and Haemostasis, Supplement. 1991;65:763. 
243.  Song KS, Kang SH, Kang MS, et al. von Willebrand disease with G4022A mutation (vWd Sungnam): a case 
report. J Korean Med Sci. 1999;14:93-96. 
244.  Hillery CA, Mancuso DJ, Sadler JE, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the 
glycoprotein Ib binding domain selectively impair ristocetin - but not botrocetin-mediated binding of von 
Willebrand factor to platelets. Blood. 1998;91:1572-1581. 
245.  Castaman G, Eikenboom JC, Rodeghiero F, Briet E, Reitsma PH. A novel candidate mutation (Arg611-->His) in 
type I 'platelet discordant' von Willebrand's disease with desmopressin-induced thrombocytopenia. Br J Haematol. 
1995;89:656-658. 
246.  Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of 
von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent 
function of vWF. Blood. 1995;86:1010-1018. 
247.  Nishikubo T, Christophe O, Lavergne JM, et al. Abnormal proteolytic processing of von Willebrand Factor 
Arg611Cys and Arg611His. Thromb Haemost. 1997;77:174-182. 
248.  Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR. Type 2M:Milwaukee-1 von 
Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain 
causes deficient binding of von Willebrand factor to platelets. Blood. 1996;88:2559-2568. 
249.  Hilbert L, Gaucher C, Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697-Val mutation in mature von 
Willebrand factor in responcible for type 2B Willebrand disease. Blood. 1994;83:1542-1550. 
250.  Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand factor 
sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor 
binding to platelet glycoprotein Ib. J Biol Chem. 1991;266:18172-18178. 
 
 
Identification of the collagen-binding site of the vWF-A3 domain 
 40
Chapter 2 
 
 
 
 
 
Identification of the collagen-binding site of the von 
Willebrand Factor A3-domain 
 
 
 
 
Roland A.P. Romijn¶†, Barend Bouma¶‡, Winnifred Wuyster†, Piet Gros‡, 
Jan Kroon‡, Jan J. Sixma† and Eric G. Huizinga†‡ 
 
† Thrombosis and Haemostasis Laboratory, Department of Haematology, 
University Medical Center and Institute of Biomembranes, HP G03.647, 
PO box 85500, 3508 GA Utrecht, The Netherlands and 
‡ Bijvoet Center for Biomolecular Research, Department of Crystal and 
Structural Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, 
The Netherlands. 
 
§ These authors contributed equally 
 
 
Published in the Journal of Biological Chemistry, 276 (13), 9985-9991, 2001 
Identification of the collagen-binding site of the vWF-A3 domain 
 41
Summary 
 
Von Willebrand factor (vWF) is a multimeric glycoprotein that mediates platelet adhesion and 
thrombus formation at sites of vascular injury. VWF functions as a molecular bridge between 
collagen and platelet receptor glycoprotein Ib. The major collagen-binding site of vWF is 
contained within the A3 domain, but its precise location is unknown. To localize the collagen-
binding site, we determined the crystal structure of A3 in complex with a Fab fragment of 
antibody RU5 that inhibits collagen binding. The structure shows that RU5 recognizes a non-
linear epitope consisting of residues 962-966, 981-997 and 1022-1026. Alanine-mutants were 
constructed of residues Arg963, Glu987, His990, Arg1016 and His1023, located in or close to 
the epitope. Mutants were expressed as fully processed multimeric vWF. Mutation of His1023 
abolished collagen binding, while mutation of Arg963 and Arg1016 reduced collagen binding by 
25 – 35%. These residues are part of loops α3β4 and α1β2 and α-helix 3, respectively, and lie 
near the bottom face of the domain. His1023 and flanking residues display multiple 
conformations in available A3-crystal structures suggesting that binding of A3 to collagen 
involves an induced-fit mechanism. The collagen-binding site of A3 is located distant from the 
top face of the domain where collagen-binding sites are found in homologous integrin I-domains. 
Identification of the collagen-binding site of the vWF-A3 domain 
 42
Introduction 
 
Platelet adhesion to damaged vessel walls is the first step in the formation of an occluding platelet 
plug, which leads to the arrest of bleeding during normal hemostasis. Platelet adhesion can also 
cause thrombotic complications such as the occlusion of aetherosclerotic arteries 1. The 
multimeric glycoprotein von Willebrand factor (vWF)1 plays an essential role in platelet adhesion 
under conditions of high shear stress 2; 3. In this process vWF serves as a molecular bridge that 
links collagen exposed by the damaged vessel wall to glycoprotein Ib located on the platelet 
surface. Collagens that act as binding sites for vWF include types I and III in perivascular 
connective tissue and type VI in the sub-endothelial matrix 3; 4. 
Mature vWF consists of a 2,050 residue monomer that contains multiple copies of so 
called A, B, C and D-type domains and one CK (cystine knot) domain arranged in the order D'-
D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK 1; 3. Disulfide-bond formation between N-terminal D3 
domains and between C-terminal CK domains generates vWF multimers that consist of up to 80 
monomers. The A1 domain contains the binding site for glycoprotein Ib 5. The A3 domain 
(residues 920-1111) contains the major binding site for collagen types I and III 6. The multimeric 
structure of vWF is essential for high-affinity collagen binding 7. Multimeric vWF binds collagen 
with an apparent Kd of 1-7 nM 8, while a recombinant A3 domain has a much higher Kd of 2 µM 
9. Deletion of the A2 and D4 domains, that flank the A3 domain, or deletion of the A1 domain 
does not decrease collagen binding of multimeric vWF 6; 8. These data show that a monomeric A3 
domain contains a fully active collagen-binding site, the only requirement for tight binding to 
collagen being the presence of multiple A3 domains within one vWF multimer.  
Integrin I-type domains are homologous to vWF A-type domains 10; 11. I-domains of 
integrin α-chains α1, α2, α10 and α11 all possess collagen-binding sites. A crystal structure of 
the α2 I-domain reveals binding of a collagen-like peptide to a groove in the surface of the ‘top’ 
face of the domain 12. This groove contains a so-called metal ion-dependent adhesion site 
(MIDAS) 13; 14 which engages a glutamate residue of collagen.  
The location of the collagen-binding site in the vWF-A3 domain is not known. Crystal 
structures of A3 do not display a collagen-binding groove in the top face, instead, the surface of 
A3 is rather smooth 15; 16. Although the MIDAS motif is partly conserved, binding of A3 to 
collagen does not require a metal ion 17; 18 and no metal ion is observed in crystal structures of A3. 
Moreover, point mutations in the MIDAS motif of A3 do not disrupt collagen binding 8; 16 
showing that the motif is not involved in collagen binding, at all. Site-directed mutagenesis 
Identification of the collagen-binding site of the vWF-A3 domain 
 43
studies of other residues in the top face of A3 have yielded conflicting results. Cruz et al. 19 
reported in abstract form that amino-acid substitutions D1069R, R1074D, R1090D and E1092R 
resulted in a 50% reduction in binding of monomeric A3 to collagen. Van der Plas et al. 8, 
however, observed normal collagen binding of fully processed multimeric vWF containing 
mutations D1069R, D1069A or R1074A. In the same study, mutations V1040A/V1042A, 
D1046A and D1066A also displayed normal collagen binding, suggesting that the collagen-
binding site of vWF-A3 is not located in its top face. 
The crystallographic study presented here was conducted to provide new clues on the 
location of the collagen-binding site of the vWF-A3 domain. We determined the structure of the 
A3 domain in complex with a Fab fragment of monoclonal antibody RU5, which inhibits binding 
of vWF to collagen. Site-directed-mutagenesis of residues located in the epitope-region show that 
the collagen-binding site is located distant from the top face of A3. 
 
Experimental procedures 
 
Purification of vWF-A3 and RU5 
 Recombinant seleno-methionine (Se-Met) A3, comprising residues 920 to 1111 of human vWF, 
was expressed and purified as described before 15. For production of monoclonal antibody RU5 
(IgG2a, κ) hybridoma cells were injected in mice and ascites fluid was collected (Eurogentec, 
Seraing, Belgium). IgG was purified on a protein G-Sepharose column and Fab fragments were 
generated using an ImmunoPure Fab Kit (Pierce, Rockford IL, USA). RU5-Fab was further 
purified with A3-affinity chromatography. For that end, 10 mg of A3 was irreversibly bound via 
its N-terminal histidine tag to cobalt(III)-iminodiacetate chelating Sepharose (Pharmacia Biotech, 
Uppsala, Sweden), according to a procedure described by Hale 20. RU5 Fab fragment was loaded 
onto the A3-affinity column, washed with PBS and subsequently eluted with 50 mM tri-
ethylamine solution (pH 10.0). Some aggregates were removed on a Superdex 75 HR 10/30 gel-
filtration column (Pharmacia, Uppsala, Sweden). Running buffer was 10 mM Tris-HCl pH 8.0, 25 
mM NaCl. Next, RU5-Fab was mixed with a twofold molar excess of (Se-Met) A3. The A3-RU5 
complex was separated from excess A3 by gel-filtration chromatography. Dynamic-light 
scattering measurements on a Dynapro-801 DLS Instrument (Protein Solutions, Charlottesville 
VA, USA) indicated the presence of 69-kDa particles in agreement with an expected molecular 
weight of about 72 kDa of the complex between A3 and RU5. 
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Determination of RU5 Variable Domain Sequences  
The amino-acid sequence of the variable domain of the heavy chain (VH) of RU5 was deduced 
from a cDNA nucleotide sequence. Cloning and sequencing was carried out using established 
procedures. Total RNA was extracted from 4*106 RU5 hybridoma cells with RNAzol using the 
RNA-isolation protocol of the supplier (Campro Scientific, Veenendaal, The Netherlands). First-
strand cDNA was synthesized using Superscript II reverse transcriptase (Gibco, Rockville MD, 
USA) in the presence of 3.2 U/µl of RNase-inhibitor RNaseOUT (Gibco, Rockville MD, USA). 
cDNA encoding the VH domain was amplified by polymerase chain reaction (PCR) with Pwo 
DNA polymerase (Boehringer, Mannheim, Germany). A backward variable-region consensus 
primer (B4: CCA GGG GCC AGT GGA TAG ACA AGC TTG GGT GTC GTT TT) was used 
together with a forward primer (B3c: CGG ATG GCC AGG T[C/G][A/C] AGC TGC AG[C/G] 
AGT C[A/T]G G) that hybridizes with a consensus sequence in the JH region 21. The PCR product 
was extended with a 3'-A overhang using Taq DNA polymerase (Promega, Madison WI, USA) 
and cloned into the pCR2.1-TOPO vector according to the manufacturer’s protocol (Invitrogen, 
Leek, The Netherlands). Nucleotide sequences of three clones were determined2 (figure 1A).  
For determination of the sequence of the variable domain (VL) of the RU5 κ-light chain, 
the same procedure was used as for the VH domain. For cloning of the VL gene, one backward 
variable-region consensus primer (PD1: GAT ATT GTG ATG ACC CAG TCT [C/G]T) and two 
forward variable-region consensus primers (PD3: CAG GAA ACA GCT ATG ACC GAG CTC 
GTG ATC ACC CAG TCT CC; PD4: TGT AAA ACG ACG GCC AGT TCT AGA TGG TGG 
GAA GAT GGA) were used. However, determination of the sequence was hampered by the 
abundance of mRNA encoding the light chain of the non-producing myeloma-fusion partner of 
the RU5 hybridoma cell, a known drawback of myeloma-cell line P363Ag8.653 22.  
 
Figure 1: Amino acid sequences 
of RU5 VL and VH domains. 
CDRs (underlined) were defined 
according to Kabat et al. 23. Strict 
sequential numbering (#) is used 
throughout the text. Numbering 
according to the convention of 
Kabat et al. 23 (#K) is also shown. 
A. The amino acid sequence of VH 
was deduced from cDNA. 
Residues 1 to 7 could not be 
deduced precisely due to the use of a primer complementary to the 5’ coding region. Asn56 in CDRH2 (shaded) is N-
glycosylated. The nucleotide sequence of VH has been deposited in the GeneBank database under Accession Number 
AF286587. B. The amino acid sequence of the VL domain was deduced from the electron density of the A3-RU5 
complex and an alignment of 110 Fab VL chains. Side chains of thirteen amino acid residues that could not be 
determined unambiguously from the electron density and the consensus sequence are shown as lower case characters. 
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Crystallization and Data Collection  
Crystals of the (Se-Met) A3-RU5 complex were grown by hanging-drop vapor-diffusion at 4° C 
using a protein concentration of 15 mg/ml and a precipitant solution consisting of 13% (v/v) iso-
propanol, 22% (v/v) 2-methyl-2,4-pentanediol (MPD) and 100 mM cacodylic acid pH 5.3. The 
crystal used for structure determination had a size of 0.1x0.1x0.2 mm3 and was equilibrated in a 
cryo-protectant solution consisting of 8% iso-propanol, 30% MPD, 100 mM cacodylic acid pH 
5.3. X-ray diffraction data were collected on beam line BW7B of the synchrotron-radiation 
facility of the EMBL outstation (Hamburg, Germany) with a Mar345 imaging plate (Mar, 
Evanston IL, USA). Data reduction, merging and scaling were performed with DENZO and 
SCALEPACK 23. Diffraction-data statistics can be found in Table I. Diffraction of the A3-RU5 
crystal was anisotropic. For structure determination, anisotropic B-factors were applied with 
SCALEIT and SFTOOLS 24 to correct for the observed anisotropy.  
 
Table I 
Diffraction-data and refinement statistics 
Diffraction data  
Wavelength (Å) 0.8469 
Resolution (Å) 29.9-2.56/2.03a 
Space group C2 
a, b, c (Å) 
α, β, γ (°) 
121.80, 183.55, 131.84 
90.0, 116.21, 90.0 
Mosaicity (°) 0.22 
Redundancy 4.2 
No. of unique reflections 143,255 
<I>/<σ(I)> 20.4 (2.4)b 
Completeness (%) 85.9 (51.5)a 
Rmerge (%)c 6.1 (40.4)  
Refinement  
Resolution (Å) 29.9 - 2.03 
R-factor 
Rfree 
0.227 
0.264 
r.m.s.d. bond distances (Å) 0.007 
r.m.s.d. angles (°) 1.41 
Average overall B-factor (Å2) 38 
No. of protein atomsd 13,889 
No. of carbohydrate atoms 100 
No. of cacodylate ions 1 
No. of solvent molecules 878 
a Data completeness is 100% between 29.9-2.56 Å resolution and drops to 
51.5% between 2.56-2.03 Å resolution, due to anisotropic diffraction. 
b Numbers in parentheses indicate statistics for highest resolution shells. 
c Rmerge = ∑h∑i|Ihi-<Ih>| / ∑h∑i|Ihi| 
d An asymmetric unit contains three A3-RU5 complexes.  
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Structure Determination and Refinement 
A self-rotation function calculated with POLARRFN 24 and the unit-cell volume suggested the 
presence of three A3-RU5 complexes in the asymmetric unit (a.u.) with a VM of 3.3 Å3/Da and a 
solvent content of 63%. Initial attempts to solve the structure by molecular replacement failed. 
Therefore, a rather weak anomalous signal (<∆Fano/σ(F)> = 1.18) arising from the presence of Se-
Met in A3 was used to locate Se sites from an anomalous Patterson map. Six Se sites could be 
assigned to Met947, Met998 and Met1097 of two A3 molecules on the basis of inter-atomic 
distances and the observed two-fold non-crystallographic symmetry (n.c.s). The positioning of 
two A3 molecules in the a.u. allowed further molecular replacement to proceed in a 
straightforward manner. A Fab-fragment of protein data bank entry 2MPA 25; 26 was oriented 
using the program AmoRe 27 followed by Patterson correlation refinement using CNS 28; 29. Cross 
translation functions calculated with CNS identified the position of three Fab-fragments. A third 
A3 molecule was placed on the basis of n.c.s. The a.u. finally contained three A3-RU5 complexes 
with an R-factor of 42.6% after rigid body refinement. 
For model building, sequences of the constant domain of the light chain (CL) and of the 
constant domain of the heavy chain (CH1) of RU5 were taken from IgG2a, κ monoclonal antibody 
4-4-20 30; 31. The sequence of residues 1 to 110 of the VL domain of RU5 (Fig. 1B) was derived 
from the electron density aided by a consensus sequence based on an alignment of 110 Fab 
sequences. For model refinement, cycles of rebuilding using O 32 and positional and B-factor 
refinement using CNS were performed until convergence. Cross validation was used throughout 
refinement using a 5% test set of reflections. Refinement used the maximum-likelihood algorithm 
33. Bulk-solvent correction and anisotropic scaling of diffraction data was applied. During the first 
cycles of refinement n.c.s. restraints were used. Based on the behavior of the free R-factor, n.c.s. 
restraints were omitted in later stages of refinement. Water molecules were placed in difference 
electron-density peaks with a peak height of at least 2.8 σ, a distance of 2.5-3.4 Å to a hydrogen-
bond donor or acceptor and a B-factor smaller than 65 Å2. 
 
Construction of vWF Point Mutants 
Point mutations were introduced in the vWF-A3 domain using the Quikchange method 
(Stratagene, La Jolla CA, USA) and specific primers (Amersham Pharmacia Biotech, Roosendaal, 
The Netherlands). First, a 518 base pair NheI-Csp45I fragment corresponding to amino acid 
residues 940 to 1113 of mature vWF was subcloned into pBluescript SKII (Stratagene, La Jolla 
CA, USA). To this end a unique Csp45I restriction site was introduced at position 5628 of 
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expression vector pNUT-vWFcas 8 in the following way. The BamHI - EcoRV fragment of 
pNUT-vWFcas was ligated into pBluescript SKII. The Csp45I site was introduced using 
Quickchange and confirmed by sequencing. The NheI – EcoRV fragment containing the new 
Csp45I site was ligated into pNUT-vWFcas generating pNUT-vWFcas2. Next, the NheI - Csp45I 
fragment of pNUT-vWFcas2 was made blunt by filling in of 5’ overhangs using Pwo DNA 
polymerase. Ligation of this fragment into EcoRI - AccI digested and Pwo treated pBluescript 
SKII, produced mutagenesis plasmid pBSvWF-NC. This plasmid retains the NheI and Csp45I 
restriction sites. Point mutations R963A, E987A, H990A, R1016A and H1023A were introduced 
in pBSvWF-NC. Mutation H1023A causes the disappearance of a NsiI restriction site. The NheI - 
Csp45I fragment of this mutant was ligated directly into pNUT-vWFcas2 and confirmed by 
restriction analysis. The NheI – Csp45I fragment of the other point mutants were ligated into 
pNUT-vWFcas2-H1023A, with reappearance of the NsiI site. 
 
Expression, Purification and Characterization of vWF 
vWF was stably expressed in fur-BHK cells, a baby hamster kidney cell line overexpressing furin 
necessary for proper removal of vWF propeptide 6; 34. VWF was purified by immuno-affinity 
chromatography using monoclonal antibody RU8, which is directed against the D4 domain 6. 
VWF-containing fractions were pooled and stored in aliquots at –20 °C until use. 
The concentration of vWF was determined by a sandwich ELISA using polyclonal α-vWF 
and horseradish peroxidase (HRP) conjugated polyclonal α-vWF (DAKO, Glostrup, Denmark) 
for immobilization and detection, respectively 6. Normal pooled plasma from 40 healthy donors 
was used as a reference. 
The multimeric structure of vWF was analyzed by agarose gel electrophoresis followed by 
Western blotting as described by Lawrie et al. 35. 
Binding of vWF to monoclonal antibody RU5 was analyzed as follows. Microtiter-plate 
wells (Costar, Cambridge MA, USA) were coated with 2.5 µg/ml polyclonal α-D’D3 8 in 50 mM 
carbonate buffer pH 9.6 (3 h, 20 oC). Wells were washed with PBS/0.1% Tween-20 (PBS/T) and 
blocked with 3 % BSA in PBS/T (1 h, 37 oC). Wells were incubated with 100 ng/ml vWF in 
PBS/T including 3% BSA (1 h, 37 oC). After washing, 5 µg/ml RU5 was added (1 h, 37 oC). 
Wells were washed and incubated with HRP conjugated swine-anti-rabbit antibody (DAKO, 
Glostrup, Denmark) diluted 1:2500 in PBS/T containing 3% BSA (1 h, 37  oC). O-
phenylenediamine was used as substrate for detection. 
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Collagen-Binding Assay 
vWF binding to fibrillar human placenta collagen type I (Sigma, St. Louis MO, USA, cat. No. C-
7774) and collagen type III (Sigma, cat. No. C-4407) was studied in a solid-state binding assay 
according to Van der Plas et al. 8. Collagen was coated at 50 µg/ml instead of 100 µg/ml as used 
previously 8. A vWF concentration of 2.5 µg/ml was used in the binding experiments. 
 
 
Results 
 
A3-RU5 Structure Determination and Refinement  
The structure of the vWF (Se-Met) A3-domain in complex with a Fab-fragment of RU5 was 
solved to 2.0 Å resolution. The structure was determined using the anomalous signal from 
selenium atoms in (Se-Met) A3 to position two A3 molecules and was completed by molecular 
replacement. The a.u. contains three A3-Fab complexes. The structure has been refined to an R-
factor of 22.7% and a free R-factor of 26.4% (Table I). 
The sequence of the RU5 VL domain could not be determined from cDNA and was 
therefore deduced from electron density aided by an alignment of 110 Fab VL sequences. The 
identity of thirteen amino acid residues could not be determined uniquely (see Fig. 1). The 
structure displays good model geometry with 88.8% of the residues in the most favored region of 
the Ramachandran plot and 10.8% in the additionally allowed region. Residue Thr51 of RU5 VL 
domains occurs in the disallowed region of the Ramachandran plot, but its electron density is 
convincing. 
The a.u. consists of three A3-RU5 complexes that are denoted A, B and C. The overall 
structure of the (Se-Met) A3 molecule is the same as the structure of native A3 15; 16. It consists of 
a central six-stranded β-sheet on both sides flanked by α-helices. The final model comprises 
amino-acid residues 921-1110 of A3 molecules in complexes A and B and residues 920-1110 of 
the A3 molecule in complex C. Positions of the N- and C-termini of A3, including disulfide bond 
Cys923-Cys1109 that connects these termini, are poorly defined. The model of RU5 consists of 
residues 1-211 of the light chains and residues 1-129 and 136-216 of the heavy chains. Residues 
130-135 of the heavy chains display very weak electron density and are excluded from the model. 
Disorder of this loop is a commonly observed feature in Fab structures 36. Asn56 of the VH 
domain is N-glycosylated. Electron density near Asn56 accounted for a GlcNAc(-Fuc)-GlcNAc 
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moiety in complexes A and B and only a GlcNAc-Fuc moiety in complex C. The model contains 
one cacodylate ion from the crystallization solution.  
 
Crystal Packing and Differences between Complexes 
In the a.u. A3-RU5 complexes B and C form a tightly interacting anti-parallel dimer and are 
related by two-fold n.c.s. A3-RU5 complex A forms a similar anti-parallel dimer with a 
crystallographically related complex A'. Complexes within dimers B-C and A-A' have large 
contact areas of 932 Å2 and 1,454 Å2, respectively (GRASP 37). These large interaction-surface 
areas suggest that the dimer of A3-RU5 complexes may also be stable in solution. DLS 
measurements, however, clearly indicated that the A3-RU5 complex does not form dimers in 
solution. Therefore, dimers observed in the crystal are a result of crystal packing. 
Superposition of Cα-atoms of the three A3-RU5 complexes gives large root-mean-square 
(r.m.s.) coordinate differences ranging from 0.7 to 0.9 Å. When superpositions are limited to A3 
molecules with bound VH and VL domains r.m.s. coordinate differences of 0.5-0.6 Å are obtained. 
Visual inspection of these superpositions (figure 2) shows that the A3-RU5 interaction region is 
well conserved, whereas regions of A3 and the variable domains located further away from the 
interaction region superimpose less well. A more detailed inspection of the A3-RU5 binding 
region reveals that all side-chain conformations are very similar (data not shown). In conclusion, 
the A3-RU5 interaction region is well conserved among the three complexes in the a.u. 
 
 
 
 
 
 
Figure 2: Structural overlay of Cα-traces of the three 
A3-RU5 Fab complexes in the asymmetric unit. For 
calculation of the best superposition Cα-atoms of A3 
and variable domains of RU5-Fab were used. The A3-
RU5 interaction region is well conserved amongst the 
three complexes, while relatively large differences are 
shown in orientations of the RU5 constant domains 
with respect to its variable domains and A3. The 
diagram was generated with MOLSCRIPT 38. 
 
 
 
The Epitope of RU5  
A3 interacts with RU5 through a non-linear epitope comprising residues in loop α1β2, loop β3α2 
followed by helix α2, and loop α3β4 (Table II). All three loops that contribute to the epitope are 
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located in the bottom face of A3 (figure 3). The N- and C-termini of A3 that are also located in 
the bottom face do not interact with RU5. This observation is in agreement with the fact that RU5 
was raised against complete vWF in which the termini connect A3 to flanking A2 and D4 
domains. Residues of RU5 that interact with loops α1β2 and α3β4 are located in CDRL1 and 
CDRL2 (figure 1). All six CDRs interact with residues in the contiguous segment formed by loop 
β3α2 and helix α2. The A3-RU5 interactions involve five hydrogen bonds and one salt bridge. 
The buried surface area of A3 molecules in the complex is approximately 1,200 Å2, which is 
about 7% of the total surface area of A3. Interestingly, the fucose moiety attached to residue 
Asn56 in CDRH2 of complex A interacts with Lys988-Ala989 of A3. The carbohydrate moieties 
attached to Asn56 in complexes B and C do not interact with A3. 
 
Conformational Changes in A3 
To analyze whether binding of RU5 causes conformational changes in A3 we compared models 
of A3 in the A3-RU5 complex with two structures of free A34 15; 16. The two structures of free A3 
were determined from different crystal forms with unrelated crystal-packing interactions. In both 
crystal forms two molecules are present in the a.u. Since the A3-RU5 complex was obtained with 
(Se-Met) A3 we also included the structure of free (Se-Met) A3 in the comparison to detect 
possible structural differences caused by Se-Met (E.G. Huizinga, unpublished results). R.m.s. 
coordinate differences after pair-wise superimposing Cα-atoms of all eight models range from 
0.24 to 0.81 Å. Large differences are restricted to three loops located within the RU5-binding site 
and to two loops that are located distant from the epitope (figure 3, Table II). 
The three conformational diverse loops located in the RU5-epitope are α1β2, β3α2 and 
α3β4 (figure 4A). Loop α1β2 has a unique conformation in the A3-RU5 complex, indicating that 
this conformation is induced by RU5. Loops β3α2 and α3β4 have considerable conformational 
freedom. Conformations observed in the A3-RU5 complex are, however, not systematically 
different from the conformations observed in free A3, indicating that the conformations observed 
in the complex are not induced by RU5. 
Distant from the RU5 epitope conformational variation is observed for loops β1α1 and 
α5β6. Loop β1α1 is located in the top face of the domain and contains part of the vestigial 
MIDAS motif. Multiple conformations are observed for residues Ser938-Phe-Pro940 (figure  4B). 
Phe939 is solvent exposed in A3-RU5 complex C and all models of free A3. In complexes A and 
B Phe939 is buried in the hydrophobic core of A3. The buried conformation is likely caused by 
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crystal packing interactions involving A3 residues 940-942. These packing interactions would not 
allow for the position of Pro940 observed in models of A3 that have an exposed conformation of 
Phe939. Since both the exposed and buried conformations of Phe939 are observed in the three 
A3-RU5 complexes the conformation of this loop is certainly not determined by binding of RU5. 
Figure 3: Ribbon diagram of A3 and RU5 variable domains. Residues of A3 that are part of the epitope of RU5 are 
indicated by yellow spheres. Regions of RU5 CDRs that interact with A3 are color-coded in light blue. Regions of A3 
that show different conformations among four crystal structures are shown in purple trace. Disulfide bond Cys923-
Cys1109 is shown in green ball-and-stick. The α-helices and β-strands of A3 are depicted in blue and red, 
respectively. For clarity, α-helix 2 is not shown by a ribbon, but in ‘coil’ representation. The VH domain of RU5 is in 
brown, the VL domain is in green. The diagram was generated with MOLSCRIPT 38 and RASTER3D 39. 
 
click on this link for rotating image 
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Table II 
The epitope of RU5 and loops of A3 that show conformational variation 
among eight models of A3 from four different crystal structures 
Residues in the RU5 epitopea 
Structural element Residues 
Loop α1β2 Pro962-Arg963 
Gln966 
Loop β3α2 Pro981-Trp-Asn-Val-Val-Pro-Glu987 
Helix α2 Lys988-Ala-His990 
Ser993-Leu994 
Asp996-Val997 
Loop α3β4 Met1022-His-Gly1024 
Arg1026 
Residues with variable conformationsb 
Structural element Residues 
Loop β1α1 Ser938-Phe-Pro940 
Loop α1β2 Gly961-Pro-Arg963 
Loop β3α2 Asn983-Val-Val-Pro-Glu987 
Loop α3β4 Thr1019-Ser-Glu-Met-His-Gly-Ala1025 
Loop α5β6 Gly1078-Pro-Ala-Gly-Asp-Ser1083 
a Residues listed are positioned within 4.0 Å distance from RU5. 
b Residues that are also part of the epitope of RU5 are underlined.  
 
Loop α5β6 located in a side face of A3 has an aberrant conformation in A3 domain B of 
the structure of Bienkowska et al. 16 (figure 4C). This aberrant conformation coincides with 
crystal contacts unique to molecule B. No crystal contacts are present in the other structures. The 
conformations observed in the A3-RU5 complex are not systematically different from the 
conformations observed in free A3. Thus, binding of RU5 does not cause conformational changes 
in regions of A3 that are distant from the epitope. 
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Figure 4: The conformation of 
five loops varies among 
different crystal structures of 
A3. Models compared include 
free A34, free (Se-Met) A3 and 
A3 from the A3-RU5 complex. 
A. Stereo picture of loops α1β2 
(residues 961-963), β3α2 (983-
987) and α3β4 (1019-1025). 
Residues of A3 in A3-RU5 
complex A are shown in thick 
line. A3 domain A from the 
structure of Huizinga et al. 15 is 
shown in gray. B. Stereo 
diagram of residues Ser938-Phe-
Pro940 in the top face of A3. 
Buried and exposed 
conformations of Phe939 are 
labeled. C. Stereo diagram of 
loop α5β6 (residues 1078-
1083). The aberrant A3 domain 
B from the structure of 
Bienkowska et al. 16 is shown in 
thick line. The diagram was 
generated with MOLSCRIPT 38.  
 
Selection and Characterization of vWF Mutants 
To confirm the location of the collagen-binding site indicated by the A3-RU5 complex we 
constructed charged-to-alanine mutations of five residues. These residues are located within 5 Å 
of the RU5 Fab fragment and are solvent exposed in free A3. Residues selected were Arg963 
located in loop α1β2, Glu987 (β3α2), His990 (α2), Arg1016 (α3), and His1023 (α3β4). Mutants 
were produced as multimeric vWF in stable baby hamster kidney cell lines. The multimer 
distribution of vWF mutants and wild-type vWF, as analyzed by agarose gel electrophoresis, were 
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indistinguishable (data not shown). RU5 binding to purified point mutants was not significantly 
different from RU5 binding to wild-type vWF (figure 5). 
  
 
 
 
 
 
Figure 5: Binding of monoclonal antibody RU5 to vWF mutants. 
VWF immobilized in microtiter-plate wells via polyclonal αD’D3 
was incubated with 5 µg/ml RU5. Bound RU5 was detected by 
horse radish peroxidase conjugated swine-anti-rabbit antibody as 
described under “Experimental Procedures”. Wild-type vWF and 
∆A3-vWF, which lacks the A3 domain 6, were used as positive 
and negative controls, respectively. Binding of RU5 to vWF 
mutants was percentualized against wt-vWF. Each data point 
represents the mean ± SD of two measurements in duplicate. 
 
 
 
Collagen Binding of vWF Mutants  
The effect of point mutations on vWF binding to collagen types I and III was investigated by 
ELISA (figure 6). Similar results were obtained for both types of collagen. Mutation H1023A 
almost completely abolished collagen binding. The level of residual binding observed for this 
mutant was similar to binding observed for ∆A3-vWF, a deletion mutant that lacks the entire A3 
domain 6. Collagen binding of mutants R963A and R1016A was reduced by 25 - 35%, whereas 
collagen binding of mutants E987A and H990A was normal. 
 
 
 
 
 
 
 
 
 
Figure 6: Binding of vWF point mutants to collagen types I 
and III. Collagen type I (white bar) or III (black bar) was 
coated in microtiter-plate wells. Wells were incubated with 
vWF at a concentration of 2.5 µg/ml and bound vWF was 
detected as described under “Experimental Procedures”. 
∆A3-vWF was used as a negative control. Bound vWF 
mutant was percentualized against wt-vWF. Each data point 
represents the mean ± SD of three independent experiments 
performed in duplicate. 
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Discussion 
 
The current study was aimed at locating the collagen-binding site of the vWF-A3 domain. For this 
purpose we solved the crystal structure of A3 in complex with a Fab fragment of RU5 that 
inhibits collagen binding. The structure of the complex shows that RU5 binds to residues within 
A3 sequences 962-966, 981-997 and 1022-1026. These residues are located in α-helix 2 and in 
loops α1β2, β3α2 and α3β4 at the bottom of one of the side faces of the A3 domain (see figure 
3). Comparison of structures of A3 shows that RU5 binding does not induce long range 
conformational changes. This excludes a mechanism in which RU5 induced conformational 
changes inhibit collagen binding. It seems likely, therefore, that RU5 inhibits collagen binding by 
steric hindrance, which implies that the collagen-binding site is located at or close to the RU5 
epitope. 
To confirm the location of the collagen-binding site we constructed five charged-to-
alanine mutations of residues located in or close to the RU5 epitope. The multimer distribution of 
these mutants was similar to that of wild-type vWF. Therefore, observed differences in collagen 
binding are not caused by the known dependence of collagen binding on vWF multimer-size 7. All 
five mutants bound normally to RU5, which shows that none of the mutated residues plays a 
dominant role in the A3-RU5 interaction and, more importantly, that the conformation of A3 in 
the neighbourhood of the epitope and the collagen-binding site is not disturbed. 
Mutation H1023A abolished collagen binding almost completely, residual-binding being 
similar to that observed for ∆A3-vWF, a deletion mutant that lacks the entire A3 domain. 
Therefore, His1023 plays a central role in A3-mediated collagen binding. His1023 is located in 
loop α3β4 and lies at the edge between the ‘front’ face of the domain, formed by helices α2 and 
α3 and strand β3, and the bottom face, which is composed of several loops and contains the N- 
and C-termini (see figure 7). A small reduction of collagen binding was observed for mutants 
R963A and R1016A located in the bottom and front face of the domain, respectively. 
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Figure 7: Residues of vWF-A3 involved in collagen binding. Stereographic representation of the vWF-A3 domain 
showing amino-acid residues that have been mutated to alanine in ball-and-stick. Mutation of His1023 (magenta) 
abolishes collagen binding almost completely. Mutation of Arg963 and Arg1016 (green) reduces collagen binding by 
25-35%. Mutation of Glu987 and His990 (gray) does not have an effect on collagen binding. To illustrate the range of 
conformations of His1023 observed in different crystal forms of A3, two conformations of this residue and the back-
bone trace of flanking residues are shown. Residues that have been mutated in previous studies 8; 16; 19 are located in 
the top face of A3 and are indicated by black spheres. The diagram was generated with MOLSCRIPT 38 and 
RASTER3D 39. 
 
Interestingly, His1023 and flanking residues display a large variety of conformations 
among eight models of A3 (figures 4 and 7). In some A3 structures His1023 protrudes 
prominently from the surface of the domain which may be a favorable position for interaction 
with collagen. Multiple conformations are also observed for loop β3α2. Like His1023, loop 
β3α2 is located at the edge between the front and bottom faces of A3. Since we did not mutate 
residues in loop β3α2 its involvement in collagen binding remains to be established. The 
observed flexibility of His1023 suggests that collagen binding may involve an induced-fit 
mechanism in which significant conformational changes occur in loop α3β4 upon binding of A3 
to collagen. 
The amino-acid sequence of collagen that is recognized by vWF-A3 has not yet been 
identified. We hypothesized previously that negatively charged residues in A3 could interact with 
basic residues on collagen 15. Residues now implicated in collagen binding are positively charged. 
Therefore, interaction of A3 with negatively charged residues on collagen appears more likely. 
In contrast to binding sites of other collagen binding domains, like the α1, α2 I-domains 
and the A-domain of S. aureus adhesin 12; 40, the collagen-binding region of A3 does not have a 
groove or trench that could accommodate a collagen triple-helix. The front face of the domain, 
harboring Arg1016, is rather flat. The bottom face, which contains Arg963 is less smooth, but no 
groove is present. Docking of a collagen triple-helix on the A3 domain is not straightforward. In 
particular, it is not obvious how His1023, Arg963 and Arg1016 could simultaneously contact a 
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triple-helix in an extended conformation. To define the collagen-binding site more precisely, 
characterization of additional mutants will be necessary. 
Previously, the collagen-binding site of A3 was proposed to be located at its top face 15; 19 
similar to the homologous I-domains of integrins α1β1 and α2β1 12; 41-43. Point mutations 
introduced in the top face of an A3 monomer 19 and in multimeric vWF 8 gave conflicting results. 
Our results now show conclusively that the collagen-binding site is located close to the bottom 
face and not in the top face of A3. 
While our results rule out a role for the top face of the A3 domain in collagen binding, this 
side of the molecule may still be engaged in other interactions, such as binding of the A1 domain. 
Interaction between A1 and A3 has been suggested to play a role in activation of the A1 domain 
for binding to platelet receptor glycoprotein Ib 44. Interesting in this respect are the buried and 
solvent exposed conformation observed for residue Phe939, which is located close to the vestigial 
MIDAS motif in the top face of the domain (figure 4B). Solvent exposure of Phe939 has been 
proposed to stabilize the buried Asp934 of the vestigial MIDAS motif in the absence of a bound 
metal ion 16. Our observation of a buried conformation shows that exposure of Phe939 is not 
critical for structural stability. The two conformations of Phe939 may, however, be relevant for 
the putative interaction between A1 and A3, since the shape and hydrophobicity of the upper 
surface of A3 differs significantly between the solvent exposed and buried conformation. 
In conclusion, the collagen-binding site of vWF-A3 is distinctly different from collagen-
binding sites of I-domains of integrins α1β1 and α2β1. VWF-A3 residues involved in collagen 
binding are located close to the bottom face of the domain. His1023 is essential for collagen 
binding, while Arg963 and Arg1016 play ancillary roles. Multiple conformations observed for 
His1023 and adjacent residues suggest that binding of A3 to collagen involves an induced-fit 
mechanism. 
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Summary 
 
Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that mediates platelet adhesion 
to collagen at sites of vascular damage. VWF binds to collagen via its A3 domain. Recently we 
identified the approximate location of the collagen-binding site in the vWF-A3 domain (JBC, 
276, 2001, 9985-9991). In  this paper we have studied 22 point mutants to map the collagen-
binding site in detail. Our results map the collagen-binding site at strand β3, helix α3 and loops 
β2β3, α2α3 and α3β4 at the “front” face of the domain. Residues Asp979, Ser1020 and His1023 in 
the lower half of the collagen-binding site are essential for collagen binding, whereas Ile975, 
Thr977, Val997, Glu1001 and Arg1016 in the upper part play an additional role. These residues define 
a rather flat collagen-binding site. Most likely, multiple collagen sequences bind to A3. Surface 
properties of the collagen-binding site indicate that collagen sequences containing hydrophobic 
and positively charged residues binds to A3.   
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Introduction 
 
Human vessel wall has a high content of collagen sub-types I, III, IV, V, VI, VIII, XII, XIII and 
XIV 1-3 that determine the thrombogenicity of the vessel wall. Blood is separated from these 
components by a thin layer of endothelial cells. Upon disruption of the endothelial cell layer 
blood is exposed to collagens in the vessel wall. 
Collagen subtypes I, III, IV and VI are strong activators of platelet adhesion and 
aggregation (see for reviews 3-6). At low shear force platelets interact directly with collagen via 
integrin α2β1 and glycoprotein (Gp) VI 5. At high shear force platelet adhesion to collagen is a 
von Willebrand factor (vWF) dependent process 6; 7. In this process, vWF functions as a 
molecular bridge between collagen and platelet receptor GpIb-IX-V complex. Human fibrillar 
collagen type I and III from perivascular connective tissue are the main collagen subtypes that 
interact with the vWF-A3 domain 8; 9. Collagen type VI from subendothelial cell matrix also 
interacts with vWF, but the binding site for collagen type VI appears to be located in the A1 
domain 10; 11.  
Mature monomeric vWF contains 2050 amino-acid residues and is composed of twelve 
domains in the order D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK 6; 12. VWF dimerises at the CK 
domains 13 and multimerises at the D3 domains 14. VWF with a reduced multimeric size has a 
decreased affinity for collagen 15. 
VWF-mediated platelet adhesion to collagen subtypes I and III involves first the binding 
of the A3 domain to collagen and subsequently the binding of the A1 domain to platelet receptor 
GpIbα in vitro 16-18. Recently, Wu et al. showed for the first time in an in vivo model that the 
vWF-A1 and A3 domains are essential in thrombus formation 19; 20. A-type domains and 
homologous integrin I-domains adopt a so-called di-nucleotide-binding fold, or Rossman fold 
composed of a central β-sheet surrounded by six or seven α-helices 21-24. Binding of the I-domain 
of integrins α1, α2, α10 and α11 to collagen involves a divalent cation 25; 26 bound to the metal ion 
dependent adhesion site (MIDAS) motif and amino-acid residues at the “top” face of the domain 
27; 28. The A3 domain does not contain a functional MIDAS motif and binding of A3 to collagen 
is cation independent 29; 30. Recently we have identified His1023, Arg963 and Arg1016 located at the 
front- and bottom face of A3 to be involved in collagen binding 31. Mutation H1023A completely 
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abolished collagen binding, whereas mutations R963A and R1016A reduced collagen binding by 
20 – 30 %. 
This study was aimed at identifying the collagen-binding site in the vWF-A3 domain in 
detail by means of site-directed mutagenesis. We did so by constructing nineteen alanine mutants 
and three histidine mutants that were expressed as multimeric vWF. Collagen-binding was 
evaluated.  
 
 
Experimental procedures 
 
Selection and construction of vWF Point Mutants 
Selection of amino-acid residues for mutagenesis was based on the approximate location of the 
collagen binding site as identified in our previous study 31 and the crystal structure of the vWF-
A3 domain 21; 22. Selected residues are solvent exposed in the isolated A3 domain. Residues 
Gln966, Ser974, Ile975, Thr977, Asp979, Val980, Pro981, Asn983, Val984, Val985, Ser993, Val997, Gln999, 
Glu1001, Gln1006, Asp1009, Ser1020, Glu1021 and Met1022 were mutated to alanine. In addition, Pro962, 
Pro981 and Pro1027 were mutated to histidine to inhibit collagen binding by steric hindrance. 
Backbone conformations of these proline residues suggested that the histidine side chain would 
protrude from the protein surface. 
Point mutations were introduced in the vWF-A3 domain using the Quikchange method 
(Stratagene, La Jolla CA, USA) as described previously 31.  
 
Expression, Purification and Characterization of vWF  
VWF was stably expressed in baby hamster kidney cells overexpressing furin required for proper 
removal of vWF propeptide 17; 32. Cells were cultured in serum-free medium. VWF was purified 
by immuno-affinity chromatography using monoclonal antibody RU8, which is directed against 
the D4 domain 17 and stored in 50 mM Hepes, 100 mM NaCl pH 7.4 at –20 °C. 
VWF concentration was determined by a sandwich ELISA using polyclonal α-vWF and 
horseradish peroxidase (HRP) conjugated polyclonal α-vWF (DAKO, Glostrup, Denmark) for 
immobilization and detection, respectively 17. Normal pooled plasma from 40 healthy donors was 
used as a reference. 
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The multimeric structure of vWF was analyzed by agarose gel electrophoresis followed 
by Western blotting as described by Lawrie et al. 33. 
Binding of monoclonal antibody RU5 34 to vWF was analysed as described before 31 with 
some modifications. Microtiter-plate wells (Costar, Cambridge MA, USA) were coated with a 
polyclonal antibody directed against the D’ and D3 domains of vWF 34 diluted to 2.5 µg/ml with 
50 mM carbonate buffer pH 9.6. Coating was carried out for 3 h at 37 oC. Wells were washed 
with PBS containing 0.1% Tween-20 (PBS-T) and blocked with 3 % BSA in PBS-T for 1 h at 37 
oC. Expression medium containing (mutant) vWF was diluted with mock medium to a final 
concentration of 1 µg/ml vWF. Wells were incubated with diluted medium for 1 h at 37 oC. After 
washing, 2 µg/ml RU5 in PBS-T containing 3% BSA was added for 1 h at 37 oC. Wells were 
washed again and incubated for 1 h at 37 oC with HRP-conjugated rabbit-anti-mouse antibodies 
(DAKO, Glostrup, Denmark) diluted 1:2500 in PBS-T containing 3% BSA. O-phenylenediamine 
was used as substrate for detection. 
 
Static Collagen-Binding Assay  
Binding of vWF in expression medium to fibrillar human placenta collagen type III (Sigma 
Chemical Co., St. Louis MO, USA, cat. No. C-4407) was studied in a solid-state binding assay at 
a vWF concentration of 0.1 µg/ml as described before 31.  
 
Surface Plasmon Resonance Collagen-binding Assay  
Surface Plasmon Resonance (SPR) binding studies were performed using a Biacore2000 system 
(Biacore AB, Uppsala, Sweden). Human placenta collagen type III was dissolved in 50 mM 
acetic acid at a final concentration of 1 mg/ml (16h, 4 oC) and immobilized on a CM5-biosensor 
chip using the amine-coupling kit as instructed by the supplier. Approximately 3000 RU, 
corresponding with ~33 fmol/mm2, collagen type III was immobilized. A reference channel was 
coated with human placenta collagen type IV (3000 RU; Sigma, cat. No. C-7521) that does not 
interact with vWF 5. Analysis was performed in Biacore standard buffer 25 mM Hepes, 125 mM 
NaCl, 2.5 mM CaCl2, 0.005% (v/v) Tween-20, pH 7.4 at 25 oC at a flow rate of 10 µl/min. 
Binding of vWF to the collagen type III-coated channel was corrected for binding to the collagen 
type IV-coated channel. Binding isotherms were determined by injecting increasing 
concentrations of vWF. Each injection was continued for 30 minutes, facilitating accurate 
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determination of the steady state (Req) by fitting the binding curve with a 1:1 Langmuir 
interaction model (Biaeveluation software version 3.0.1), which gave the best fit with the 
experimental data. The delay between two subsequent injections was seven minutes in which the 
biosensor chip was flushed with biacore-standard buffer without regeneration. After measuring 
all concentrations of a vWF-variant, the biosensor chip was regenerated by injection of 1 mM 
EDTA, 1 M NaCl, 0.1 M sodium citrate, pH 5.0 (1 min, 10 µl/min) and 10 mM taurodeoxycholic 
acid, 100 mM Tris, pH 9.0 (1 min, 10 µl/min) and 0.1 M H3PO4 (1 min, 10 µl/min). 
Binding isotherms were constructed using the computer program GraphPad Prism 3.0 35. 
The response units at equilibrium (Req) were plotted against the injected vWF concentration and 
the data points were fitted with a 1:1 interaction model Req=Req,max*[vWF]/(KD + [vWF]), where 
Req,max is the response at infinite vWF concentration and KD is the dissociation constant. Since the 
interactions between vWF and collagen are multivalent and we used a 1:1 interaction model, the 
calculated dissociation constants must be regarded as apparent values. 
 
 
Results 
 
Characterization of vWF Mutants  
The conformation of the A3 domain and the multimeric size of vWF determine its reactivity 
towards collagen. Multimer distributions of vWF mutants and recombinant wt-vWF were 
indistinguishable (data not shown). The conformation of the A3 domain was evaluated with 
conformation dependent monoclonal antibody RU5. Binding of RU5 to 18 of the 22 point 
mutants was similar as the binding of RU5 to wt-vWF. As expected, RU5 did not bind to vWF 
lacking the A3 domain, ∆A3-vWF 17 (figure 1A). Four of the point mutants, P962H, P981A, 
V984A and V985A, had a significantly reduced RU5 binding, ranging from 60 to 80 % compared 
to wt-vWF. However, collagen binding of these mutants was normal (see below). Reduced RU5-
binding can be explained by direct interactions of these residues with RU5, as observed in the 
crystal structure of the A3•RU5 complex 31. Overall, these data suggest that the A3 domain of all 
vWF-variants is correctly folded. 
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Figure 1: Characterisation of vWF-A3 mutants. A: Binding of conformation dependent monoclonal antibody RU5. 
VWF was immobilized in microtiter-plate wells via polyclonal antibody αD’D3. Immobilized vWF was incubated 
with RU5 and bound RU5 was detected as described under “Experimental Procedures”. Wild-type vWF and ∆A3-
vWF, which lacks the A3 domain 17, were used as a positive and negative control, respectively. Binding of RU5 to 
vWF mutants is expressed as a percentage of wt-vWF binding. Each data-point represents the mean ± SD of three 
experiments performed in duplicate. B: Binding of vWF point mutants to fibrillar collagen type III in a solid-state 
collagen-binding assay. Human placenta collagen type III was coated in microtiter-plate wells. Wells were incubated 
with vWF at a concentration of 0.1 µg/ml. Bound vWF was detected as described under “Experimental Procedures”. 
∆A3-vWF 17 was used as a negative control. Bound vWF is expressed as a percentage of wt-vWF binding. Each data 
point represents the mean ± SD of three independent experiments performed in duplicate. 
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Collagen Binding Affinity of vWF Mutants  
In a first screen the effect of the mutations in collagen type III binding was assessed by a solid-
state collagen-binding assay (figure 1B). Immobilized collagen was incubated with expression 
medium at a vWF concentration of 0.1 µg/ml. Binding of ∆A3-vWF to collagen was only 8 % 
compared to wt-vWF. Mutations I975A, T977A, D979A, P981H, V997A, E1001A and S1020A 
strongly reduced collagen binding, showing a residual binding of less than 25 %. To further 
investigate the effect of the seven mutations, these mutants, and mutant H1023A from our 
previous study 31, were purified by immuno-affinity chromatography. Collagen binding of the 
purified mutants was analysed by surface plasmon resonance (SPR). In addition to wt-vWF, 
mutants P981A and E1021A that bound normally to collagen in the solid-state collagen-binding 
assay were selected as positive controls. 
Binding isotherms of purified vWF-variants were determined. Human placenta collagen 
type III was coated at a density of 3000 RU. Wild-type vWF bound dose dependent and saturable 
to collagen type III, with an apparent KD of 3.6 ± 0.4 nM and a maximum binding at equilibrium, 
Req,max, of 521 ± 14 RU (figure 2, Table I). 
 
Figure 2: Binding-isotherms of vWF mutants to collagen type III in an SPR-based assay. Human placenta collagen 
types III and IV were immobilized on a CM5 biosensor chip for a detection and reference channel, respectively. 
Wild-type vWF and wt-vWF pre-incubated with a five-fold molar excess of RU5 Fab-fragment were used as a 
positive and negative control, respectively. Sequentially, increasing concentrations of vWF variants were injected 
and equilibrium binding was determined.  
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Table I 
Dissociation- and maximum binding at equilibrium 
  for the vWF – collagen interaction 
vWF variant KD1 (± SD) (nM) Req,max1 (± SD) (RU)  
wt-vWF 3.6 (0.4) 521 (14) 
P981A 2.9 (0.0059) 440 (0.14) 
E1021A 6.3 (0.69) 540 (14) 
I975A 19 (3.0) 352 (20) 
T977A 27 (4.7) 419 (38) 
V997A 26 (2.7) 551 (23) 
E1001A 42 (8.8) 310 (31) 
D979A2  50 
P981H 1.8 (0.26) 120 (3.4) 
S1020A2  30 
H1023A2  50 
1 Since vWF and collagen are multivalent and we used a 1:1 interaction 
model to fit the experimental data these values must be regarded as 
apparent. 
2 Collagen-binding of these variants was to low to calculate reliable 
dissociation constants. 
 
 Addition of the RU5 Fab fragment to wt-vWF almost completely inhibited collagen 
binding, confirming that the A3 domain contains the binding site for collagen type III. Mutants 
P981A and E1021A that bound normally to collagen in the solid-state collagen-binding assay 
also had similar binding affinities and number of binding sites as wt-vWF for collagen in the 
SPR-based assay. Mutants that exhibited strongly reduced collagen-binding in the solid-state 
assay divided in two populations in the SPR collagen-binding assay. Mutations I975A, T977A, 
V997A and E1001A reduced the affinity of vWF for collagen five to ten fold, whereas at 
saturation the number of binding sites was at least 60 % compared to wt-vWF (Table I). Mutants 
D979A, P981H, S1020A and H1023A had a residual binding at saturation of less than 20 % 
compared to wt-vWF. The affinity could be calculated only for mutant P981H and it was similar 
to wt-vWF. 
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As shown in figure 3A, mutations that reduce collagen binding are located at the front 
face of the domain and define a rather flat collagen-binding site. Mutations at the bottom face did 
not have an effect. Interestingly, mutations that strongly inhibit collagen binding cluster at the 
lower part of the collagen-binding site, whereas mutations that partially inhibit collagen binding 
cluster at the upper part.  
 
 
 
Figure 3: Characteristics of 
the collagen-binding site on 
the vWF-A3 domain. The 
front-face of the A3 domain 
is shown. A: Representation 
of the A3 domain that shows 
the effect of mutations in 
collagen-binding by colour. 
Residues in magenta display 
strongly reduced collagen 
binding. Residues in green 
display a partially reduced 
collagen binding, whereas 
collagen binding of residues 
in grey is comparable to 
recombinant wt-vWF. Pro981 
is shown in red. The effect of 
five mutations investigated in 
our previous study 31, R963A, 
E987A, H990A, R1016A and 
H1023A, are included in the 
figure. 
B: Solvent accessible surface 
with electrostatic potential 
contoured from red (-10kT/e) 
to blue (+1- kT/e). C: Solvent 
accessible surface with 
hydrophobic- and hydrophilic 
regions in green and white, 
respectively. D: CPK-
representation of the A3 
domain with two collagen 
triple helices that indicate the 
putative range of orientations 
for the A3-collagen 
interaction. Residues of A3 
are color-coded as in figure 
3A, except that residues that 
show no effect in collagen 
binding are colored in yellow 
and residues of which no data 
are available are shown in 
grey. 
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Surface properties of the collagen binding site are shown in figures 3B and 3C. The upper 
part of the collagen binding site contains a small negatively charged patch. In addition, the 
collagen binding site contains one large and two smaller hydrophobic patches. 
 
Docking of a Collagen Triple Helix on A3  
Identification of residues involved in collagen binding allows us to dock a collagen triple helix on 
A3. Attempts using an automated procedure 36 were not successful. Possibly this was caused by 
the use of a triple helix consisting of glycine-proline-hydroxyproline repeats, because specific 
collagen sequences that interact with A3 have not been identified. Therefore, we manually 
docked a collagen triple helix on A3 using the computer program O 37 and the following 
constraints: (i)  the diameter of a collagen triple helix is approximately 17 Å, (ii) all residues 
shown to be involved in collagen binding should contact the triple helix, and (iii) since RU5 
blocks collagen binding to A3, the position of the triple helix should overlap the position of the 
RU5 Fab fragment 31. A broad range of orientations of a collagen triple helix on A3 fulfil these 
constraints (figure 3D). Six to eight consecutive collagen residues interact with the A3 domain. 
 
 
Discussion 
 
Von Willebrand Factor A-type domains are found in many proteins including collagens, 
complement proteins and integrins where they are named I-domains. These proteins are involved 
in several biological functions like cell-cell interaction and ligand-receptor binding. In integrins, 
these interactions are mediated by a divalent cation present in the MIDAS motif at the top of the 
domain. 
vWF contains three A-type domains, of which the A3 domain binds to collagen. The 
vWF-A3 domain does not contain a functional MIDAS motif and collagen binding is cation 
independent 21; 29. Previously, we have identified the approximate location of the collagen binding 
site 31. Based on these results we constructed a panel of twenty-two point mutants in which 
solvent exposed residues were mutated to either alanine or histidine. These mutations were 
introduced into multimeric vWF, and collagen-binding was evaluated. 
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Collagen binding of the point mutants was screened in a solid-state collagen-binding 
assay. Seven of the twenty-two mutants, I975A, T977A, D979A, P981H, V997A, E1001A and 
S1020A, displayed reduced collagen binding. Because the solid-state collagen-binding assay is a 
static assay that reveals collagen-binding under non-equilibrium conditions, we further 
characterised these seven mutants and mutant H1023A, which also binds strongly reduced to 
collagen 31, by SPR under equilibrium conditions. The apparent dissociation constant of wt-vWF 
for collagen was 3.6 nM, which is similar to values determined by van der Plas et al. and Saenko 
et al. 34; 38. Addition of a five-fold molar excess of the RU5 Fab fragment to wt-vWF completely 
abolished collagen binding. Interestingly, at equilibrium conditions the mutants that were 
qualified as “strongly reduced” in the solid-state assay now separated in two groups. Collagen 
binding of mutants D979A, S1020A and H1023A, was 80 – 90 % inhibited and therefore these 
residues are essential for collagen binding. Mutants I975A, T977A, V997A and E1001A, were 
characterised by a 5 – 10 fold reduced affinity, but had a normal number of binding sites 
suggesting that these residues are involved in collagen binding, but are not essential. Mutation 
P981H strongly reduced collagen binding but the apparent affinity is similar to wt-vWF. 
Interestingly, mutation P981A did not reduce collagen binding. This indicates that Pro981 is 
spatially very close, but does not interact with the collagen triple helix. Most likely, mutation 
P981H inhibits via sterical hindrance the binding of collagen sequences that contain large 
residues, but does not affect the binding of other collagen sequences.  
Mutated residues that displayed reduced collagen binding define the collagen-binding site 
at the front face of A3. Residues that are essential in collagen binding, residues Asp979, Ser1020 
and His1023, cluster at the lower part of the collagen-binding site and are located in strand β3 and 
loop α3β4. Residues that bind to collagen, but are not essential, residues Ile975, The977, Val997, 
Glu1001 and Arg1016, cluster at the upper part of the collagen-binding site and are located in loops 
β2β3, α2α3, helix α3 and strand β3. Previously we hypothesised the possible involvement of 
loop β3α2 in collagen binding 31, but mutations in this loop did not inhibit collagen binding 
excluding its involvement. None of the mutations at the bottom-face of A3 reduced collagen 
binding and therefore we excluded the A3 bottom face to be involved in collagen binding.  
 High affinity sites within collagen to which vWF binds are still unknown. Based on the 
surface characteristics of the collagen-binding site, we suggest that a collagen triple helix 
containing positively charged and hydrophobic residues binds A3. Since mutation P981H 
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strongly reduces the number of collagen binding sites with retaining normal affinity, whereas 
mutation P981A does not affect collagen-binding at all, it suggests that the collagen triple helix is 
spatially close to Pro981 and may contain a large residue. In addition to this it is likely that A3 
recognizes multiple collagen sequences. Also for the I-domain of α1 integrin it has been observed 
that it recognizes multiple collagen sequences 39. 
Manual docking of a collagen triple helix on the front face of the A3 domain suggested a 
broad range of engagements of a collagen triple helix on the A3 domain (figure 3D). Therefore 
the models must be regarded as a crude approximation. This model predicts that at most eight 
consecutive residues in a collagen molecule interacts with A3. 
The vWF-A3 collagen-binding site is located at the front face of the domain, whereas the 
collagen-binding site of homologous integrin I-domains is located at the top and requires a 
functional MIDAS motif 27; 40. The collagen-binding site of I-domains contain a protruding helix 
that determines the specificity towards collagen 24; 41. The collagen-binding site of A3 does not 
contain such a protruding helix and it is rather flat. This suggests a low specificity of A3 for 
collagen sequences. 
Recently, four mutations (S968T, Q971H, I978T, Q999R) in the A3 domain have been 
identified in patients that have either no or mild bleeding problems 42; 43. This questions the 
relevance of the A3 domain for immobilisation of vWF to the vascular matrix 42. However, Wu et 
al. 20 characterised a monoclonal antibody that binds to A3 and inhibits platelet adhesion in vivo, 
confirming the relevance of the A3 domain in the vWF – collagen interaction. In addition, these 
four residues are located in the region of the collagen-binding site that contains residues that are 
involved but not essential in collagen binding. Such mutations may therefore not give bleeding 
symptoms. In contrast, mutations in the region that contains residues that are essential in collagen 
binding may be associated with bleeding symptoms.  
 In summary, we mapped the collagen-binding site at the front face of the domain. 
Residues in the lower half of the collagen-binding site are essential for collagen binding, whereas 
residues in the upper half are involved but not essential. We suggest that a collagen triple helix 
that interacts with A3 contains hydrophobic and positively charged residues. Further 
understanding of the vWF-collagen interaction requires the identification of specific collagen 
sequences involved in vWF binding. 
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Summary 
 
vWF is a multimeric plasma glycoprotein that mediates platelet adhesion at sites of vascular 
damage. The collagen-binding site has been mapped to the front face of the vWF-A3 domain. 
Recently a patient has been reported with mutation Ser968Thr in the A3 domain that reduced 
collagen type I binding. In the present study we have evaluated binding of Ser968Thr-vWF to 
collagen type III. In addition platelet adhesion to collagen type III was evaluated in the presence 
of vWF containing this mutation. Whereas collagen binding of Ser968Thr-vWF was similar as 
the binding of wt-vWF to collagen, platelet adhesion in the presence of Ser968Thr-vWF was 40 
% reduced. 
We solved the crystal structure of Ser968Thr-A3. In the crystal structure we did not observe 
long- or short range conformational changes. However, since some loops at or close to the 
collagen binding site are flexible, we suggest that mutation Ser968Thr shifts the equilibrium 
between the conformations of these loops. This switches A3 from a high- to a low-affinity 
conformation and thereby reduces collagen binding. 
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Introduction 
 
Von Willebrand factor (vWF1) is a large multimeric plasma glycoprotein. At sites of vascular 
damage it serves as a molecular bridge between collagen and the glycoprotein Ib-IX-V complex 
on the platelet, thereby initiating thrombus formation (reviewed in 1). A dysfunctional vWF may 
lead to bleeding complications. 
Mature vWF contains 2050 amino-acid residues that are arranged in domains D’-D3-A1-
A2-A3-D4-B1-B2-B3-C1-C2-CK. Dimer formation involves interchain disulfide bond formation 
between CK domains, whereas multimers are formed by interchain disulfide bonds between D3 
domains. VWF multimers contain up to 80 monomers 2. Multimerisation is important for the 
function of vWF, because smaller multimers have a reduced affinity toward collagen and are less 
active in platelet aggregation 3. The vWF-A3 domain is essential for platelet adhesion in vivo 4, 
since it contains the primary binding site collagen for collagen types I and III 5 that are 
constituents of the deeper layers of the vessel wall 6. The collagen-binding site in A3 is located at 
the front face of the domain 7. This is in contrast to homologous integrin I-domains, like the α2-I 
domain, which contains the collagen-binding site at the top face 8. Moreover, collagen binding by 
the vWF-A3 domain is cation independent 9, whereas integrin I-domains require the presence of a 
divalent cation in the metal ion dependent adhesion site motive 10; 11. 
Qualitative or quantitative defects in vWF cause von Willebrand disease (vWD) 12, a very 
mild to severe bleeding disorder. Recently a new dysfunctional phenotype of vWF has been 
found with a reduced collagen binding activity, resulting in a mild bleeding tendency 13. This was 
caused by mutation Ser968Thr in the vWF-A3 domain. In A3, residue Ser968 is not solvent 
exposed but it is located under the surface of the collagen binding site 7. The mechanism by 
which this mutation reduces the affinity of A3 for collagen is not understood. 
In this study, we investigated the platelet adhesive properties of recombinant multimeric 
vWF containing mutation Ser968Thr in a perfusion system. To investigate structural effects of 
the mutation, the crystal structure was solved of monomeric Ser968Thr-A3.  
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Experimental procedures 
 
Construction, Expression, Purification and Characterization of Ser968Thr-A3 
Mutation Ser968Thr was introduced in the isolated A3 domain using the Quikchange method 
(Stratagene, La Jolla CA, USA) and plasmid pET15b-A3 that contains vWF residues 920– 1111 
14. The presence of the mutation was confirmed by sequencing.  
Ser968Thr-A3 was expressed in E. coli BL21(DE3). Bacteria were cultured in LB 
medium containing 10 g/l peptone, 5 g/l yeast extract and 10 g/l NaC in 1 litre flasks. At a cell 
density of OD600 1.6 induction was started by the addition of isopropyl-β-D-galactopyranoside 
(0.5 mM final concentration). Bacteria were cultured for an additional 3 hours, collected by 
centrifugation and stored at –20 oC. Ser968Thr-A3 was purified according to a procedure 
published by Huizinga et al. 14.  
 
Construction, Expression, Purification and Characterization of Ser968Thr-vWF  
 Mutation Ser968Thr was introduced in multimeric vWF using the Quikchange method as 
described before 7. Briefly, the mutation was introduced into mutagenesis plasmid pBSvWF-NC 
containing vWF residues 940 to 1113, generating pBSvWF-NC-Ser968Thr, and the presence of 
the mutation was confirmed by sequencing. The NheI – Csp45I fragment of pBSvWF-NC-
Ser968Thr was ligated with NheI – Csp45I digested pNUTvWFcas2, generating plasmid 
pNUTvWFcas2-S968T. 
Ser968Thr-VWF was stably expressed in baby hamster kidney cells that overexpress 
furin, necessary for proper removal of vWF propeptide 5; 15. Cells were cultured in serum-free 
medium. 
 Ser968Thr-VWF was purified by immuno-affinity chromatography using monoclonal 
antibody RU8, which is directed against the D4 domain 5. Ser968Thr-VWF was eluted in 50 mM 
Tris, 100 mM NaCl pH 7.4 and vWF-containing fractions were stored at –20 °C. 
The vWF concentration was determined by a sandwich ELISA using polyclonal α-vWF 
and horseradish peroxidase (HRP) conjugated polyclonal α-vWF (DAKO, Glostrup, Denmark) 
for immobilization and detection, respectively 5. Normal pooled plasma from 40 healthy donors 
was used as a reference. 
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The vWF multimeric structure was analyzed by agarose gel electrophoresis followed by 
Western blotting as described by Lawrie et al. 16. 
Binding of monoclonal antibody (MoAb) RU5 to vWF was analyzed as described before 
with a few modifications 7. Microtiter-plate wells (Costar, Cambridge MA, USA) were coated 
with 2.5 µg/ml polyclonal α-D’D3 17 in 50 mM carbonate buffer pH 9.6 (3 h, 20 oC). Wells were 
washed with PBS/0.1% Tween-20 and blocked with 3 % BSA in PBS/0.1% Tween-20 (1 h, 37 
oC). Wells were incubated with 1 µg/ml vWF in mock medium (1 h, 37 oC). After washing, 2 
µg/ml RU5 in PBS/0.1% Tween-20 containing 3% BSA was added (1 h, 37 oC). Wells were 
washed and incubated with HRP conjugated rabbit-anti-mouse antibody (DAKO, Glostrup, 
Denmark) diluted 1:2500 in PBS/0.1% Tween-20 containing 3% BSA (1 h, 37  oC). O-
phenylenediamine was used as substrate for detection. 
 
Solid-State Collagen-Binding Assay 
VWF binding to fibrillar human placenta collagen type III (Sigma chemical CO., St. Louis MO, 
USA, cat. No. C-4407) was studied in a solid-state collagen-binding assay as before 7; 17. 
Collagen was coated in microtiter plate wells at a concentration of 50 µg/ml in 20 mM sodium 
phosphate pH 7.4 by centrifuging the mircotiter-plate 15 minutes at 1500 rpm in a table-top 
centrifuge. After blocking with 3% BSA in PBS/0.1% Tween-20, expression medium containing 
vWF was added at indicated concentrations (1 h, 37 oC). After washing with running tap water, 
wells were incubated with horseradish peroxidase conjugated anti-vWF antibody (DAKO, 
Glostrup, Denmark) in PBS/0.1% Tween-20 containing 3% BSA (1 h, 37 oC). O-
phenylenediamine was used as substrate for detection. The binding-isotherms for vWF-collagen 
interaction were fitted with a 1:1 interaction model Yeq=Yeq,max*[vWF]/(KD + [vWF]), in which Y 
represents the amount of bound vWF. 
 
Platelet Adhesion to Ser968Thr-vWF under Flow  
Human placenta collagen type III coated Thermanox® coverslips were prepared as described 
before 18; 19. Citrated plasma was depleted from endogenous vWF by 3 passages over an immuno-
affinity column using monoclonal antibody RU2 that is directed against the vWF-A2 domain 20; 
21. Residual endogenous vWF was less than 1% (data not shown). Reconstituted blood was 
prepared from vWF depleted plasma by adding recombinant vWF (8 µg/µl), washed red blood 
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cells (40 % (v/v) final concentration) and platelets (2*105 cells/µl) from a blood group O+ donor 
22; 23. Perfusion, using prewarmed perfusate, was done in a miniaturized linear flow perfusion 
system at a wall-shear rate of 1600 s-1 (5 min., 37 oC) 19. Coverslips were stained with May-
Grünwald/Giemsa 24 and platelet adhesion was evaluated using a light microscopy at 400 fold 
magnification connected to an Image Analyzer (AMS 40-10, Saffron Walden, UK) and the 
program Optimas 6.0 (Optimas corporation, Washington, USA). Twenty fields perpendicular to 
the flow axis at the center of each coverslip were analysed, and platelet adhesion was expressed 
as a percentage of the covered surface area. As positive and negative control, washed red blood 
cells and platelets were added to the platelet-donors plasma or to vWF-depleted plasma, 
respectively. Each data point represents the mean ± SD of at least three experiments in triplicate. 
 
Crystallization, Data Collection and Processing  
Crystals of Ser968Thr-A3 were grown by the hanging-drop vapor-diffusion method at 4 oC using 
a precipitant solution consisting of 27 % (v/v) PEG 3000, 0.2 M sodium acetate pH 4.6, 0.1 M 
Tris/HCl pH 8.5 and a protein concentration of 6.5 mg/ml. Crystals that were obtained after 30 
days. The crystals were soaked in cryoprotectant containing 30% (m/v) PEG 3000, 0.2 M sodium 
acetate pH 4.6, 0.1 M Tris/HCl pH 8.5, 15% (v/v) glycerol for 1 - 2 minutes and snap frozen in 
liquid nitrogen. Diffraction data were collected at the European Synchrotron Radiation Facility 
(Grenoble, France) on beam line ID14-EH3. Diffraction data were processed using the programs 
DENZO and Scalepack 25. Diffraction data statistics are summarized in Table I. 
 
Structure Determination and Refinement 
The structure was solved by molecular replacement using the program CNS 26 with the structure 
of wt-A3 14 as a search model. Two Ser968Thr-A3 molecules were identified in the asymmetric 
unit, denoted A and B. Rebuilding using O 27 and positional- and B-factor refinement using CNS 
were performed until convergence. Non-crystallographic symmetry restraints were applied in the 
initial stages of refinement. Cross validation was used throughout refinement using a 5% test set 
of reflections. Refinement used the maximum-likelihood algorithm 28 and bulk-solvent correction 
was applied. Water molecules were placed in difference electron-density peaks if the peak height 
was at least 3.0 σ and the distance to a hydrogen-bond donor or acceptor was 2.7-3.2 Å. Water 
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molecules with a B-factor above 100 Å2 were rejected. The final model was analyzed with 
PROCHECK 29 and WHATIF 30. Refinement statistics are summarized in Table I. 
 
Results 
 
Characterization of Ser968Thr-vWF  
Since vWF binding to collagen is dependent on the multimer distribution and the conformation of 
the A3 domain, the multimeric pattern and binding of conformation specific MoAb RU5 to 
Ser968Thr-vWF were analyzed. The multimer distribution of Ser968Thr-vWF was similar to wt-
vWF (data not shown), indicating proper post-translational processing. Binding of conformation 
dependent monoclonal antibody RU5 to Ser968Thr-vWF was similar to binding to wt-vWF 
(figure 1), suggesting that the mutation does not disrupt the overall conformation of the A3-
domain. 
 
Figure 1: Binding of monoclonal 
antibody RU5 to Ser968Thr-vWF. VWF 
was immobilized in microtiter plate 
wells via polyclonal αD’D3 and was 
incubated with RU5. Bound RU5 was 
detected as described under 
“Experimental Procedures”. Wild-type 
vWF and ∆A3-vWF, which lacks the A3 
domain 5, were used as a positive and 
negative control, respectively. Binding 
of RU5 to vWF mutants is expressed as 
a percentage of wt-vWF. Each data-
point represents the mean ± SD of two 
independent measurements. 
 
Collagen binding of Ser968Thr-vWF was evaluated in a solid-state collagen-binding 
assay (figure 2). Wild-type vWF bound saturably and concentration dependent to collagen with a 
dissociation constant of 1.3 µg/ml. As expected, binding of ∆A3-vWF to collagen was markedly 
reduced with a maximal binding of 23 % at a concentration of 10 µg/ml. Binding of Ser968Thr-
vWF to collagen was saturable and concentration dependent. At 10 µg/ml, the maximum binding 
Ser968Thr-vWF to collagen type III was 10 % reduced compared to wt-vWF while the 
dissociation constant was increased to 1.4 µg/ml. Differences between Ser968Thr-vWF and wt-
vWF in binding to collagen are not significant. 
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Figure 2: Binding of Ser968Thr-
vWF to collagen type III in a solid-
state collagen-binding assay. 
Fibrillar human placenta collagen 
type III was coated in microtiter 
plate wells. Wells were incubated 
with vWF at a concentrations 
indicated and bound vWF was 
detected as described under 
“Experimental Procedures”. ∆-A3 
vWF was used as a negative control. 
Bound vWF is expressed as a 
percentage of wt-vWF. Each data 
point represents the mean ± SD of 
three experiments performed in 
duplicate. 
 
 
The effect of mutation Ser968Thr in platelet adhesion to a collagen type III coated surface 
was evaluated in a perfusion system that mimics the in vivo situation. To this end, either wt-vWF, 
∆A3-vWF or Ser968Thr-vWF was added to vWF-depleted plasma. In each set of experiments, 
depleted plasma was supplemented with platelets isolated from different healthy donors, yielded 
a surface coverage of 9.9%, 9.3%, 30.3% and 43.4% for wt-vWF. Although the variation in 
platelet adhesion is rather high, donor variation has been reported before and was hypothesized to 
correlate with surface expression of α2β1 on the platelet 31;32. Platelet adhesion mediated by ∆A3-
vWF and Ser968Thr-vWF was normalized against wt-vWF within each experiment. Platelet 
adhesion in the presence of these variants was reduced by 88 % and 49 %, respectively (figure 3). 
 
 
 
 
Figure 3: Platelet adhesion on collagen 
surface mediated by vWF variants. 
Human placenta collagen type III was 
coated on Thermanox® coverslips. VWF 
variants were added at a concentration of 
8 µg/ml to reconstituted blood containing 
endogenous vWF depleted citrated 
plasma. Platelet coverage was evaluated 
after 5 minutes perfusion at a wall shear-
rate of 1600 s-1.  
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Crystal Structure of Ser968Thr-A3  
Ser968Thr-A3 was purified from E. coli and concentrated to approximately 6.5 mg/ml. During 
concentration a significant fraction of the protein precipitated, suggesting that the mutation may 
influence the conformation of the A3 domain. Crystals of Ser968Thr-A3 were obtained by 
hanging-drop vapor-diffusion crystallisation at 4 oC. Crystallographic data statistics of a 
Ser968Thr-A3 crystal that was measured at the ESRF are summarized in Table I. Two molecules, 
denoted A and B, were observed in the asymmetric unit of which one is shown in figure 4A. The 
structure was refined to a R-factor of 18.2 % and a free R-factor of 22.8 %, contains 279 water 
molecules and 4 glycerol molecules. Refinement statistics are summarized in Table I. Judged 
from the Ramachandran plot the models were of good geometry, because 93.8 % of the residues 
were in the most favored region and 6.2 % in the additional allowed regions. 
 
Figure 4: Crystal structure of Ser968Thr-A3. (A) Crystal structure of one of the Ser968Thr molecules is shown. 
Ser/Thr968 is shown in the structure and is buried just below the surface containing residues that are involved in 
collagen binding. (B) Superposition of one wt-A3 and one Ser968Thr-A3 model. Except for a small movement of the 
Trp982 side chain, the mutation does not induce local conformational changes. 
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Table I 
Diffraction data and refinement statistics 
Diffraction data  
  Space group P21 
  a, b, c (Å) 39.9, 61.7, 60.4 
  α, β, γ (o) 90.0, 104.1, 90.0 
  Mosaicity (o) 0.5 
  Redundancy 2.7 
  No. of unique reflections 21523 
  I/σ(I), 16.1 (3.0)a 
  Completeness (%) 95.6 (90.6)a 
  Rmergeb (%) 7.4 (39.5)a 
Refinement  
  Resolution (Å) 1.90 (1.97-1.90)a 
  R-factor 18.2 
  Rfree 22.8 
  r.m.s.d. bond distances (Å) 0.0050 
  r.m.s.d. angles (o) 1.2 
  Average overall B-factor for protein atomsc (Å2) 16.1 (21.0)  
  Protein residues observed A: 925 – 1108 
 B: 925 – 1099 
  No. of protein atoms 2696 
  No. of solvent moleculesd 279 (33.7) 
  No. of glycerol moleculesd 4 (35.0) 
a Number between parentheses indicate statistics for highest resolution shell. 
b Rmerge =  ∑i(Ii-<Ih>)2 / ∑i(Ii)2. 
c Main chain atoms. Number between parenthesis is from side chain atoms. 
d Average B-factor of the molecules in Å2 is given between parenthesis. 
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The A3 construct contains residues 920 – 1111 of mature vWF, but the N- and C-termini 
are disordered in the crystal. For molecule A we observe residues 925 – 1108 while we see for 
molecule B residues 925 – 1099. In both molecules the Cys923-Cys1109 disulfide bridge that 
links the N- and C-terminal regions of the domain could not be observed. Possibly the disulfide 
bridge was broken by the intense X-ray beam of the synchrotron. Breaking of a disulfide bond at 
the surface of  a protein by X-rays has been observed before in other proteins 33. This had the 
most structural consequences in molecule B in which C-terminal residues Leu1100 to Ser1111 could 
not be observed. 
 
Structural Comparison of wt-A3 and Ser968Thr-A3  
Superposition of Ser968Thr-A3 molecules A and B shows variation in the conformation of loops 
α1β2 (residues 961 – 963), β3α2 (residues 983 – 987) and α5β6 (residues 1078 – 1084). 
However, a similar variation is observed within wt-A3 models 7, indicating that these loops are 
flexible in both wt- and mutant A3. In the proximity of Thr968 no variation in the backbone or 
side chains is observed between molecules A and B. 
To investigate whether mutation Ser968Thr introduces conformational changes in the A3 
domain, molecules A and B of the mutant and eight known wt-A3 models were superimposed 7; 
14; 34. The overall structure Ser968Thr-A3 and wt-A3 were indistinguishable indicating that the 
mutation does not induce long-range effects in A3. 
In wt-A3, Ser968 is located just beneath the surface of the protein in close proximity of 
residues Ile975, Thr977, Asp979, Val997, Glu1001, Arg1016, Ser1020 and His1023 that are involved in 
collagen binding 7. The Ser968 side chain adopts two conformations, indicating that there is some 
flexibility (figure 4B). In one conformation the hydroxyl group points to the interior of the 
domain, whereas in the other conformation it points to the surface and its hydroxyl group forms a 
hydrogen bond with the backbone carbonyl oxygen of Val980. In both models of the mutant, the 
hydroxyl group of Thr968 points to the interior of the domain and occupies the same position as 
the inwards-oriented hydroxyl of Ser968 in the wild-type protein. This conformation gives some 
strain due to a short distance of 3.1 Å between the methyl group of the of Thr968 side chain and 
the side chain of Trp982. Although the side chain of Trp982 moves slightly, the displacement is too 
small to relief the strain. No conformational changes are observed for residues at the surface of 
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the domain that are involved in collagen binding. Therefore, apart from the small movement of 
Trp982, mutation Ser968Thr does not introduce local conformational changes. 
 
 
Discussion 
 
Recently, two related patients have been described who suffer from slightly increased bleeding 
times 13. These patients have a mutation in the A3 domain. This mutation, Ser968Thr, is the first 
identified mutation in the A3 domain that reduces the affinity of vWF for collagen. In the present 
study we investigated the effect of the mutation multimeric vWF in platelet adhesion in a flow 
system. In addition, to identify conformational changes induced by the mutation we solved the 
structure of Ser968Thr-A3. 
The multimeric structure of vWF is essential for a proper function, because vWF with a 
reduced multimeric size has a decreased affinity for collagen 3. Multimeric composition of 
Ser968Thr-vWF was indistinguishable from wt-vWF. Moreover, binding of conformation-
dependent, function-inhibiting MoAb RU5 to Ser968Thr-vWF was not reduced compared to wt-
vWF. This is in agreement with Ribba et al. 13 who found that the binding of monoclonal 
antibodies 505 and B200 to Ser968Thr-vWF was normal. These results indicate that mutation 
Ser968Thr does not destroy the protein by means of post-translational modification or folding. 
Any observed effects in collagen-binding are therefore due to the (direct) involvement of Ser968 
in collagen binding. 
Collagen-binding was evaluated in a solid-state collagen-binding assay. We found that 
collagen-binding of Ser968Thr-vWF was not significantly reduced compared to wt-vWF, 
whereas Ribba et al. measured 50 % reduced collagen binding 13. These authors have expressed 
vWF in COS-7 cells which do not cleave off the vWF propeptide. We have used vWF expressed 
in BHK cells that also overexpress furin that removes the vWF propeptide. However, this 
difference is not likely to cause the observed discrepancy. Another, more significant, difference is 
that in the study of Ribba et al. collagen binding was evaluated using human placenta collagen 
type I while we have used human placenta collagen type III. Apparently, mutation Ser968Thr has 
a different effect on different types of collagen. 
Structure of Ser968Thr 
 90
Whereas mutation Ser968Thr did not significantly reduce the collagen-binding affinity in a 
solid-state collagen-binding assay, the mutation partially inhibited platelet adhesion to a collagen 
type III coated surface at high shear stress. This suggests that mutation Ser968Thr may have a 
different effect under shear compared to static conditions. It may be that mutation Ser968Thr 
does not influence the affinity under static conditions, but under conditions of shear stress it may 
shift the affinity to a low state.  
In the crystal structure of Ser968Thr-A3 no long- or short-range conformational changes 
could be observed. This is in agreement with the normal reactivity of conformation dependent 
MoAb’s 505, B200 13 and RU5 towards Ser968Thr-vWF. However, this does not indicate that 
there are no conformational changes induced by the mutation. We have hypothesized before that 
collagen binding by the A3 domain involves an induced-fit model involving residues within loop 
α3β4 that is close to Ser968 and loop β3α2 located somewhat further away 7. Among wild-type 
structures loop α3β4 is observed in two conformations, whereas in the mutant only one 
conformation is observed (data not shown). In the mutant similar flexibility for loop β3α2 was 
observed as in wt-A3. It may be that the mutation shifts the equilibrium of these loops to the low-
affinity conformation, but that during the crystallization process there is preference for one of 
these conformations. Based on the experimental data it is not conclusive whether the high- or 
low-affinity conformation crystallizes. 
Based on above assumptions we can not exclude that mutation Ser968Thr does not 
introduce long- or short range conformational changes in the A3 domain, but we are not able to 
observe these conformational changes in the crystal structure. Our data suggest that under shear 
conditions mutation Ser968Thr shifts the equilibrium between a high- and a low-affinity 
conformation and thereby reduces collagen binding. 
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Summary 
 
Transient interactions of platelet-receptor glycoprotein Ibα (GpIbα) and plasma-protein von 
Willebrand Factor (VWF) reduce platelet velocity at sites of vascular damage and play a role 
in haemostasis and thrombosis. Here we present structures of the GpIbα N-terminal domain 
and its complex with VWF domain A1. In the complex GpIbα wraps around one side of A1 
providing two contact areas bridged by an area of solvated charge interaction. The structures 
explain the effects of gain-of-function mutations related to bleeding disorders and provide a 
model for shear-induced activation. These detailed insights into the initial interactions in 
platelet adhesion are relevant for the development of anti-thrombotics. 
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Results and Discussion 
 
Transient interactions of platelet-receptor glycoprotein Ibα (GpIbα) and immobilized von 
Willebrand Factor (VWF) mediate rolling of platelets at sites of vascular damage. Rolling 
reduces platelet velocity and prolongs the contact time with reactive components of the cell 
matrix. This facilitates platelet-activation and subsequent integrin-mediated firm attachment 1. 
Platelet GpIbα and VWF coexist in the circulation, but do not interact at a detectable level 
unless shear stress is applied or exogenous modulators like the snake venom botrocetin are 
added 2. Four types of congenital bleeding disorders have been defined that are caused by 
mutations in GpIbα or VWF either enhancing or reducing complex formation. Shear-induced 
GpIbα-VWF interaction in occluded atherosclerotic arteries or at the surface of ruptured 
atherosclerotic plaques contributes critically to the onset of arterial thrombosis 3. 
GpIbα is the central component of a receptor complex consisting of glycoproteins Ibα, 
Ibβ, IX and V. It anchors the complex to the cytoskeleton and harbors the VWF-binding 
function in its ~290 N-terminal residues. The VWF-binding site is exposed well above the 
platelet surface, being connected to a ~45 nm long highly O-glycosylated stalk 4. The ~250-
kDa VWF protein forms large disulfide-bonded multimers with molecular weights of up to10 
MDa. It is found in plasma and the sub-endothelial cell matrix and is released from storage 
granules when platelets and endothelial cells are activated. A VWF-multimer acts as bridging 
ligand between platelets and the cell matrix, through collagen binding by its A3 domain and 
binding to GpIbα by its A1 domain 5. 
Although the crystal structure of VWF-A1 is known 6; 7 and there is a large body of 
mutagenesis data 8-15, the precise interactions between GpIbα and A1, the mechanism of 
shear-induced activation and the molecular basis of related bleeding disorders are poorly 
understood. We present crystal structures of the N-terminal domain of GpIbα (residues 1-290) 
and its complex with the VWF-A1 domain (residues 498-705; VWF residue numbering used 
starts at the first residue of the mature subunit, addition of 763 converts the numbering to that 
of preproVWF) (Table 1). We expressed recombinant GpIbα with the mutations N21Q and 
N159Q to remove N-glycosylation sites. Crystallization of the complex required the use of 
gain-of-function mutants GpIbα-M239V and A1-R543Q that are associated with platelet-type 
and type 2B von Willebrand diseases and cause an enhanced affinity for complex formation 
(Kd = 5.8 nM). 
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The crystal structure of the von Willebrand factor-binding domain of GpIbα displays 
an elongated curved shape (figure 1) that is typical for proteins containing leucine-rich repeats 
(reviewed in 16). Eight short leucine-rich repeats, seven of which were predicted based on the 
amino-acid sequence, make up the central region of the molecule. Flanking sequences, which 
are conserved among numerous extra-cellular proteins including the other members of the 
GpIb-IX-V complex, cap the leucine-rich repeats. The N-terminal sequence forms a 14-
residue β-hairpin delimited by a conserved disulfide bond between Cys4 and Cys17. The tip 
of the β-hairpin, which we refer to as β-finger, protrudes from the protein surface and is 
disordered in one of the two molecules in the asymmetric unit. The C-terminal sequence, up 
to residue 267, contains a 9-residue α-helix and four short 310-helices. The anionic region 
beyond residue 267 was not visible in the electron-density and was not modeled. Conserved 
disulfide bonds between Cys209 and Cys248 and between Cys211 and Cys264 stabilize the 
irregular fold of the C-terminal region. Residues 227 to 241 project from the concave face of 
the molecule forming a highly flexible loop that shows disorder in both molecules in the 
asymmetric unit. Sequence alignment of C-terminal flanking regions 17 shows that the 
protruding loop is not a conserved feature in this domain-family. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 click on this link for rotating image 
 
Figure 1: Structures of the VWF-binding domain of GpIbα and the complex of GpIbα with the A1 domain of 
VWF. Ribbon representation of GpIbα. The N-terminal β-hairpin, called 'β-finger', is colored blue; the eight 
leucine-rich repeats are green. The C-terminal flanking region is colored red and contains a disordered loop 
(residues 227-241), called 'β-switch'. Disulfide bridges are indicated in yellow ball-and-stick representation. 
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The crystal structure of the complex GpIbα − VWF-A1 shows that the globular A1 
domain interacts with the concave face of GpIbα (figure 2). The interaction surface is 
extended, but discontinuous, comprising two distinct areas of tight interactions (figure 3A). 
The first and most extensive contact site is located near the top of A1 and buries a solvent 
accessible surface of ~1700 Å2. In this contact site leucine-rich repeats 5 to 8 and the C-
terminal flank of GpIbα interact with A1 helix α3, loop α3β4 and strand β3 (figure 3A and 
B). The second and smaller contact site buries a surface of ~900 Å2 and involves interactions 
of the N-terminal β-hairpin and the first leucine-rich repeat of GpIbα with loops α1β2, β3α2, 
and α3β4 at the bottom-face of the A1 domain. As for the native structure of GpIbα, we did 
not observe electron density for the C-terminal anionic region of GpIbα in the complex. This 
is surprising since this region affects rolling of GpIbα expressing CHO cells over VWF 18, but 
is consistent with our observation that the anionic region has no significant effect on binding 
to VWF-A1. 
 
 
Figure 2: Stereo view of a ribbon representation of the complex GpIbα-A1. GpIbα is shown in green and A1 in 
blue with mutations GpIbα−M239V and A1−R543Q shown in red and the disulfide bridge in A1 shown in 
yellow ball-and-stick representation. The β-switch of GpIbα adopts a β-hairpin structure that aligns with the 
central β-sheet of A1. 
 
click on this link for rotating image 
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Figure 3: A: Stereo representation of residues at the A1-GpIbα interface, excluding residues located in the β-
switch of GpIbα and strand β3 of A1. Residues involved in inter-molecular contacts shorter than 4.0 Å are 
shown in stick representation; they form two sites of tight contact separated by an area of solvated interactions. 
Remarkably, Lys549, Trp550 and Arg571 of A1 contacting the β-finger and the first leucine-rich-repeat of 
GpIbα are disordered showing reduced electron density for their side chains. B: Close-up of the β-switch and its 
interaction with strand β3 of A1. Main-chain hydrogen bonds are shown by dotted lines. Amino acids known to 
have gain-of-function mutations related to platelet-type von Willebrand disease have red labels and likely induce 
β-hairpin formation in the β-switch of GpIbα. 
 
 
The flexible loop 227-241 in the C-terminal flank of GpIbα undergoes a 
conformational change upon complex formation.  In the complex this loop, that we call the β-
switch, forms a 16-residue β-hairpin that extends from residues 227 to 242 and aligns with 
strand β3 of A1 (residues 562-566) forming a continuous β-sheet shared between the two 
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molecules (figure 3B). Interestingly, gain-of-function mutations related to platelet-type von 
Willebrand disease, are all found in the β-switch. The specific mutation M239V that we used 
to obtain crystals of the complex, enhances binding ~3-fold and is located in the β-switch 
strand that directly hydrogen bonds to β3 of Α1. Val239 provides two intermolecular main-
chain hydrogen bonds and its side-chain contacts Tyr600 of helix α3 in A1. Based on the 
structure similar interactions with methionine in the wild-type protein may be expected. Other 
known gain-of-function mutations include G233V, that like M239V is detected in patients 
with platelet-type von Willebrand disease 19; 20, and V234G, D235V and K237V that have 
been identified by site-directed mutagenesis 14; 15. Four of the five gain-of-function mutations 
involve amino-acid substitutions known to stabilize β-hairpin structures by introducing a Cβ-
branched residue in the strands (G233V, M239V and K237V) or a glycine residue in the tight 
turn (V234G)21. The mutation M239V increases the association rate three-fold, and hardly 
affects the dissociation rate, which is consistent with stabilization of the β-hairpin priming the 
mutant GpIbα for A1-binding. Unclear at this stage is how D235V, at the second position in 
the tight turn, induces β-hairpin formation and enhances the binding affinity. However, all 
five mutations support an indirect mechanism by influencing the conformation, because the 
side chains have either no or few direct contacts to A1 in the complex. Other valine 
substitutions in this region (K231V, Q232V, A238V and T240V) that reduce binding affinity 
15 may be explained in part by steric hindrance (Q232V and A238V) and loss of a hydrogen 
bond with Asp560 of A1 (T240V). Overall, we conclude that the conformational equilibrium 
of the β-switch of GpIbα is a critical factor in the precisely balanced affinity of the interacting 
partners. 
Gain-of-function mutations related to type 2B von Willebrand disease cluster at the 
bottom face of A1 (figure 4) adjacent to the interaction site with the β-finger of GpIbα.  Type 
2B mutation R543Q that we used in the structure determination of the complex is located 20 
Å away from the interaction site. It causes a ~2.5 fold increase in binding affinity of the 
isolated A1 domain. However, the affinity of the wild-type A1 domain (Kd  ~30 nM) is 
already much higher than the affinity of multimeric VWF, for which we do not detect any 
binding up to a concentration of 150 nM. Similarly, other studies have indicated that the 
affinity depends on the length of the A1-containing VWF fragment employed (see e.g. ref. 9). 
Therefore, the A1 domain used for crystallization lacks key structural elements that suppress 
GpIbα binding in multimeric VWF. In the crystal structure of the wild-type domain 7 the N- 
and C-termini of A1 approach the β-finger interaction site (figure 4), suggesting that longer 
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terminal peptides could shield the binding site of the β-finger in multimeric VWF. Type 2B 
mutations likely destabilize a network of interactions observed between the bottom face of A1 
and its terminal peptides in the wild-type A1 structure 7, thereby making the binding site 
accessible. In the complex we indeed observe a displacement of the termini away from the 
interaction site and a partial disordering of the N-terminus. In comparison, the homologous 
integrin I-type domains bind their ligands at a different site and the large conformational 
changes observed upon ligand binding in I-domains 22 do not occur in A1. The mechanism of 
affinity modulation in the A1 domain is therefore different from that of I-type domains and 
likely involves conformational changes at the N- and C-termini. Shear stress may induce these 
changes in immobilized VWF causing activation in the platelet adhesion process. 
 
 
 
 
 
 
 
 
 
 
Figure 4: Structural changes at the N- and C-terminal side of VWF-A1. The bottom face of the A1 domain, as 
observed in the complex with GpIbα, is shown in space-filling representation with the N- and C-terminal 
peptides shown as Cα-traces in yellow. The position of the β-finger of GpIbα is given by a Cα-trace in green. In 
red we indicated the Cα-traces of the N- and C-terminal peptides of the uncomplexed, wild-type A1 domain 7. 
Residues with known gain-of-function mutations, yielding a type 2B von Willebrand disease phenotype, are 
either shown in ball-and-stick representation in the (wild-type) N- or C-terminal peptides or colored blue in the 
space-filling model of the bottom face. In full-length VWF flanking peptides of A1 possibly shield the binding 
site of the β-finger of GpIbα. 
 
 
The electrostatic surface-potentials of GpIbα and A1 are characterized by large 
patches of opposite charge at the GpIbα-A1 interface that induce long-range electrostatic 
attraction (figure 5). Besides the positively charged patch at the interface, A1 also shows a 
large negatively charged patch on the opposite side of the domain. Possibly, the asymmetric 
charge distribution on A1 helps in steering the long-range interactions. Crystal structures of P- 
and E-selectins bound to sialyl LewisX or a sulfated peptide from PSGL-1, components that 
mediate rolling of leukocytes over inflamed endothelium, also indicated dominant 
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electrostatic interactions 23. However, in the GpIbα-A1 complex, residues making up the 
charge potentials at the interface are not involved in direct contacts, but are either fully or 
partially solvated. Thus, it appears that the surfaces of A1 and GpIbα are organized for long-
range electrostatic attraction avoiding the energetically unfavorable desolvation of charged 
residues 24 in the formation of the final complex.  
 
 
 
 
 
 
 
 
Figure 5: Electrostatic surface potentials of the A1 domain of VWF 
and GpIbα. Potentials were calculated for the individual molecules. 
The surface is colored blue for potentials of > 6kT/e and red for 
potentials of < -6kT/e. The Cα-traces of the partner molecules in the 
complex are shown in white for clarity. The areas of large electrostatic 
potentials at the interface of A1 and GpIbα coincide with the region of 
loose, solvent-mediated contacts between the two molecules. 
Calculations were performed with GRASP 25. 
 
 
The Bernard-Soulier syndrome and type 2M von Willebrand disease are characterized 
by loss of function mutations in GpIbα and VWF-A1, respectively. Loss of function 
mutations in the VWF-binding domain of GpIbα occur at buried sites (L57F, C65R, L129P 
and A156V) or in a disulfide bond (C209S) and likely disturb the structural integrity of the 
domain causing a reduction in binding affinity. Numerous, loss-of-function mutations, 
detected in von Willebrand disease type 2M patients 8 or identified by site-directed 
mutagenesis 9-13 scatter throughout the A1 domain. Sixteen loss-of-function mutations involve 
residues in or directly next to the GpIbα binding site, whereas 10 occur at buried positions 
inside the A1 domain, and are likely to disrupt the A1 structure or induce conformational 
changes to A1 incompatible with binding to GpIbα. The remaining 14 mutations are scattered 
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over the surface outside the observed GpIbα binding site and cannot be explained based on 
the structure of the A1-GpIbα complex. 
Our data suggest that GpIbα and VWF are attracted by long-range electrostatic 
interactions and indicate two contact sites in the final complex, which present primary targets 
for development of drugs for the treatment or prevention of arterial thrombosis. Interaction at 
the larger contact site depends on conformational changes in the β-switch of GpIbα, whereas 
the second, smaller site requires most likely dislodging of the termini of the A1 domain 
uncovering the site of interaction. Mutations that cause gain-of-function diseases favor the 
bound conformation at both contact sites. It is conceivable that under physiological conditions 
shear stress on immobilized VWF displaces the termini of the A1 domain exposing the second 
binding site and hence enhances platelet association to the site of vascular damage. 
 
 
Methods 
 
Protein expression and purification 
GpIbα residues 1 to 269 and 1 to 290 preceded by the signal peptide and fused to a C-terminal 
(His)6 or Arg-(His)6 sequence, respectively, were cloned into expression vector pCDNA3.1. 
The QuikChange kit from Stratagene was used to introduce mutations N21Q and N159Q, 
removing two N-glycosylation sites, and mutation M239V, a platelet-type von Willebrand 
disease mutation. Proteins were expressed in stable BHK cell-lines. BHK cells were cultured 
in Dulbecco’s MEM/ F-12 Ham medium containing 5% fetal calf serum. During protein 
production serum was replaced by 1% Ultroser G (Gibco). GpIbα fragments were purified 
from expression medium by Ni2+/NTA chromatography followed by anion exchange 
(MonoQ) and gel filtration (Superdex 200). Typically, 1 mg of GpIbα could be purified from 
1 liter of medium. The protein was concentrated to ~7 mg/ml in the gel filtration buffer (50 
mM NaCl, 20 mM Tris/HCl pH 8.0). Anion exchange of wild-type and mutant GpIbα(1-290) 
proteins yielded four base-line separated peaks. Electro-spray mass spectroscopic analysis 
showed that these peaks contain GpIbα modified by sulfation at 0, 1, 2 or 3 sites, likely 
tyrosine residues in the anionic region (data not shown). Fully sulfated GpIbα was used for 
crystallization experiments.  
Wild-type VWF-A1 domain residues 498 to 705 and mutant A1 R543Q were cloned in 
expression vector pPIC9 and over-expressed in Pichia pastoris strain GS115, according to the 
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Invitrogen manual. After 3 days of induction expression medium was collected and dialyzed 
against standard buffer (25 mM Tris, 100 mM NaCl, pH 7.8). The protein was purified on 
heparin Sepharose, followed by gel filtration (Superdex 200). It was dialyzed against standard 
buffer and concentrated to ~4 mg/ml. 
Multimeric recombinant VWF was produced and purified according to a published procedure 
26. 
 
Crystallization 
Crystals were grown using the hanging-drop vapor-diffusion technique. GpIbα  (N21Q, 
N159Q) crystals were obtained at 28 oC by mixing 1 µl of protein solution and 1 µl reservoir 
solution (1.8 M ammonium sulfate, 0.2 M lithium sulfate and 100 mM CAPS pH 8.2). Before 
flash cooling, crystals were transferred to a cryo-protective solution (25% (w/v) PEG 3000, 
200 mM NaCl, 100 mM Tris pH 8.2 and 15% (v/v) glycerol). GpIbα crystals have space 
group C2 with cell constants: a = 121.5 Å, b = 54.5 Å, c = 101.8 Å, β = 103.7o, and contain 
two molecules per asymmetric unit. 
Crystals of a complex of GpIbα mutant (N21Q, N159Q, M239V) and A1 mutant (R543Q) 
were obtained at 4 oC by mixing 1 µl protein solution containing a 1:1 molar ratio of A1 and 
GpIbα and 1 µl precipitant solution (10% (w/v) PEG 3000, 200 mM NaCl and 100 mM MES 
pH 5.5). Before flash cooling crystals were transferred to precipitant solution containing 20 % 
(v/v) glycerol. Crystals have space group P61 with cell constants: a = b = 89.8 Å, and c = 
124.6 Å, and contain one complex per asymmetric unit.  
 
Structure determination 
Data were collected on beam line ID14-2 at the ESRF and on beam line X11 at the EMBL 
outstation (DESY). Data were processed with DENZO and SCALEPACK 27. Structures were 
solved in conjunction by molecular replacement. A model of A1 7 was placed in the unit cell 
of the complex using CNS 28. Solvent flattening with CNS revealed β-strands of GpIbα 
leucine-rich repeats. A mask was constructed around the putative GpIbα molecule and 
electron density inside the mask was used for molecular replacement with AMoRe 29. This 
identified two molecules in the asymmetric unit of the GpIbα crystal. Improved electron 
density obtained after density modification and phase extension to 2.5 Å was used for model 
building with O 30. The model was refined at 1.8 Å resolution using CNS and then used 
together with the model of A1 7 as the starting point for refinement of the GpIbα-A1 complex. 
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Refinement included bulk solvent correction and calculation of Rfree using 5% of the 
reflections. Diffraction data and refinement statistics are given in Table I. The structures of 
GpIbα and the GpIbα-A1 complex have been deposited in the PDB with ID numbers 1M0Z 
and 1M10, respectively. 
 
Table I. 
Data collection and refinement statistics 
 GpIbα(ESRF) GpIbα-A1 (DESY) 
Data collection statistics*   
Space group C2 P61 
Unit cell dimensions (Å, °) 
 
a = 121.5, b = 54.5, c = 101.8, 
β = 103.7 
a = b = 89.8, c = 124.6 
 
Resolution (Å) 40.0-1.85 (1.9-1.85) 40.0-3.1 (3.2-3.1) 
Completeness (%) 97.8 (80.8) 99.9 (99.9) 
Mosaicity (°) 0.4 0.2 
Redundancy 3.6 (2.4) 5.8 (5.4) 
Rmerge (%) 7.3 (33.7) 8.7 (48.0) 
I/σI 16.3 (2.9) 19.3 (3.6) 
Refinement statistics   
Rfactor (%) 18.7 23.4 
Rfree (%) 21.7 29.6 
No. of protein atoms 4115 (dimer) 3690 
No. of waters 687 0 
r.m.s.d. bonds (Å) 0.005 0.009 
r.m.s.d. angles (°) 1.3 1.6 
* Values in parentheses are for the highest resolution shell. 
 
Biacore analysis 
Binding studies were performed on a Biacore 2000 (Biacore AB, Uppsala Sweden). GpIbα 
monoclonal antibody 2D4 was immobilized on CM5-sensorchips by amine-coupling as 
instructed by the supplier. A control channel was activated and blocked by using the amine-
coupling reagents in the absence of protein. Proteins were dialysed to standard Biacore buffer 
(150 mM NaCl, 0.005% (v/v) Tween-20 and 25 mM HEPES pH 7.4) and analyzed at 25 oC. 
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GpIbα (150 nM) was injected for 1 minute, followed by a 2 minute association phase of A1 
(5-100 nM) or multimeric recombinant VWF (150 nM). Finally, standard buffer was injected 
and the dissociation phase was recorded for 5 minutes. The sensor-chip was regenerated by 
injections of 50 mM triethylamine, 10 mM sodium formate pH 2.0 containing 150 mM NaCl 
and another injection of 50mM triethylamine. Each interaction was analyzed at five different 
VWF-A1 concentrations. Data evaluation was performed with Bia evaluation software 
(Biacore AB) using a 1:1 Langmuir model with baseline drift to compensate for the slow 
release of GpIbα from 2D4. Control experiments included immobilization of GpIbα via His-
tag antibody 3D5 (Novagen), which excluded artifacts caused by antibody 2D4, and a 
comparison of glycosylated and non-glycosylated mutant GpIbα to confirm that glycosylation 
has no effect on binding. 
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Summary 
 
Thrombus formation is initiated by platelet arrest at sites of vascular injury. This process is 
dependent on von Willebrand Factor (vWF) and requires the interaction of its A1 domain with 
glycoprotein (Gp) Ibα on the platelet. VWF must be activated before GpIbα binding occurs, 
either via surface adsorption, vWD type 2B mutations or exogenous agonists. 
We have investigated the binding kinetics of wild type- and vWD mutant Arg543Gln-vWF 
and of wild type- and Arg543Gln-A1 to GpIbα. In contrast to wt-vWF, wt-A1 bound 
spontaneous to GpIbα indicating that the isolated A1 domain is already activated. The effect 
of mutation Arg543Gln in the isolated A1 domain is small compared to the effect in vWF. 
We have solved three crystal structures of wt-A1 and three crystal structures of Arg543Gln-
A1 and compared their conformation with the A1•GpIbα complex, Ile546Val-A1 and 
published wt-A1 structures. In wt-A1, the N- and C-terminal flanking peptides approach the 
GpIbα binding site at the bottom of A1. Probably in vWF the peptides overlap the GpIbα 
binding site. In type 2B-A1 the peptides adopt a different conformation and do not overlap the 
GpIbα binding site. Probably this conformation resembles vWF under conditions of shear 
after binding to the vascular matrix.  
In conclusion, these crystallographic data confirm the activation mechanism of A1 involving 
conformational changes in the N- and C-terminal flanking peptides. These conformational 
changes switch the A1 domain from a low- to a high affinity state by opening the GpIbα 
binding site at the bottom face of the domain. 
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Introduction 
 
Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that is essential for platelet 
adhesion at sites of vascular injury. The primary function of vWF is to form a molecular 
bridge between collagen from the subendothelial connective matrix of a damaged vessel wall 
and the platelet receptor glycporitein (Gp) Ib-IX-V complex.  
Mature vWFa consists of 2050 amino-acid residues in five different domain subtypes 
in the order D´-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK. After synthesis, vWF dimerisation 
occurs at the cystine knot (CK) domain and multimerisation at the D3 domain 1. A vWF 
multimer can contain up to 80 monomers 2. Multimerisation of vWF is essential for a normal 
function, because low vWF multimers have a decreased affinity for their ligands 3. The A1 
domain, spanning residues Cys509 - Cys695, contains the GpIbα binding site 4; 5. 
In normal haemostasis the vWF-A1 domain does not bind spontaneously to GpIbα. In 
vivo, immobilisation of vWF to the subendothelial connective tissue induces GpIbα binding, 
especially under conditions of high shear 6. In vitro, binding to GpIbα can be induced by 
modulators like the toxin botrocetin 7 from Bothrops jararaca or the antibiotic ristocetin 8 
from Nocardia lurida. Botrocetin and ristocetin bind to different regions in A1 9. Ristocetin 
interacts with the C-terminal flanking peptide of A1 10;11 and mimics shear-induced GpIbα 
binding 12. However, the activation mechanism of vWF at a molecular level is a poorly 
understood process.  
Recently we have solved the crystal structure of the A1 domain in complex with the 
290 amino-terminal residues of GpIbα that contains the A1-binding site 13. A1 and GpIbα 
have an extended, but discontinuous, interaction site. There are two areas of tight interactions. 
The first interaction site is located near the top of A1 and involves residues in helix α3, loop 
α3β4 and strand β3. The second interaction site comprises several loops at the bottom-face of 
A1. We hypothesized that in inactive vWF the second interaction site is blocked by the N- and 
C-terminal flanking peptides and that GpIbα binding may be induced by a conformational 
change in these peptides 
In patients, so-called von Willebrand disease (vWD) type 2B mutations at the bottom 
of the A1 domain, or in its flanking peptides, also induce spontaneous GpIbα binding and 
cause platelet clumping, thrombocytopenia, low plasma vWF levels and a bleeding tendency. 
A mechanism by which vWD type 2B mutations activate the A1 domain has been proposed 
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by Celikel et al. 14. In this model, mutation Ile546Val at the bottom of A1 induces a 
conformational change in hairpin β2β3 that is part of the GpIbα-binding site, but is located 
close to the top of A1. Although in the A1•GpIbα complex minor conformational changes are 
observed for loop β2β3, larger conformational changes occur in the N- and C-terminal 
flanking peptides 13. 
In this study we have solved crystal structures of three different crystal forms of either 
wt-A1 and gain-of-function mutant Arg543Gln-A1, yielding eleven new models. Together 
with the previously published wt- and type 2B mutant A1 structures this set of structures was 
used for the analysis of conformational changes in A1 required for activation. Observed 
conformational changes in the N- and C-terminal flanking peptides explain the activation 
mechanism of vWF resulting in GpIbα binding. 
 
 
Methods 
 
Construction of Pichia pastoris expressing A1 
VWF residues 498 – 705 (VWF residue numbering used starts at the first residue of the 
mature subunit, addition of 763 converts the numbering to that of preproVWF) containing the 
A1 domain, were cloned into expression vector pPIC9 (Invitrogen, Breda, The Netherlands). 
The wt- and Arg543Gln-A1 domains were amplified by PCR from plasmids pNUT-vWFcas 
and pNUT-vWF-Arg543Gln 15; 16, respectively using primers  GGACTCGAGAAAGAGAG-
GCTGAAGCTGACATCTCGGAACCGCCGTTGC and GCGGCCGCTTAAGTAGGA-
GGAGGGGCTTCAGGGG (sequences in bold are from vWF, other sequences are from 
pPIC9) and PWO polymerase (Roche, Almere, The Netherlands). The PCR product was 
extended by an additional adenine nucleotide using Taq polymerase (Enzyme Technologies, 
United Kingdom), ligated into pCR2.1-TOPO vector (Invitrogen, Breda, The Netherlands) 
generating TOPO-A1 and sequenced (Hubrecht laboratories, Utrecht, The Netherlands). 
TOPO-A1 was digested with restriction enzymes XhoI and NotI and the fragment containing 
A1 was ligated with XhoI – NotI digested plasmid pPIC9 using Rapid ligase (Roche, Almere, 
The Netherlands) generating expression vectors pPIC9-vwf498/705 and pPIC9-vwf498/705-
Arg543Gln. 
                                                                                                                                                        
a Throughout the text: vWF represents multimeric vWF and A1 represents the isolated A1 domain. 
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The expression vectors were linearised by digestion with BglII or SacI and transformed to 
Pichia pastoris strain GS115. Twenty colonies were picked and grown in 4 ml BMGY 
medium, containing 1 % yeast extract, 2 % peptone, 100 mM potassium phosphate pH 6.0, 
1.34 % yeast nitrogen base, 4*10-5 % biotin and 1 % glycerol, for 72 hours. Cells were 
harvested by centrifugation and grown in 4 ml BMMY medium, containing 1 % yeast extract, 
2 % peptone, 100 mM potassium phosphate pH 6.0, 1.34 % yeast nitrogen base, 4*10-5 % 
biotin and 0.5 % methanol, for an additional 72 hour. Expression medium was collected by 
centrifugation and A1 expression levels were analysed by ELISA. To this end, expression 
medium was diluted 10, 100 or 1000 fold in 50 mM carbonate buffer pH 9.6 and coated in 
microtiter plate wells at 37 oC for 3 hours. Wells were washed with PBS/0.1% Tween-20, 
blocked with 1 % protifar (Nutricia, Zoetermeer, The Netherlands) in PBS/0.1% Tween-20 
(1/2 h, 37 oC), washed with running tap-water and incubated with HRP conjugated polyclonal 
α-vWF (DAKO, Glostrup, Denmark) diluted 1:2500 in PBS/0.1% Tween-20 containing 1 % 
protifar (1 h, 37  oC). O-phenylenediamine was used as substrate for detection. Three clones 
displaying the highest expression were stored in 20 % glycerol stocks at –80 oC. 
 
Expression and purification of vWF-A1 
For large-scale expression of A1, a single colony was inoculated in 6 * 300 ml BMGY 
medium and grown for 90 h at 30 oC. Cells were collected by centrifugation, suspended in 6 * 
300 ml BMMY medium and grown for 72 h at 30 oC. Expression medium was collected by 
centrifugation, filtered (0.22 µm) and dialysed against 20 volumes of a buffer containing 25 
mM Tris, 100 mM NaCl, pH 7.8 (o/n, 4 oC). After filtration A1 was loaded on a 12 ml heparin 
sepharose column (Amersham Pharmacia Biotech, Roosendaal, The Netherlands). The 
column was extensively washed with 25 mM Tris, 200 mM NaCl, pH 7.8. and A1 was eluted 
with 25 mM Tris, 1 M NaCl, pH 7.8. A1 containing fractions were pooled and purified over a 
HiLoad 16/60 Superdex 200 prep grade column (Amersham Pharmacia Biotech, Roosendaal, 
The Netherlands) in 25 mM Tris, 250 mM NaCl, pH 7.8. Fractions were analysed by SDS-
PAGE, pooled, dialysed against 25 mM Tris, 100 mM NaCl, pH 7.8 (o/n, 4 oC), concentrated 
to 4-4.5 mg/ml and stored at –20 oC. Typically, 6 mg of purified A1 was obtained from 1 l 
expression medium. The purified and concentrated A1 domain migrated on a non-reducing 
SDS-PAGE gel as a single band with minor contaminating bands. 
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Expression, purification and characterisation of wt- and Arg543Gln-vWF 
VWF was stably expressed in baby hamster kidney cells overexpressing furin required for 
proper removal of vWF propeptide 17; 18. Cells were cultured in serum-free medium. VWF 
was purified by immuno-affinity chromatography 17 and stored in 50 mM Hepes, 100 mM 
NaCl pH 7.4 at –20 °C until use. The vWF concentration and multimeric structure were 
determined by sandwich ELISA 17 and agarose gel electrophoresis 19, respectively. 
 
Expression, purification and characterisation of GpIbα 
GpIbα was stably expressed in baby hamster kidney cells that were cultured in serum free 
medium. GpIbα was purified as described before 13 and migrated as a single 25 kDa band on a 
non-reducing SDS-PAGE gel.  
 
Surface Plasmon Resonance Analysis 
Binding studies were performed using surface plasmon resonance (SPR) in a Biacore 2000 
biosensor (Biacore AB, Uppsala Sweden). Monoclonal antibody 2D4 directed against GpIbα 
was immobilized on a CM5-sensorchip using the amine-coupling kit as instructed by supplier, 
yielding 3300 reference units (RU) that corresponds with 22 fmol/mm2 immobilised 2D4. A 
control channel was activated and blocked using the amine-coupling reagents in the absence 
of protein. Proteins were dialyzed against standard buffer (150 mM NaCl, 0.005% (v/v) 
Tween-20, 25 mM Hepes, pH 7.4) and analysed at 25 oC. For each determination, 350 nM 
GpIbα was injected at a flow rate of 5 µl/min for 4 minutes (yielding 500 RU, 15 fmol/mm2), 
followed by a 2 minute association phase by injection of vWF- or A1 variants (5 – 150nM) at 
20 µl/min and a 5 minute dissociation phase. The sensor-chip was regenerated by injections of 
50 mM triethylamine, 10 mM sodium formate pH 2.0 containing 150 mM NaCl and another 
injection of 50 mM triethylamine. The binding of vWF- and A1-variants to GpIbα was 
evaluated at five concentrations, each determined in triplicate, and analysed with Bia-
evaluation software (Biacore AB, Uppsala Sweden) using a 1:1 Langmuir model with 
baseline drift to compensate for the slow dissociation of GpIbα from 2D4. Binding to GpIbα 
coated channels was corrected for binding to non-coated channels. 
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Crystallisation and data collection 
A1 crystals were obtained using the hanging-drop vapour-diffusion method at 4 oC. Small 
differences in the composition of the precipitant solution resulted in different crystal forms 
(Table I). Micro-seeding was used to increase crystal-size. The dimensions of the crystals 
used for data collection ranged from 50 to 200 µm. Crystals were equilibrated in precipitant 
solution containing 30 – 35 % glycerol and flash-cooled in liquid nitrogen. X-ray diffraction 
data were collected at the ESRF synchrotron-radiation facility, beam lines ID14-EH2, ID14-
EH3 and ID9 (Grenoble, France). Data reduction, merging and scaling were performed with 
DENZO and SCALEPACK 20. Diffraction data statistics are summarised in table I. 
 
Structure Determination and Refinement 
Structures were solved by molecular replacement using CNS 21 with wt-A1 22 as a search 
model. For model refinement, cycles of rebuilding using O 23 and positional and B-factor 
refinement using CNS were performed until convergence. In some cases non-crystallographic 
symmetry restraints were applied, but only in the initial stages of refinement. Cross validation 
was used throughout refinement using a 5% test set of reflections. Refinement used the 
maximum-likelihood algorithm 24 and bulk-solvent correction was applied. Water molecules 
were placed in difference electron-density peaks with a peak height of at least 3.0 σ, a 
distance of 2.7-3.2 Å to a hydrogen-bond donor or acceptor. Water molecules with a B-factor 
above 100 Å2 were rejected. Refinement statistics are summarised in table I. 
Strong positive electron density peaks observed in A1 structures wt-P41212, wt-P21, 
RQ-P41212 and RQ-P43212 were interpreted as cadmium and chloride ions based on peak 
height and chemical environment (Table I). The cadmium ions mediate important crystal 
contacts, since crystals that were transferred to EDTA-containing precipitant solution 
dissolved. 
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Table I 
Diffraction-data and refinement statistics 
Crystal and Diffraction 
data wild-type A1
c,e Arg543Gln-A1d,f 
Space group P41212 P21 P212121 P43212 P41212 P212121 
Crystallisation condition 
0.1 M Tris pH 8.5, 
0.2 M NaCl,  
12-16 % PEG8k 
0.1 M Tris pH 8.5, 
0.1 M NaCl, 
9 % PEG8k 
0.1 M Tris pH 8.5, 
0.2 M Li2SO4, 
 35 % PEG3k,  
1.3 mM EDTA 
0.1 M Tris pH 7.5, 
0.4 M NaCl,  
9% PEG8k, 
5 mM CdCl2 
0.1 M Tris pH 8.5?, 
18 % PEG 8k, 
 
0.1 M Tris pH 8.5, 
0.2 M Li2SO4, 
30% PEG 3k, 
1.3 mM EDTA 
a, b, c (Å) 
α, β, γ (°) 
75.9,75.9, 93.5 
90, 90, 90 
76.8, 60.6, 87.6 
90, 95.1, 90 
50.5, 61.3, 67.6 
90, 90, 90 
80.5,80.5,125.3 
90, 90, 90 
81.6,81.6,124.2 
90, 90, 90 
50.3, 61.6, 67.0 
90, 90, 90 
Redundancy 7.1 3.5 7.0 14.1 6.6 6.7 
No. of unique reflections 20539 37963 14579 21965 12773 14492 
<I>/<σ(I)> a 36.1 (5.8) 15.8 (2.2) 17.2 (2.9) 28.7 (7.8) 18 (3.3) 18 (3.6) 
Completeness (%)a 100 (100) 98 (84) 84 (38) 100 (100) 99.7 (98.7) 99.3 (93.8) 
Rmerge (%)a,b 3.6 (37.7) 4.6 (28.4) 8.8 (24.8) 6.9 (30.0) 7.5 (45.4) 7.3 (28.0) 
       
Refinement       
Resolution (Å) 1.95 (2.00-1.95) 2.25 (2.33-2.25) 1.90 (1.94-1.90) 2.2 (2.25-2.20) 2.6 (2.69-2.60) 2.0 (2.07-2.00) 
R-factor (%) 
Rfree (%) 
18.8 
22.2 
20.1 
27.5 
18.2 
23.8 
21.2 
26.3 
21.9 
30.5 
18.3 
23.7 
r.m.s.d. bond distances (Å) 0.008 0.006  0.005   
r.m.s.d. angles (°) 1.4 1.2  1.2   
Average overall B-factor (Å2) 23.7 38.9 19.1 26.5 52.7 39.8 
No. of observed residuesg 
 
501-704 
 
501-703 (B,D) 
499-704 (C,E) 
503-703 
 
501-703 (a) 
505-705 (b) 
506-704 (c) 
500-705 (d) 
503-701 
 
No. of protein molecules 1 4 1 2 2 1 
No. of Cd2+ ions 1 4  7 2  
No. of Cl- ions 1 2  6 1  
No. of  SO42- ions   2   1 
No. of glycerol molecules   1   2 
No. of solvent molecules 197 513 220 241 59 181 
a Numbers in parentheses indicate statistics for highest resolution shells. 
b Rmerge = ∑i(Ii-<Ih>)2 / ∑i(Ii)2 
c wt-A1 models are denoted as follows: P41212 model is denoted A; P21 models are denoted B, C, D, E; P212121 model is denoted F; PDB 
entry 1oak is denoted G; PDB entry 1auq is denoted H. Additionally, models are denoted wt-P41212, wt-P21, wt-P212121, wt-1oak and wt-
1auq, respectively. 
d Mutant A1 models are denoted as follows: P43212 models are denoted a, b; P41212 models are denoted c, d; P212121 model is denoted e; 
PDB entry 1FNS (mutant Ile546Val) is denoted f; Arg543Gln-A1 in complex with GpIbα is denoted g. Additionally, models are denoted 
RQ-P43212, RQ-P41212, RQ-P212121, IV-1fns and Arg543Gln-A1•GpIbα, respectively. 
e Structures have been deposited at PDB accession numbers xxx, yyy, zzz, respectively. 
f Structures have been deposited at PDB accession numbers aaa, bbb, ccc, respectively. 
g When more than one model is observed in the asymmetric unit, the models are indicated by characters between parenthesis.
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Results and Discussion 
 
Local structural effects of mutation Arg543Gln in A1 
The process of A1 activation that results in binding to GpIbα is a poorly understood process. 
Activation of A1 can be induced by vWD type 2B mutations. In this study we investigated 
structures of wild type and 2B mutant Arg543Gln-A1 and analysed conformational changes. 
Both wt- and Arg543Gln-A1 crystallised in three different crystal forms, depending on small 
differences in crystallisation conditions. X-ray diffraction data were collected to a resolution 
limit ranging from 1.9 to 2.6 Å and the structures were determined by molecular replacement. 
Crystallographic and refinement statistics are summarised in table I. As it turned out several 
crystal forms contain multiple A1 domains in the asymmetric unit yielding a total of 6 atomic 
models of wt-A1 and five atomic models of Arg543Gln-A1.   
The overall structure of all eleven A1 domains determined by us are similar to 
published structures of A1 13; 14; 22; 25 and consists of a central six-stranded β-sheet flanked on 
each side by three α-helices. The N- and C-terminal regions of the domain are connected by a 
disulphide bond between Cys509 and Cys695. We will refer to the Cys509-Cys695 loop structure 
as the body of the domain while the residues on either side of the disulphide-bonded loop will 
be called the N- and C-terminal flanking peptides.  
VWD type 2B mutation Arg543Gln strongly activates vWF 16. Residue Arg543 is 
located at the end of α-helix 1 close to the bottom face of the domain (figure 1A). 
Replacement of Arg543 by glutamine does not change its backbone conformation. In the 
mutant the glutamine side chain points in a different direction and interacts with residues 
Arg687 and Asp688. As a consequence, the conformation of these residues and nearby residues 
Asp539 and Met540 changes slightly, the largest shift being 1.9 Å for the side-chain of Met540. 
In five of the six wild-type structures the head-group of Arg543 packs against one face of the 
five-membered ring of the His505 side-chain providing favourable van der Waals interactions. 
This interaction with His505 is not possible in the mutant. In four of the five mutant structures 
His505 undergoes a large shift. This shifted conformation is also observed in one wild-type 
structure. In one mutant structure His505 shifts only slightly, but a hydrogen bond to Glu542 
that is observed in the wild-type structures, is lost. Thus, mutation Arg543Gln destabilises 
two types of interactions of His505 namely van der Waals interactions with the arginine side 
chain and, indirectly, hydrogen bonding to Glu542.  
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Figure 1: Conformations of the 
N- and C-terminal flanking 
peptides. Superposition of 
different A1 models that are 
colour coded as follows: wild-
type A1, green; Arg543Gln-A1, 
blue; A1•GpIbα, red. A) 
Stereographic representation of 
the A1 domain local to Arg543. In 
wt-A1 Arg543 forms tight van der 
Waals interactions with His505 
that is directed in an ideal 
orientation for hydrogen-bond 
formation with Glu542. In 2B-A1 
the side chain of Gln543 is shorter 
and the polar head-group is now 
oriented to the interior of the 
domain. This has no effect on the 
conformation of the local main-
chains, but induces small shifts in 
the side chains of Met540, Arg687 
and Asp688. Moreover, the 
orientation of the Gln543 side 
chain abolishes the positioning of 
His505 to Glu542. B) Stereographic 
representation of a part of the 
lower half of the A1 domain 
showing long-range effects of mutation Arg543Gln. In six of the seven wt-A1 models the N-terminal flanking 
peptide adopts the shielded conformation and forms many interactions with the body of the domain (see table 
III). In three out of four Arg543Gln models and in A1•GpIbα the N-terminal flanking peptide adopts the 
unshielded conformation. The C-terminal flanking peptide adopts the shielded conformation only in three wt-A1 
models. Several residues in the body of A1 that interact with the N- and C-terminal flanking peptides are 
subjected to type 2B mutations. The shielded conformation of the N- and C-terminal flanking peptides suggest 
that they block the GpIbα binding site in multimeric vWF. 
In the shielded conformation of the N-terminal flanking peptide, Pro503 stabilises the conformation of Tyr508 that 
directly interacts with loop α1β2. Therefore loop α1β2 may be less stabile in the unshielded conformation (as 
observed by the significant movement of Tyr508), but it does not adopt a different conformation. This suggests 
that GpIbα may induce a conformational change in the loop. The diagrams were generated with MOLSCRIPT 34 
and RASTED3D 35 
 
Structural comparison of A1 structures 
To analyse the occurrence of long range conformational changes in A1 induced by vWD type 
2B mutations we compared all wild-type and mutant crystal structures currently available. In 
addition to the five wild-type and six mutant structures determined in this study, the 
comparison included a model of Arg543Gln-A1 from the A1•GpIbα complex 13, the structure 
of wild-type A1 published by Emsley et al. 22 and structures of wild-type A1 and A1 mutant 
Ile546Val published by Celikel et al. 14; 25. The latter two structures of A1 were crystallised in 
complex with a Fab-fragment of function inhibiting antibody NMC-4 and lack the N-terminal 
flanking peptide up to residue 508. 
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Pair wise superposition of all free A1 models (Table II, first three columns) shows no 
conformational changes in the α-helices and β-strands, indicating that conformational 
changes as observed in the α2 I-domain after collagen binding 26 do not occur in A1 
containing a type 2B mutation. Within the body of A1 considerable variation is observed for 
several loops. However, differences among wild-type models and among mutant models are 
similar in magnitude as differences between wild-type and mutant models. This suggests that 
the variation in these loops is due to inherent flexibility and is not a consequence of the 
mutation. Also comparison of A1•GpIbα with free wt- or mutant A1 structures shows 
significant differences for the body of the domain, i.e. the disulphide bond, loop α1β2 and 
hairpin β2β3 (Table II, last two columns). The latter two regions interact directly with GpIbα. 
However, the differences between wt-A1 and A1•GpIbα are not larger than differences 
between type 2B A1 and A1•GpIbα. This suggests that these differences are introduced by 
GpIbα binding and not by the mutation. 
 
Table II 
Structural variation among mobile loops in wt-A1, vWD-2B A1, and A1•GpIbα  
(R.m.s.d.a values in Å) 
  
Structural 
element 
 
Residues 
 
wt-A1 
 
2B-A1 
wt- v.s.  
2B-A1 
wt-A1 v.s.  
2B-A1-
GpIbα 
2B-A1 v.s.  
2B-A1-
GpIbα 
Body 509-695 0.38 0.37 0.38 0.56 0.52 
N-terminal flanking peptide 2.61  3.28  4.60  4.79  4.23  
 509-511 0.33 0.42 0.43 1.77 1.58 
α1β2 544-550 0.30 0.38 0.33 1.18 1.21 
β2β3 559-563 0.63 0.56 0.61 0.94 0.87 
α2α3 584-592 0.61 0.36 0.58 0.66 0.43 
α3β4 610-613 0.57 0.47 0.53 0.76 0.77 
α5β6 668-671 0.72 0.83 0.75 0.49 0.58 
 
693-695 0.34 0.28 0.35 1.13 1.05 
C-terminal flanking peptide 2.34  1.20  1.93  5.48  3.88  
a Root mean square deviation in positions (r.m.s.d.) values were calculated using the program LSQMAN 33. Values 
(black) for the mobile loops are given when the r.m.s.d. for the loop was 1.5 fold increased compared to the overall 
r.m.s.d.. Not significant values are given in grey.  
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The most prominent structural variation is observed in the flanking peptides. For the 
N-terminal flanking peptide the root-mean-square deviation in the position of the individual 
peptides (r.m.s.d.) between wild-type models is significantly smaller than the difference 
between wt- and 2B A1. Thus for the N-terminal flanking peptide the variation is correlated 
with the presence of a type 2B mutation. The variation seems not to be correlated for the C-
terminal flanking peptide. The differences in the N- and C-terminal flanking peptides in the 
A1•GpIbα complex is larger than differences among free wt- and free 2B A1 models. This 
suggests that GpIbα binding to A1 induces additional conformational changes in the N- and 
C-terminal flanking peptides. 
  
The conformation of the flanking peptides 
Conformations of the N-terminal flanking peptides can be divided in two groups based on the 
observed main-chain conformation at Asp506. In the first group the peptide makes a 90o turn at 
Asp506 and folds over the body of the domain (figure 1B). In this conformation Asp498 
approaches the GpIbα-binding site at the bottom of A1 within 7 Å. Although this residue 
itself does not overlap the GpIbα-binding site, one or two additional residues may be 
sufficient to do so. This conformation will be referred to as the shielded conformation. The 
shielded conformation dominates in the wild-type structures. It is observed in six out of seven 
models of wt-A1 and in only one model of Arg543Gln-A1. In the alternative 'open' 
conformation the N-terminal flanking peptide makes a turn in the opposite direction at Asp506 
and points away from the GpIbα-binding site. This conformation is observed in three out of 
four models of Arg543Gln-A1 and in one model of wt-A1.  In the open conformation the N-
terminal flanking peptide has few interactions with the body of the domain. As a consequence 
the peptide is more flexible: on average fewer residues are visible in the electron density and 
the r.m.s.d. is large compared to the shielded conformation (1.73 Å for the open conformation 
and 0.89 Å for the shielded conformation). The shielded conformation of the N-terminal 
flanking peptide is stabilised via multiple interactions with the body of the domain (figure 1B, 
table III). Many of the residues involved in these interactions, either located in the flanking 
peptide or in the body of the domain, are subject to vWD type 2B mutations. In the A1•GpIbα 
complex the N-terminal flanking peptide adopts the open conformation. However, its 
conformation differs from other open conformations, due to an additional shift of the 
disulphide bond and a concomitant movement of Tyr508. Therefore, binding of GpIbα to A1 
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involves additional conformational changes that are not induced by the type 2B mutations 
studied here. 
 
Table III 
Interactions of the N- and C-terminal flanking peptides with the body of the A1 
domain and the effect of vWD type 2B or 2M mutations 
N-terminal flanking peptide C-terminal flanking peptide 
Residue Type of 
vWD 
Residue Type of 
vWD 
Residue Type of 
vWD 
Residue Type of 
vWD 
Asp498 2Ba Ser500 n.d. Asp696 normala Arg511 2B 
Ile499 n.d. Arg571 2M   Ser692 n.d. 
  Arg573 normal   Tyr693 n.d. 
Ser500 n.d. Asp498 2Ba   Leu694 2B 
Glu501 2Ba Arg573 normal   Ala698 2B 
  Pro574 n.d. Leu697 2B Ser615 n.d. 
  Ser575 n.d.   Tyr693 n.d. 
Pro502 n.d. Leu504 n.d.   Leu694 2B 
Pro503 2B His505 2B   Cys695 2B 
  Tyr508 n.d. Ala698 2B Arg511 2B 
Leu504 n.d. Glu542 2Ba   Leu512 n.d. 
  Arg578 2B   Leu513 2M 
His505 2B Pro503 2B   Ser615 n.d. 
  Phe507 n.d.   Leu694 2B 
  Glu542 2Ba   Cys695 2B 
  Arg543 2B   Asp696 n.d. 
Asp506 2Ba Tyr508 n.d.   Glu700 normala 
Phe507 n.d. His505 2B Pro699 n.d. Arg511 2B 
  Arg543 2B   Leu512 n.d. 
  Asp688 2Ba   Glu613 2M 
  Val691 n.d.   Ser615 n.d. 
  Ser692 n.d.   Ala701 2B 
Tyr508 n.d. Pro503 2B Glu700 n.d. Arg511 2B 
  Asp506 2Ba   Ala698 2B 
  Ser510 n.d.   Pro699 n.d. 
  Glu542 2Ba Ala701 2B Pro699 n.d. 
  Arg543 2B Pro702 2Ma Leu512 n.d. 
  Leu544 n.d. Pro703 2Ma   
  Arg545 2B     
n.d.; not discribed in literature. 
a The phenotype has been assigned although the effect of the mutation was studied in a vWF-
variant containing more than one mutation. 
 
The C-terminal flanking peptide protrudes like a stalk from the bottom of A1 (figure 
1B). The conformation can roughly be divided in two groups depending on the orientation of 
the main chain at Glu700. In one group, containing three wild-type and one 2B structure, 
residues Pro702 and Pro703 are within 2 and 3 Å, respectively, of the GpIbα-binding site. This 
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would block GpIbα binding. In analogy to the N-terminal flanking peptide we call this the 
shielded conformation. In the other conformation, observed in five wt-A1 models and all but 
one model of mutant A1, the C-terminal flanking peptide is located further away from the 
GpIbα-binding site due to a rotation of 180 degrees around the Glu700 peptide bond. In the 
A1•GpIbα complex an open conformation is observed. 
Since the closed conformation of the N- and C-terminal flanking peptides is observed 
predominantly, but not exclusively, in free wt-A1 and the open conformation in Arg543Gln-
A1, it suggest that both conformations exists in wt-A1 and mutant A1, but that a type 2B-
mutation shifts the equilibrium to the open conformation. 
 
The conformation of loop α1β2  
Loop α1β2, comprising residues Ile544 to Trp550, occupies a central position at the bottom face 
of the domain. In the shielded conformation this loop contacts the N- and C-terminal flanking 
peptides via a tight stacking of the side chains of residues Pro503, Tyr508, Arg545 and Trp550, 
and a looser interaction with Ala701 (figure 1B). These residues, except Tyr508 of which no 
data are available, are subject to vWD type 2B mutations (Table III). In the A1•GpIbα 
complex the conformation of loop α1β2 is different compared to the conformation in wt-A1. 
In addition, loop α1β2 in the complex is mobile and interacts directly with GpIbα, suggesting 
that it is involved in activation. However, the conformation of loop α1β2 in wt-A1 and 2B-A1 
is similar, indicating rather an indirect than a direct role in activation. 
 
The conformation of hairpin β2β3 
A closer look at hairpin β2β3 (residues 551-566) was prompted by the hypothesis formulated 
by Celikel et al. that mutation Ile546Val induced a conformational change 28 Å further in the 
domain in hairpin β2β3 resulting in a higher affinity for GpIbα 14. Our comparison of a much 
larger set of structures now shows that hairpin β2β3 adopts a range of conformations (Table 
II). Part of the observed variability of β2β3 is accounted for binding of cadmium and chloride 
ions to residues Glu557, His559, Asp560, and His563 in several of our structures (Table I) and in 
the structure of Emsley et al 22. A superposition of all models not affected by ion binding 
(figure 2) stills shows substantial variation in the conformation of β2β3, in particular for 
main-chain and side-chain atoms of residues Asp560, Gly561, Ser562, His563. However, the 
conformation of β2β3 in the Ile546Val- and Arg543Gln-A1 mutants is different from the 
conformation observed in the A1•GpIbα complex. Clearly, hairpin β2β3 is inherently flexible 
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and its conformation as observed in the structure of type 2B mutants is not a high-affinity 
state of the A1 domain. Alternatively, the 2B phenotype of the Ile546Val mutant may involve 
a conformational change in the N-terminal flanking peptide. However, this could not have 
been observed in the crystal structure of Ile546Val-A1, since the construct used for 
crystallisation did not contain the N-terminal flanking peptide. 
 
 
 
 
 
 
Figure 2: Conformations of hairpin β2β3. 
Superposition of A1 models wt-P212121, 
green, wt-1oak, dark grey, RQ-P212121, 
blue, IV-1fns, light grey, and A1•GpIbα, 
red. The conformation of hairpin β2β3 in 
the two wt-A1 models are not identical but 
differ at residues Asp560, Ser562 and His563. 
In addition, the conformation in two vWD 
type 2B A1 variants of A1 are not similar at 
these residues and do not resemble the 
conformation of the hairpin in the 
A1•GpIbα complex that contains by 
definition the active conformation.  
 
 
Binding of the A1 domain and vWF to GpIbα 
To investigate if GpIbα binding to the A1 domain is similar as to vWF, we analysed GpIbα-
binding by SPR. These results have been summarised before 13, but will be discussed here in 
detail. Wild-type vWF did not spontaneously bind to GpIbα up to a concentration of 150 nM, 
but Arg543Gln-vWF did (figure 3). In contrast, wt-A1 bound spontaneously to GpIbα with an 
affinity of 27 nM. Therefore the wt-A1 domain is already activated. Mutation Arg543Gln in 
the A1 domain reduced the KD only 3 fold showing that the effect of the mutation is subtle in 
A1498-705. This observation is in agreement with our crystallographic data, since we observed 
that only the C-terminal flanking peptide partially overlaps the GpIbα binding site at the 
bottom of A1. The N-terminal flanking peptide in A1498-705 approaches, but does not overlap 
this GpIbα binding site and is therefore not able to prevent GpIbα binding. Probably 
additional elements in the flanking peptides outside residues 498-705 are required to keep A1 
in a low-affinity state as has been demonstrated for other shorter  and longer  A1-constructs 27; 
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28;29;30. Most likely the N- and C-terminal flanking peptides act in concert, because only 
simultaneously deletion of the peptides in vWF result in activation 31.  
 
Figure 3: Binding of multimeric vWF and the isolated A1 domain to immobilised GpIbα was analysed by 
surface plasmon resonance in a Biacore system. Wild-type A1 bound spontaneously to GpIbα, KD 27 nM, and 
mutation Arg543Gln increased the affinity for GpIbα three fold. Wild-type vWF did not bind to GpIbα, 
suggesting a KD of at least 5 ? µM. Mutation Arg543Gln in multimeric vWF induced spontaneous binding. 
 
Conclusion 
 
We have investigated structures of wt- and type 2B mutants A1 in relation to GpIbα binding. 
Conformational changes induced by type 2B mutations within the body of the A1 domain 
were not observed. However, conformational changes were observed for the N- and C-
terminal flanking peptides. In wt-A1 the peptides are directed to the GpIbα binding site at the 
bottom of A1, suggesting that these peptides overlap the binding site in vWF. In type 2B A1 
the peptides are directed differently and probably do not overlap the binding site in type 2B 
vWF. The importance of the N- and C-terminal flanking peptides in vWF-activation is 
underlined ristocetin, which interacts with the N- and C-terminal flanking peptides 9; 32. 
Ristocetin-induced activation resembles shear-induced activation 12. 
Our crystallographic analysis supports a mechanism for activation of vWF as depicted 
in figure 4. In normal circulation the N- and C-terminal flanking peptides shield the GpIbα – 
β-finger binding site at the bottom of A1 and vWF has a low-affinity conformation. 
Pathological shear forces acting on vWF in occluded arteries or drag forces generated by the 
blood flow acting on immobilised vWF pulls the flanking peptides away by a hinge motion at 
residues Asp506 and Glu700 that exposes the GpIbα binding site. VWD type 2B mutations 
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likely affect the equilibrium between the shielded and open conformation and switch vWF 
from the low- to the high-affinity state. 
 
 
 
 
 
 
Figure 4: Mechanism of vWF-A1 
activation. In vWF both the N- and C-
terminal flanking peptides shield the 
GpIbα – β-finger binding site and vWF 
adopts its low-affinity state. Due to shear 
activation or a vWD type 2B mutation, the 
N- and C-terminal flanking peptides are 
rotated around a hinge (Asp506 and Glu700, 
respectively, indicated by the blue circles). 
This opens the GpIbα-binding site and 
switches A1 to the high-affinity state. 
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Haemostatic plug formation at sites of vascular injury is required to stop bleeding. This 
process is started by platelet adhesion and aggregation and is followed by fibrin formation. 
Platelet adhesion and aggregation requires the subendothelial matrix, von Willebrand Factor 
(vWF), platelet receptors glycoprotein (Gp) Ib-IX-V complex, GpVI, integrins α2β1, α2bβ3 
and fibrinogen. 
Adhesion of platelets at sites of vascular damage is initiated by binding of the vWF A3 
domain to the subendothelial matrix, followed by rolling and tethering of platelets over this 
immobilised vWF. The latter process requires the A1 domain of vWF and GpIbα on the 
platelet. Rolling reduces the velocity of the platelets, a process that is also mediated by GpVI 
and integrin α2β1. Now the platelets become firmly attached and activated. This allows 
additional platelets to interact with these initial immobilised platelets; the process of thrombus 
growth is initiated. Platelet-platelet interactions within the thrombus are mediated by the 
GpIb-IX-V complex, integrin α2bβ3 and vWF and fibrinogen. Finally fibrinogen is converted 
to fibrin, giving the haemostatic plug its final strength. 
 
Von Willebrand Factor is stored in specific organelles in platelets and endothelial cells 
and it circulates free in plasma. Because vWF and platelets both circulate free in plasma, vWF 
should not bind spontaneously to platelets. To this end, vWF needs to be activated. The 
activation mechanism is not understood, but activation can be achieved in several ways.  
 
1) Binding of vWF to the subendothelial matrix, in particular to collagen 1. 
2) Binding of exogenous ligands to vWF, for example the antibiotic ristocetin-A 2 or 
snake toxins botrocetin 3 or bitiscetin 4. 
3) Von Willebrand Disease (vWD) type 2B mutations in the A1 domain 5. 
4) Platelet-type vWD mutations in GpIb 6. 
 
The studies in this thesis were conducted to investigate the above processes. In particular, we 
investigated at a molecular level (i) the binding of the A3 domain to collagen type III, (ii) the 
structure of the A1•GpIbα complex and (iii) conformational changes that activate the A1 
domain for binding to GpIbα. 
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Binding of vWF to collagen. 
 
Insight at the molecular level how vWF immobilises platelets on the subendothelial matrix 
may be useful to develop new anti-arterial thrombotic compounds. To this end, we 
investigated the interaction of the A3 domain with collagen type III. These results are 
described in chapters 2, 3 and 4. Based on the homology with integrin I-domains, which bind 
collagen at the top-face of the domain, several groups, including ours, have introduced 
mutations at the top face of A3. However, these mutations did not reduce collagen binding 
suggesting that the collagen-binding site in A3 should be located somewhere else. To obtain 
information about the approximate location of the collagen-binding site, we solved the crystal 
structure of the A3 domain in complex with a Fab fragment of function inhibiting antibody, 
RU5 (chapter 2). We identified the RU5-epitope at the front- and bottom face of A3. 
Subsequent mutations introduced in and around the RU5 epitope indeed resulted in a reduced 
collagen-binding. The collagen-binding site in A3 has now been mapped solely to the front 
face of the domain. Based on the quantitative effects of the mutations in collagen binding, we 
hypothesise that residues in the lower part of the collagen-binding site are essential in 
collagen binding, whereas residues in the upper part are involved but not essential in collagen 
binding. Since the collagen-binding site in the A3-domain contains negatively charged and 
hydrophobic amino-acid residues, it is evident that A3 binds to positively charged and 
hydrophobic residues within a collagen triple-helix. The front face of the A3 domain is rather 
flat and specific collagen sequences that bind to vWF are unknown. Therefore an automated 
procedure to dock a collagen molecule failed. Manually we identified a range of orientations 
of the engagement of a collagen triple helix on the A3 domain (figure 1). 
 
 
Figure 1: Binding-orientations of a collagen triple helix 
to the vWF-A3 domain. The front-face of the A3 domain 
is shown. Residues in magenta are essential in collagen 
binding, residues in green are involved but not essential 
in collagen binding, and residues in yellow are not 
involved at all. The collagen molecule is close to Pro981, 
shown in red, but does not interact with it. Two collagen 
molecules that enclose the range of orientations for the 
A3-collagen interaction are shown and the ange is 
indicated by the arrows. 
 
Schneppenheim et al. described several patients with a mutation in the A3 domain that 
inhibited collagen binding in a solid-state collagen-binding assay 7. Surprisingly, the patients 
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are without bleeding problems. However, the mutated residues co-localise with the region of 
A3 that is involved, but not essential for collagen binding. On the other hand, mutations in the 
region that is essential in collagen binding may give bleeding problems, but these mutations 
are not yet identified in patients.  
Ribba et al. described two related patients suffering from mild bleeding problems, 
with a mutation in the A3 domain 8. Residue Ser968 is mutated to threonine. Ser968 is not 
solvent exposed, but is buried under the collagen binding site. Therefore a direct effect in 
collagen binding seems unlikely. In the study described in chapter 4 we solved the crystal 
structure of A3 with this mutation. Interestingly, we did not observe any conformational 
changes in A3. As we have described in chapter 2, two loops at the lower part of the front face 
of A3 are rather mobile, suggesting an induced-fit model for the binding of A3 to collagen. 
Ser968 is close to one of these loops and we hypothesised that the mutation shifts the 
equilibrium to the low-affinity conformation and thereby reduces the affinity of A3 for 
collagen. 
For the α2-I domain it has been shown that collagen binding induces conformational 
changes within the domain. To investigate if conformational changes occur in A3 upon 
collagen binding, co-crystallisation experiments should be performed of A3 in complex with a 
short collagen-triple helix. However, it is still not known which collagen sequence (and 
probably it is not a single sequence but multiple) binds to A3 with high affinity. This may be 
investigated by several approaches: (i) monoclonal antibodies raised against collagen type III 
may inhibit binding of vWF to collagen. Via phage-display-technology the epitope of the 
antibody can be determined, (ii) cross-linking of collagen-bound vWF and subsequent 
digestion of the vWF-collagen complex. Via N-terminal protein sequencing the specific 
collagen sequences may be identified.  
It has been argued that in vivo the A3 domain is not involved in immobilizing platelets 
to the vessel wall, because patients with a mutation in the collagen-binding site do not have a 
bleeding problem 7. However, we have shown that these mutated residues are located in the 
upper part of the collagen-binding site that is involved, but not essential in collagen binding. 
Recently the relevance of the binding of A3 to collagen in vivo has been demonstrated by 
injection of monoclonal antibodies directed against the A3 domain in baboons 9. This resulted 
in an elongated bleeding time. To tackle these discrepancies further, bleeding-time 
experiments in vWF knock-out mice should be performed after infusion with either mouse 
wild-type vWF or mouse vWF lacking the A3 domain. 
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The A1•GpIbα complex and conformational changes in A1. 
 
VWF becomes activated when it is immobilised to a surface. As mentioned above, the 
activation-mechanism is not understood. Most likely it requires conformational changes in the 
A1 domain. It is generally believed that these conformational changes are similar to the 
conformational changes induced by vWD type 2B mutations. 
To address this problem we solved a crystal structure of GpIbα and of GpIbα in 
complex with the A1 domain (chapter 5 and figure 2). The leucine-rich repeats of GpIbα 
adopt a horse-shoe like structure that is sandwiched on either side by flanking elements. The 
N-terminal flanking structure contains the so-called β-finger that protrudes from the domain.  
The C-terminal flanking structure contains the so-called β-switch, which is structurally 
disordered, and is followed by the anionic region. In the A1•GpIbα complex we identified 
two sites in A1 that tightly interact with GpIbα. The first interaction site is at the upper part of 
A1 and involves residues of hairpin β2β3 and nearby residues. This interaction site binds to 
the GpIbα – β-switch and several other GpIbα residues in the vicinity of the β-switch. When 
the β-switch interacts with the A1 – β2-β3 hairpin, the β-switch undergoes a conformational 
change and adopts a β-hairpin conformation. Since platelet-type vWD mutations are located 
in the β-switch and involve mutations that favour β-strand formation, it is likely that these 
mutations induce the β-hairpin structure in the β-switch and thereby activate GpIbα. The 
second GpIbα binding site in A1 is located at the lower part of the domain, close to the region 
in A1 that contains the type 2B mutations. This region interacts with the GpIbα β-finger.  
 
 
 
 
 
Figure 2: Crystal structure of the A1•GpIbα complex. 
A1 is shown in blue and GpIbα is shown in red. 
GpIbα has two main interaction sites within A1. The 
β-finger interacts with several loops, including loop 
α1β2, at the bottom of A1. The β-switch interacts with 
strand β3 of hairpin β2β3 and several other residues at 
the top of A1. Several long-range charge-charge 
interactions between the GpIbα LRRs and the body of 
A1 provide an additional  interaction site. 
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In the past, two structures of wt-A1 and one structure of vWD type 2B mutant 
Ile546Val have been published 10-12. In the study described in chapter 6 we solved the 
structure of three different crystal forms of wt-A1498-705, yielding six models, and three 
different crystal forms of type 2B mutant Arg543Gln-A1, yielding five models. In all wt- and 
type 2B A1 models the overall fold of the body of the domain was similar. In contrast, the N- 
and C-terminal flanking peptides adopted a different conformation in type 2B mutant 
Arg543Gln-A1 compared to the conformation in wild-type A1. In most of the wt-A1 models 
the N- and C-terminal flanking peptides are directed towards the GpIbα – β-finger binding 
site suggesting that in multimeric vWF they overlap with the β-finger binding site. This is the 
so-called shielded conformation. In most of the Arg543Gln-A1 models the N- and C-terminal 
flanking peptides are pointed in a different direction due to a hinge motion around Asp506 and 
Glu700, respectively, thereby opening the β-finger binding site. This motion of the flanking 
peptides could activate the A1 domain for GpIbα binding. It is likely that shear activates A1 
via a similar mechanism, because vWF that is immobilised via its A3 domain may “sense” the 
forces generated by the flowing blood. As a result, vWF may partially unwind that induces the 
conformational change in the N- and C-terminal flanking peptides of the A1 domain. 
 
 
 
 
 
Figure 3: Schematic representation of A1 activation. In 
inactive vWF the N- and C-terminal flanking peptides of 
A1 fold over the body of the domain and shield the β-
finger binding site. Activation induces a motion around 
two hinges (indicated by the blue circle) that opens the 
binding site. 
 
Based on our observations we disagree with the hypothesis of Celikel et al. 12 who 
postulated that A1 is activated due to a conformational change in the β2β3 hairpin of A1. In 
our structural analysis we observed conformational flexibility of hairpin β2β3 that is not 
correlated with the presence of a type 2B mutation. Celikel et al. were not able to observe a 
conformational change in the N-terminal flanking peptide, because these residues were absent 
in their A1-construct. 
 The exact number of residues in the N- and C-terminal flanking sequences that are 
required to prevent spontaneous GpIbα-binding is still unknown. Residues upstream of Asp498 
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and downstream of Thr705 are required to suppress GpIbα binding, because various A1-
constructs with longer N-and C-terminal flanking peptides do not bind spontaneously to 
GpIbα, whereas A1498-705 does. It is also known that O-linked glycan residues are required to 
prevent spontaneous GpIbα binding, because non-glycosylated (i.e. bacterial) or desialated 
A1 fragments bind spontaneously to GpIbα, whereas identical glycosylated A1 fragments do 
not. It is, however, still not known which residues require O-glycosylation. To address the 
above problems, an A1-construct should be developed that is fully glycosylated and does not 
bind spontaneously to GpIbα. Next, the number of residues in the N- and C-terminal flanking 
peptides should be systematically decreased and O-linked glycosylation sites should be 
specifically removed. Additionally, the A1 construct which does not interact spontaneously 
with GpIbα should be crystallised to study the interactions of the N- and C-terminal flanking 
peptides with the body of the domain at a molecular level.  
Binding of vWF to a surface like glass, collagen or endothelial cell matrix triggers 
binding of GpIbα on the platelet to vWF. As is described in chapters 5 and 6, activation of 
vWF involves conformational changes in the N- and C-terminal flanking peptides of the A1 
domain. These conformational changes may be induced by binding of the A3-domain to 
collagen, or by hydrodynamic forces generated by the flowing blood. In addition, it can not be 
excluded that GpIbα mediated binding of platelets to immobilized vWF is an effect of the 
increased local vWF concentration. Therefore Biacore-experiments should be performed at 
multiple flow-rates in which different vWF-densities are immobilised via collagen or via a 
monoclonal antibody to the sensor chip. 
 
In summary, our investigations identified the collagen-binding site on the vWF-A3 domain. 
Based on the surface characteristics of the collagen-binding site, a hypothesis of the nature of 
the collagen triple helix to which A3 will bind has been made. The identification of specific 
collagen sequences that interact with A3 is subject for future research. Crystal structures of 
GpIbα, A1•GpIbα, wt- and R543Q-A1 have been solved. Based on these structures we 
hypothesised that the N- and C-terminal flanking peptides of A1 shield one of the two GpIbα 
binding sites in A1 and thereby prevent GpIbα binding. A1-activation involves a 
conformational change in these flanking peptides. The exact number of residues in the N- and 
C-terminal flanking peptides that shield A1 completely is subject for further research.  
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In conclusion, we have gained insight in the collagen-vWF-GpIbα interactions at a molecular 
level. It has not escaped our notice that these results are of significant value for the 
development of new drugs against arterial thrombosis.   
 
 
 
Reference list 
 
 
 1.  Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in 
platelet thrombus formation under flow. Cell. 1998;94:657-666. 
 2.  Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and 
mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem. 1991;266:8149-8155. 
 3.  Usami Y, Fujimura Y, Suzuki M, et al. Primary structure of two-chain botrocetin, a von Willebrand factor 
modulator purified from the venom of Bothrops jararaca. PNAS. 1993;90:928-932. 
 4.  Obert B, Houllier A, Meyer D, Girma JP. Conformational changes in the A3 domain of von Willebrand 
factor modulate the interaction of the A1 domain with platelet glycoprotein Ib. Blood. 1999;93:1959-
1968. 
 5.  Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions. 
For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on 
von Willebrand Factor of the Scientific and Standardization Committee of the International Society on 
Thrombosis and Haemostasis. Thromb Haemost. 1993;69:177-184. 
 6.  Miller JL. Platelet-type von Willebrand disease. Thromb Haemost. 1996;75:865-869. 
 7.  Schneppenheim R, Obser T, Drewke E, et al. Isolated Molecular Defects of Von Willebrand Factor 
Binding to Collagen Do Not Correlate with Bleeding Symptoms [abstract]. Blood. 2001. 
 8.  Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand 
factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost. 
2001;86:848-854. 
 9.  Wu D, Vanhoorelbeke K, Cauwenberghs N, et al. Inhibition of the von Willebrand (VWF)-collagen 
interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet 
thrombus formation in baboons. Blood. 2002;99:3623-3628. 
 10.  Emsley J, Cruz M, Handin R, Liddington RC. Crystal structure of the von Willebrand factor A1 domain 
and implications for the binding of platelet glycoprotein Ib. J Biol Chem. 1998;273:10396-10401. 
 11.  Celikel R, Varughese KI, Madhusudan, Yoshioka A, Ware J, Ruggeri ZM. Crystal structure of the von 
Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nature Struct Biol. 
1998;5:189-194. 
 12.  Celikel R, Ruggeri ZM, Varughese KI. Von Willebrand Factor conformation and adhesive function is 
modulated by an internalized water molecule. Nature Struct Biol. 2000;7:881-884. 
Nederlandse samenvatting 
 135
Hoofdstuk 8 
 
 
 
 
 
 
Samenvatting in het Nederlands 
Nederlandse samenvatting 
 136
Inleiding 
 
Het stoppen van een bloeding bestaat uit twee processen: bloedstelping en 
bloedstolling. Tijdens de bloedstelping worden bloedplaatjes aan de beschadigde vaatwand 
gebonden en ontstaat de plaatjesprop. Bloedstolling is het proces van fibrinevorming, dat de 
plaatjesprop zijn uiteindelijke sterkte geeft. Het in dit proefschrift beschreven onderzoek 
betreft een onderdeel van de bloedstelping. 
 Binding van bloedplaatjes aan een beschadigde vaatwand is een complex proces en is 
afhankelijk van componenten uit de vaatwandmatrix, waaronder collageen, verschillende 
receptoren op het bloedplaatje, waaronder GpIb-IX-V, GpVI, α2β1 en α2bβ3, en plasma-
eiwitten zoals von Willebrand factor en fibrinogeen. In dit proefschrift worden onze studies 
naar Von Willebrand factor beschreven. 
 Von Willebrand factor, vWF, is een multimeer eiwit dat aan collageen op de plaats 
van de beschadiging in de vaatwand bindt. Vervolgens vinden er veranderingen in de 
structuur van vWF plaats waardoor vWF ook aan receptor GpIb-IX-V op het bloedplaatje kan 
binden. Nu is het bloedplaatje geïmmobiliseerd op de plaats van de beschadigde vaatwand. De 
binding tussen het geïmmobiliseerde bloedplaatje en de vaatwand wordt versterkt door 
interacties van plaatjes receptoren GpVI en α2β1 met collageen. Vervolgens binden andere 
bloedplaatjes aan de eerste laag plaatjes via interactie van plaatjes receptor α2bβ3 met 
fibrinogeen en vWF uit het plasma en ontstaat de plaatjesprop. De binding van vWF aan 
collageen en GpIb-IX-V zijn de specifieke onderwerpen van dit proefschrift. 
 
 
Resultaten 
 
 In hoofdstuk één wordt een algemene inleiding over bloedstelping gegeven. Primair 
wordt de aandacht gelegd op von Willebrand Factor (vWF). Beschreven wordt hoe en waar 
vWF gesynthetiseerd wordt en waar het gelokaliseerd is in het lichaam. Verder wordt 
beschreven uit welke domeinen vWF is opgebouwd en wat de functie deze domeinen is. 
Specifiek wordt ingegaan op de A1 en A3 domeinen. 
 
 In hoofdstuk twee en drie zijn de experimenten beschreven waarmee de collageen 
bindingsplaats op het A3 domein is gelokaliseerd. In analogie met homologe I-domeinen, die 
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collageen binden aan de bovenkant van het domein, waren in het verleden aan de bovenkant 
van het A3 domein mutaties geïntroduceerd. Echter, collageen binding van deze mutanten 
was normaal waardoor geconcludeerd kon worden dat collageen niet aan de bovenkant van 
A3 bindt. Om de collageen bindingsplaats op het A3 domein grof te bepalen hebben we de 
kristal structuur van A3 in complex met het Fab-fragment van monoclonaal antilichaam RU5 
bepaald. RU5 remt de binding van vWF aan collageen waardoor het waarschijnlijk is dat het 
epitoop van RU5 en de collageen bindingsplaats (partieel) overlappen. In de kristal structuur 
van het A3•RU5 complex was duidelijk dat RU5 aan de voor- en onderzijde van A3 bindt en 
niet aan de bovenkant. Op basis van deze structuur hebben we 27 aminozuren geïdentificeerd 
die betrokken zouden kunnen zijn in collageen binding. Deze aminozuren hebben we 
gemuteerd. Een aantal van deze mutanten bezit een verlaagde affiniteit voor collageen, wat 
inhoudt dat de gemuteerde aminozuren zeer waarschijnlijk betrokken zijn bij de collageen 
binding. Op basis hiervan hebben we geconcludeerd dat de collageen bindingsplaats aan de 
voorkant van het A3 domein ligt. Uit de experimenten bleek tevens dat de aminozuren in de 
onderste helft van de collageen bindingsplaats essentieel zijn voor de collageen binding, 
terwijl aminozuren in de bovenste helft slechts additioneel betrokken zijn. Een hypothetisch 
model van de binding van collageen aan A3 is gegeven in figuur 1. 
Collageen residuen die aan A3 binden zijn nog niet geïdentificeerd. Nu de collageen 
bindingsplaats op het A3 domein gelokaliseerd is kunnen we op basis van de karakteristieken 
van de bindingsplaats een uitspraak doen over collageen sequenties die aan A3 binden. Op 
basis hiervan is het waarschijnlijk dat hydrofobe- en positief geladen collageen sequenties aan 
A3 binden. 
Figuur 1. De collageen bindingsplaats 
op het vWF-A3 domain. Ruimtelijk 
model van de voorkant van het vWF-A3 
domein. Residuen in roze, Asp979, 
Ser1020 en His1023, zijn essentieel voor de 
collageen binding en residuen in groen, 
Ile975, Thr977, Val997, Glu1001 en Arg1016, 
zijn betrokken bij de collageen binding, 
maar zijn niet essentieel. Residuen in 
geel hebben geen interactie met 
collageen. Residuen in grijs hebben we 
niet gemuteerd. Pro981, in rood, bindt 
niet aan collageen, maar als het wordt 
gemuteerd naar een histidine, remt het 
de collageen binding via sterische 
hindering. 
Twee collageen moleculen zijn 
weergegeven in blauw en bruin welke 
de range van mogelijke oriëntaties 
aangegeven hoe collageen aan A3 kan 
binden.  
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Onderwerp voor verdere studie is de identificatie van collageen sequenties die aan A3 
binden en het bepalen van de kristalstructuur van een A3•collageen complex.  
 
In hoofdstuk vier is de kristal structuur van het A3 domein beschreven dat mutatie 
Ser968Thr bevat. Deze mutatie is gevonden bij een patiënt met een bloedingsneiging. 
Aminozuur Ser968 is echter niet gelokaliseerd aan het oppervlak van A3, maar net onder de 
collageen bindingsplaats. Daardoor is een directe rol voor Ser968 in collageen binding niet 
waarschijnlijk. Mutatie Ser968Thr veranderde niet zichtbaar de conformatie van het A3 
domein. Echter, uit de vergelijking van vele A3 kristalstructuren bleek dat de collageen 
bindingsplaats van A3 meerdere conformaties kan aannemen. Hoewel er geen directe 
experimentele aanwijzingen zijn, veronderstellen we dat een aantal conformaties wel in staat 
is om collageen te binden en andere conformaties niet. Waarschijnlijk heeft de mutatie 
invloed op de ratio van de actieve- en de niet-actieve conformatie en wordt het evenwicht 
verschoven naar de niet-actieve conformatie. 
 
 Het A1 domein van vWF bindt aan de receptor GpIb-IX-V op het bloedplaatje. In het 
onderzoek zoals beschreven in hoofdstuk vijf werd de kristal structuur van het A1-bindende 
deel van GpIb-IX-V, de 290 N-terminale residuen van de GpIbα subunit, bepaald (zie figuur 
2). Tevens werd de structuur bepaald van A1 in complex met dit deel van GpIbα. Het vWF-
A1 domein heeft twee bindingsplaatsen voor GpIbα. Eén bindingsplaats is gelokaliseerd  aan 
de bovenkant van het A1 domein en bevat aminozuren die op basis van mutatiestudies al 
eerder waren geïdentificeerd. Dit deel van A1 bind aan de zogenaamde β-swich op GpIbα. 
Onverwacht was de tweede bindingsplaats voor GpIbα aan de onderkant van A1 dat interactie 
heeft met de β-finger van GpIbα. Verder zijn er verschillende lange-afstand lading interacties 
van residuen in de β-strands van de GpIbα leucine-rich-repeats met A1. 
 Patiënten met een zogenaamde “Platelet-type von Willebrand Disease” mutatie in 
GpIbα hebben een bloedingsneiging doordat GpIbα spontaan aan vWF bindt. Hierdoor 
ontstaan plaatjes-aggregaten die geklaard worden in de milt. De GpIbα en A1•GpIbα-
complex structuren verklaren deze spontane vWF-GpIbα interactie. Deze mutaties komen 
namelijk voor in de zogenaamde β-switch van GpIbα die niet geordend is in vrij GpIbα, maar 
een β-hairpin conformatie heeft in het A1•GpIbα complex. De mutaties promoten de β-
hairpin conformatie waardoor GpIbα spontaan aan A1 kan binden. 
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Figuur 2. Kristal structuren van GpIbα en A1•GpIbα.  De β-switch in vrij GpIbα heeft een wanordelijke 
structuur. Echter, als GpIbα aan A1 bindt ondergaat de β-switch een conformatieverandering naar een β-hairpin 
structuur. De β-switch en andere locale GpIbα residuen binden aan de bovenkant van A1. De β-finger bindt aan 
de onderkant van A1 vlak bij het gebied in A1 waar de activerende 2B mutaties liggen. Residuen in de β-strands 
van de leucine-rich-repeats  van GpIbα hebben lange afstand lading interacties met A1. 
 
 
 In normale situaties bindt het A1 domein van vWF niet spontaan aan GpIbα. Von 
Willebrand Factor moet eerst worden geactiveerd. Activering vindt plaats doordat vWF aan 
de vaatwand bindt. Er zijn patiënten met een zogenaamde von Willebrand Disease type 2B 
mutatie in het A1 domein waardoor vWF spontaan aan GpIbα bindt zonder dat vWF aan de 
vaatwand gebonden is. Deze patiënten hebben een laag vWF- en plaatjes niveau in hun bloed. 
Dit leidt tot bloedingen met allerlei complicaties. In hoofdstuk 6 is deze activering 
bestudeerd. De kristalstructuren van wild-type A1 en van A1 met type 2B mutatie Arg543Gln 
werden bepaald. De enige conformatie verschillen werden waargenomen in de flankerende 
peptiden van A1. In wild-type A1 zijn deze peptiden georiënteerd in de richting van de GpIbα 
bindingsplaats en overlappen ze waarschijnlijk de GpIbα bindingsplaats in multimeer vWF. 
In Arg543Gln-A1 hebben de peptiden een andere oriëntatie welke niet kan overlappen met de 
GpIbα bindingsplaats. Op basis hiervan is de hypothese opgesteld zoals in figuur 3 
weergegeven is. Niet geïmmobiliseerd vWF bevat een inactive conformatie doordat de 
flankerende peptiden de GpIbα bindingsplaats overlappen. Vaatwand-gebonden vWF is 
onderhevig aan hydrodynamische krachten van de bloedstroom waardoor de flankerende 
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peptiden van A1 als het ware van het domein worden losgetrokken en de GpIbα 
bindingsplaats geëxposeerd wordt.  
 
 
 
 
Figuur 3. Activatie-mechanisme 
van het vWF-A1 domein. In rood 
is de GpIbα bindingsplaats  op A1 
weergegeven. In inactief A1 
overlappen de flankerende peptiden 
de GpIbα bindingsplaats. Door 
activatie worden de peptiden anders 
georiënteerd door een rotatie om 
een bepaald residue, aagegeven 
door de blauwe cirkel, aan de basis 
van de peptiden. Hierdoor wordt de 
GpIbα bindingsplaats geëxposeerd 
en kan GpIbα binden. 
 
 
 
Onderwerpen voor verder onderzoek zijn: (i) het minimum aantal residuen in de 
flankerende peptiden in A1 dat nodig is om spontane GpIbα binding van geïsoleerd A1 te 
voorkomen en (ii) verdere bestudering van het activeringsmechanisme met als vraagstelling of 
activering plaats vindt doordat vWF geïmmobiliseerd wordt, of dat collageen conformatie 
veranderingen induceerd.  
 
 
Conclusie 
 
Von Willebrand Factor (vWF) is een essentieel eiwit voor de vorming van de 
haemostatische plug; vWF bindt bloedplaatjes via hun receptor GpIb-IX-V aan collageen op 
de plaats van vaatwandbeschadiging. Disfunctionering van collageen – vWF – GpIb-IX-V–as 
kan bloedingsneiging of arteriële trombose tot gevolg hebben. Het onderzoek zoals 
beschreven in dit proefschrift heeft inzicht verschaft op moleculair niveau in de interacties 
van vWF met zowel collageen als met GpIbα. Deze gegevens kunnen van belang zijn voor de 
ontwikkeling van medicijnen tegen arteriële trombose. 
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Ziezo, het proefschrift is dan eindelijk klaar. 
 
Daarom wil ik een aantal mensen bedanken die mij al die jaren op het lab. en daarbuiten 
hebben bijgestaan. Jan Sixma, mijn promotor, bedankt voor alle enthousiasme en kennis die je 
de afgelopen vier jaren hebt over gebracht. Nu ik – als je laatste AIO – het vWF-project heb 
afgesloten, kun je rustig van een welverdiende oude dag gaan genieten. Piet Gros, tweede 
promotor, je bent waarschijnlijk voorlopig nog niet van mij af, want kristallografie is een 
mooi vak. Eric Huizinga, co-promotor, bedankt voor alle inspiratie en toewijding je mij hebt 
gegeven. Winnifred Wuyster, dankzij  jou zijn hoofdstukken twee en drie mogelijk geworden! 
Iedereen van lab 1, Marion, Shizuko, Martin IJ, Martin B, Martijn, Douwe, Chantal, Hanneke, 
Domenico, Ya-Ping, Wilco, lab 2, lab 3, kristallograven, Barend, Lucy, Mitja, Sjors, Classien, 
Annika, en alle anderen die ik onbewust ben vergeten: jullie waren en zijn fijne collega’s. 
 
Verder gaat mijn grote dank uit naar jullie, mijn ouders en schoonmoeder, want jullie hulp 
was echt geweldig. 
 
Monique, je hebt altijd gezegd dat er meer in het leven is dan wetenschap alleen. Nu mijn 
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